

SUISSE
Deutsch:

2006



Auteur - Editeur:

philippe_furger@investimed.ch

Last update: 3.2.2015

Scheme used for classification of the evidence

M	Meta-analysis; use of statistical methods to combine results from clinical trials
Ra	Randomized controlled trials; also known as experimental studies
Re	Retrospective analyses; also known as case-control studies
F	Prospective study; also known as cohort studies, including historical or prospective follow-up studies
X	Cross-sectional survey; also known as prevalence studies
Pr	Previous review or position statements
C	Clinical interventions (nonrandomized)

Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiac care. *JAMA* 1992; 268: 2171-2295.

Stiell IG, Hebert PC, Weitzman BN, et al. High-dose epinephrine in adult cardiac arrest. *N Engl J Med* 1992; 327: 1045-50.

Niemann JT. Cardiopulmonary resuscitation. *N Engl J Med* 1992; 327: 1075-80.

Kloeck W, Cummins R, Chamberlain DA, et al. The universal ALS Algorithm: an advisory statement by the advanced life support working group of the international liaison committee on resuscitation. *Resuscitation* 1997; 34: 109-11.

Walpoth BH, et al. Outcome of survivors of accidental deep hypothermia and circulatory arrest treated with extracorporeal blood warming. *N Engl J Med* 1997; 337: 1500-5.

Advanced life support working group of the european resuscitation council. The 1998 european resuscitation council guidelines for advanced life support. *Resuscitation* 1998; 37: 81-90.

Beveridge R, Ducharme J, Janes L et al. Reliability of the canadian emergency department triage and acuity scale: interrater agreement. *Ann Emerg Med* 1999; 34: 1555-9.

American Heart Association in collaboration with the International Liaison Committee on Resuscitation (ILCOR). International guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care - A consensus on science. *Resuscitation* 2000; 46: 103-252.

Cummins RO, Hazinski MF, Baskett PJF, et al. Introduction to the international guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. A consensus on science.

SOINS INTENSIFS

Réanimation

www.americanheart.org/eccguidelines
www.erc.edu

www.americanheart.org/cpr
www.circ.ahajournals.org

Advanced Life Support Working Party of the European Resuscitation Council. Guidelines for advanced life support: a statement by the Advanced Life Support Working Party of the European Resuscitation Council. *Resuscitation* 1992; 24: 111-21.

Emergency cardiac care committee and subcommittee, American

Resuscitation 2000; 46: 3-15.

Eisenberg MS, Mengert TJ. Cardiac resuscitation. *N Engl J Med* 2001; 344: 1304-13.

De Latorre F, Nolan J, Robertson C, et al. European resuscitation council guidelines 2000 for adult advanced life support. *Resuscitation* 2001; 48: 211-21.

Fumaux T, Dussoix P, Unger PF. Réanimation cardiopulmonaire en 2001: qu'est-ce qui a changé? *Med Hyg* 2001; 59: 1046-9.

Bernard SA, Gray TW, Buist MD, et al. Treatment of Comatose Survivors of Out-of-Hospital Cardiac Arrest with Induced Hypothermia. *N Engl J Med* 2002; 346: 557-63.

Holzer M and The Hypothermia after Cardiac Arrest Study Group. Mild Therapeutic Hypothermia to Improve the Neurologic Outcome after Cardiac Arrest. *N Engl J Med* 2002; 346: 549-56.

Wenzel V, Krismer AC, Arntz HR, et al. A comparison of vasopressin and epinephrine of out-of-hospital cardiopulmonary resuscitation. *N Engl J Med* 2004; 350: 105-13.

AHA in Collaboration with International Liaison Committee on Resuscitation. Guidelines 2005 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation* 2005; 112: IV-1-IV-211.

Coudray A, Romand J-C, Treggiari M, et al. Fluid reponsiveness in spontaneously breathing patients: a review of indexes used in intensive care. *Crit Care Med* 2005; 33: 2757-62.

European Resuscitation Council. ERC Guidelines for Resuscitation 2005. *Resuscitation* 2005; 67: 157-341.

Holzer M, Bernard SA, Hachimi-Idrissi S, et al. Hypothermia after neuroprotection after cardiac arrest: systematic review and individual patient data meta-analysis. *Crit Care Med* 2005; 33: 1449-52.

Skowronski GA. Therapeutic Hypothermia After Cardiac Arrest - Not so Fast. *Crit Care Resusc* 2005; 7: 322-4.

Aberle J, Kluge S, Prohl J, et al. Hypothermie nach Reanimation durch Konduktion und Konvektion. *Intensivmedizin* 2006; 43: 37-43.

Monnet X, Rienzo N, Osman D et al. Passive leg raising predicts fluid responsiveness in the critically ill. *Crit Care Med* 2006; 34:1402-7.

Morrison LJ, Visentin LM, Kiss A, et al. Validation of a Rule for Termination of Resuscitation in Out-of-Hospital Cardiac Arrest. *N Engl J Med* 2006; 355: 478-87.

Nielsen N, Wetterslev J, Cronberg T et al. Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest. *N Engl J Med* 2013; 369: 2197-206.

Défibrillation

Dell'Orfano JT, Naccarelli GV. Update on external cardioversion and defibrillation. *Curr Opin Cardiol* 2001; 16: 54-7.

Adgey AA, Walsh SJ. Theory and practice of defibrillation: (1) Atrial fibrillation and DC conversion. *Heart* 2004; 90: 1493-8.

Hubner PJ, Gupta S, McClellan I. Simplified cardioversion service with intravenous midazolam. *Heart* 2004; 90: 1447-9.

Nurmi J, Rosenberg P, Castrén M. Adherence to guidelines when positioning the defibrillation electrodes. *Resuscitation* 2004; 61: 143-7.

Adgey AA, Spence MS, Walsh SJ. Theory and practice of defibrillation: (2) defibrillation for ventricular fibrillation. *Heart* 2005; 91: 118-

Triage

<http://www.oru-mip.fr/docs/ccmu.pdf>

Gertz MF, Bucknall TK. Triage nurses' clinical decision making. An observational study of urgency assessment. *J Adv Nurs* 2001; 34: 550-61.

Wuerz R. Emergency severity index triage category is associated with six-month survival. ESI Triage Study Group. *Acad Emerg Med* 2001; 8: 61-4.

Wuerz RC, Travers D, Gilroy N et al. Implementation and refinement of the emergency severity index. *Acad Emerg Med* 2001; 8: 170-6.

Fishman D, Guyot E, Bertin N et al. Les urgences prises d'assaut: à qui le tour? *Me Hyg* 2004; 62: 1550-3.

Tanabe P, Gimbel R, Yarnold PR et al. Reliability and validity of scores from The Emergency Severity Index version 3. *Acad Emerg Med* 2004; 11: 59-65.

Ventilation mécanique — SDRA/ARDS

Lodato RF. Oxygen toxicity. *Crit Care Clin* 1990; 6: 749-65.

Schluster DP. A physiologic approach to initiating, maintaining, and withdraw mechanical ventilatory support during acute respiratory failure. *Am J Med* 1990; 88: 268-78.

Feihl F, Perret C. Permissive hypercapnia. How permissive should we be? *Am J Respir Crit Care Med* 1994; 150: 1722-37.

Slutsky AS. Consensus conference on mechanical ventilation – January 28-30, 1993 at Northbrook, Illinois, USA. Part 1. *Intensive Care Med* 1994; 20: 64-79.

Slutsky AS. Consensus conference on mechanical ventilation – January 28-30, 1993 at Northbrook, Illinois, USA. Part 2. *Intensive Care Med* 1994; 20: 150-62.

Bernard GR, Artigas A, Brigham KL, et al. The american-european consensus conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 1994; 149: 818-24.

Corbridge TC, Hall JB. The assessment and management of adults with status asthmaticus. *Am J Respir Crit Care Med* 1995; 151: 1296-1316.

Kollef MH, Schuster DP. The acute distress syndrome. *N Engl J Med* 1995; 332: 27-37.

Thorens JB, Jolliet P, Ritz M, Chevrolet JC. Effects of rapid permissive hypercapnia on hemodynamics, gas exchange, and oxygen transport and consumption in ARDS. *Intensive Care Med* 1996; 22: 182-91.

Antonelli M, Conti G, Rocco M, et al. A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. *N Engl J Med* 1998; 339: 429-35.

Amato MBP, Barbas CSV, Medeiros DM, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. *N Engl J Med* 1998; 338: 347-54.

Artigas A, Bernard GR, Carlet J, et al. The american-european consensus conference on ARDS, part 2. *Am J Respir Crit Care Med* 1998; 157: 1332-47.

Eckert Ph, Burdet L, Liaudet L, et al. Stratégies ventilatoires actuelles du syndrome de détresse respiratoire aiguë. *Med Hyg* 1998; 56: 1920-4.

International Consensus Conferences in Intensive Care Medicine: ventilator-associated lung injury in ARDS. *Am J Respir Crit Care Med* 1999; 160: 2118-24.

The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000; 342: 1301-8.

Ware L, Matthay MA. The acute respiratory distress syndrome. *N Engl J Med* 2000; 342: 1334-49.

Gattinoni L, Tognoni G, Pesenti A, et al. Effect of prone positioning on the survival of patients with acute respiratory failure. *N Engl J Med* 2001; 345: 568-73.

Tobin MJ. Advances in mechanical ventilation. *N Engl J Med* 2001; 345: 1986-96.

Taskforce by the american college of chest physicians: Evidence-based guidelines for weaning and discontinuing ventilatory support. *Chest* 2001; 120: Suppl. 375S-395S.

Esteban A, Frutos-Vivar F, Ferguson ND, et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. *N Engl J Med* 2004; 350: 2452-60.

Malhotra A. Low-Tidal-Volume Ventilation in the Acute Respiratory Distress Syndrome. *N Engl J Med* 2007; 357: 1113-20.

Acute Respiratory Distress Syndrome. The Berlin Definition. The ARDS Definition Task Force. *JAMA* 2012; 307: 2526-2533.

Claude Guérin C, Reigner J, Richard J-C et al. Prone Positioning in Severe Acute Respiratory Distress Syndrome. *N Engl J Med* 2013; 368: 2159-68.

Intubation en cas de trauma crânien

Grande CM, Stene JK. Airway management: considerations in the trauma patient. *Crit Care Clin* 1990; 6: 37-59.

Yang KL, Tobin MJ. A prospective study of indexes predicting the outcome of trials of weaning from mechanical ventilation. *N Engl J Med* 1991; 324: 1445-50.

Walls RM. Rapid-sequence intubation in head trauma. *Ann Emerg Med* 1993; 22: 1008-11.

Bullock R, Chesnut RM, Clifton G. Guidelines for the management of severe head injury. *Eur J Emerg Med* 1996; 2: 109-27.

Ely EW, Baker AM, Dunagan DP, et al. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. *N Engl J Med* 1996; 335: 1864-9.

Koleff MH. Critical care. In: *Atyana SN, et al. (eds.) The Washington Manual of medical therapeutics*. Lippincott Williams & Wilkins, 2001; p. 195-216.

Moeschler O, Engler A. Un tournus de médecine d'urgence au cours de la formation en anesthésiologie. *Med Hyg* 1998; 56: 2368-73.

Hyperthermie

- Allen GC. Malignant hyperthermia and associated disorders. *Curr Opin Rheumatol* 1993; 5: 719-24.
- Miranda AD, Donovan LA, Schuster LL, et al. Malignant hyperthermia. *Am J Crit Care* 1997; 6: 368-76.
- Ording H, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group. Results of testing patients surviving fulminant MH and unrelated low-risk subjects. *The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand* 1997; 41: 955-66.
- Denborough M. Malignant hyperthermia. *Lancet* 1998; 352: 1131-6.
- Morrison AG, Serpell MG. Malignant hyperthermia during prolonged surgery for tumor resection. *Eur J Anaesthesiol* 1998; 15: 114-7.
- Chastonay P, Bracco D, Freymond D, Ravussin P. L'hyperthermie maligne. *Rev Med Suisse Rom* 1999; 119, 191-202.
- Denborough M. Malignant hyperthermia. *Lancet* 1998; 3; 352:1131-6.
- Ali SZ, Taguchi A, Rosenberg H. Malignant hyperthermia. *Res Clin Anaesthesiol* 2003;17: 519-33.

Brûlures

- Scheuler JJ, Munster AM. The Parkland formula in patient with burns and inhalation injury. *J Trauma* 1982; 22: 869-71.
- 4ème Conférence de consensus en réanimation et en médecine d'urgence. Choix des produits de remplissage vasculaire pour le traitement des hypovolémies chez l'adulte. *Rean Soins Intens Med Urg* 1989; 5: 295-304.
- Warden GD. Burn shock resuscitation. *World J Surg* 1992; 16: 16-23.
- Ryan CM, Schoenfeld DA, Thorpe WP, et al. Objective estimates of the probability of death from burn injuries. *N Engl J Med* 1998; 338: 362-6.

Choc cardiogénique

- Scheidt S, Wilner G, Mueller H, et al. Intra-aortic balloon counterpulsation in cardiogenic shock: report of a co-operative clinical trial. *N Engl J Med* 1973; 288: 979-84.
- Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction: incidence and mortality from a community-wide perspective, 1975 to 1988. *N Engl J Med* 1991; 325: 1117-22.
- Califf RM, Bengtson JR. Cardiogenic shock. *N Engl J Med* 1994; 330: 1724-30.
- F. Follath F, Cleland J, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. *Lancet* 2002; 360: 196-202.
- Mebazaa A, Nieminen MS, Packer M, et al - SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. *JAMA* 2007; 297: 1883-1891.

Choc anaphylactique

- Valentine MD. Insect venom allergy: Diagnosis and treatment. *J Allergy Clin Immunol* 1984; 73: 299-304.
- Bochner BS, Lichtenstein LM. Anaphylaxis. *N Engl J Med* 1991; 324: 1785-90.
- Muller U, Mosbech H, Blaauw P, et al. Emergency treatment of allergic reactions to Hymenoptera stings. *Clin Exp Allergy* 1991; 21: 281-8.
- Atkinson TP, Kaliner MA. Anaphylaxis. *Med Clin North Am* 1992; 76: 841-55.
- Muller U. Adrenaline for emergency kits; EAACI position paper. *Allergy* 1995; 50: 783-7.
- Nicklas R, Bernstein IL, Li JT, et al. The diagnosis and management of anaphylaxis. *J Allergy Clin Immunol* 1998; 101(Suppl.): S465-528.
- Project Team of the Resuscitation Council (UK). The emergency treatment of anaphylactic reactions. *J Accid Emerg Med* 1999; 16: 243-7.

SIRS - Sepsis - choc septique

- Davis JP, Chesney PJ, Want PJ, et al. Toxic-shock syndrome. *N Engl J Med* 1980; 303: 1429-35.
- The ACCP/SCCM Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Crit Care Med* 1992; 20: 864-74. Also published in: *Chest* 1992; 101: 1644-55.
- Rangel-Fausto MS, Pittet D, et al. The natural history of the syste-

- mic inflammatory response syndrome. *JAMA* 1995; 273:117-23.
- Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. *Circulation* 1997; 96 (Suppl): II-286-90.
- Case definitions for infectious conditions under public health surveillance. *Morb Mortal Wkly Rep* 1997; 46: 39.
- Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. *Circulation* 1997; 95: 1122-5.
- Zanetti G, Baumgartner JD, Glauser MP. Sepsis and septic shock. *Schweiz Med Wochenschr* 1997; 127: 489-99.
- Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. *Crit Care Med* 1999; 27: 639-60.
- Abraham E, Matthay MA, Dinarello CA, et al. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. *Crit Care Med* 2000; 28: 232-5.
- Wheeler AP, Bernard G. Treating patients with severe sepsis. *N Engl J Med* 1999; 340:207-14.
- Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med* 2001; 344: 699-709. Editorial: 2001; 344: 759-62.
- Werdan K. Intravenous immunoglobulin for prophylaxis and therapy of sepsis. *Curr Opin Crit Care* 2001; 7: 354-61.
- Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. *Crit Care Med* 2001; 29: 487-93.
- Vincent JL. Hemodynamic support in septic shock. *Intensive Care Med* 2001; 27 Suppl. 1: S80-S92.
- Matthay MA. Severe sepsis - a new treatment with both anticoagulant and antiinflammatory properties. *N Engl J Med* 2001; 344: 759-62.
- Alejandria MM, Lansang MA, Dans LF, et al. Intravenous immunoglobulin for treating sepsis and septic shock. *Cochrane Database Syst Rev* 2002; 1: CD001090.
- Anname D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA* 2002; 288: 862-71.
- Patel BM, Chittock DR, Russel JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. *Anesthesiology* 2002; 96: 576-82.
- Vincent JL, de Carvalho FB, De Backer D. Management of septic shock. *Ann Med* 2002; 34: 606-13.
- Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. *Clin Infect Dis* 2002; 34: 1084-93.
- Dhainaut JF, Laterre PF, Janes JM, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from PROWESS trial. *Crit Care* 2003; 24 april [epub ahead of print]
- Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. *N Engl J Med* 2003; 348: 138-50.
- Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definition conference. *Intensive Care Med* 2003; 29: 530-8; also published in: *Crit Care Med* 2003; 31: 1250-6.
- Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. *Crit Care Med* 2003; 31: 834-40.
- Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference. *Crit Care Med* 2003; 31: 1250-6.
- Dhainaut JF, Laterre PF, Janes JM, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from PROWESS trial. *Crit Care* 2003; 29: 894-903.
- Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis guidelines for management of sepsis and septic shock. *Crit Care Med* 2004; 32: 858-73.
- Gaieski DF, Mikkelsen ME, Band RA et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. *Crit Care Med* 2010; 38: 1045-53.

Delir auf der IPS

- Siegemund M, Massarotto P, Reuthebuch P et al. Postoperatives

Delirium: Pathophysiologie und Diagnose. Schweiz Med Forum 2011;11: 354-357.

Toxic shock syndrom

Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Recomm Rep 1997; 46: 1-55.

Oliveira DC, Tomasz A, de Lencastre H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin-resistant *Staphylococcus aureus*. Lancet Infect Dis 2002; 2: 180-9.

Coma

Höjer J. Diagnostic utility of flumazenil in coma with suspected poisoning: a double blind, randomized controlled study. Br Med J 1990; 301: 1308-11.

Geller R. Risks and benefits of therapy with flumazenil in mixed drug intoxications. Eur Neurol 1991; 31: 241-50.

Bates D. The management of medical coma. J Neurol Neurosurg Psychiatry 1993; 56: 589-98.

Enrico JF. Le coma non traumatique en pratique extrahospitalière. Schweizerische Rundschau für Medizin 1995; 45: 1321-30.

Hoffman RS. The poisoned patient with altered consciousness. JAMA 1995; 274: 562-9.

GLASGOW-Score

Teasdale G, Jennett B. Assessment of coma impaired consciousness. Lancet 1974; 2: 83.

Maladies de haute altitude

Johnson TS, Rock PB. Acute mountain sickness. N Engl J Med 1988; 319: 841-5.

Levine BD, Yoshimura K, Kobayashi T, et al. Dexamethasone in the treatment of acute mountain sickness. N Engl J Med 1989; 321: 1707-13.

Oelz O, Maggiorini M, Ritter M, et al. Nifedipine for high altitude pulmonary edema. Lancet 1989; 2: 1241-4.

Bärtsch P, Maggiorini M, Ritter M, et al. Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med 1991; 325: 1284-9.

Sutton JR, Coates G, Huston CS (eds). In: The Lake Louise Consensus on the definition and quantification of altitude illness. Queen City Printers, Burlington, Vermont, 1992.

Cook S, Duplain H, Egli M, Sartori Claudio, et al. Cédème pulmonaire de haute altitude: physiopathologie et traitement. Med Hyg 2000; 58: 1520-3.

Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001; 345: 107-14.

Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002; 346: 1631-6.

Egli M, Sartori C, Scherrer U. Les maladies aiguës liées à la haute altitude. Recommandations pour leur prise en charge et avancées expérimentales récentes. Med Hyg 2003; 61: 1007-13.

Maggiorini M, Brunner-La Rocca HP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med 2006 3; 145:497-506.

Rhabdomyolyse

Grossman RA, Hamilton RW, Morse BM, et al. Nontraumatic rhabdomyolysis and acute renal failure. N Engl J Med 1974; 291: 807-11.

Schiff HB, MacSearraigh ET, Kallmeier JC. Myoglobinuria, rhabdomyolysis and marathon running. Q J Med 1978; 47: 463-72.

Lonka L, Pedersen RS. Fatal rhabdomyolysis in marathon runner (letter). Lancet 1987; 11: 857-8.

Eiser AR, Neff MS, Slikin RF. Acute myoglobinuric renal failure. A consequence of the neuroleptic malignant syndrome. Arch Intern Med 1982; 142: 601-3.

Knochel JP. Rhabdomyolysis and myoglobinuria. Annu Ref Med 1982; 33: 435-43.

Curry SC, Chang D, Connor D. Drug- and toxin-induced rhabdomyolysis. Ann Emerg Med 1989; 18: 1068-84.

Naschitz JE, Yeshurun D, Shagrani I. Rhabdomyolysis in pneumococcal sepsis. Am J Med 1989; 87: 479-80.

Better OS, Stein JH. Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med 1990; 322: 825-9.

Shemin D, Cohn PS, Zipin SB. Pheochromocytoma presenting as

rhabdomyolysis and acute myoglobinuric renal failure. Ach Intern Med 1990; 150: 2384-5.

Torin P, Lewis P, Sevidi S, et al. Metabolic causes of myoglobinuria. Ann Neurol 1990; 27: 181-5.

Singhal PC, Kumar A, Desroches L, et al. Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia. Am J Med 1992; 92: 458-64.

Barrett SA, Mourani S, Villareal CA, et al. Rhabdomyolysis associated with status asthmaticus. Crit Care Med 1993; 21: 151-3.

Knochel JP, Moore GE. Rhabdomyolysis in malaria (letter). N Engl J Med 1993; 329: 1206-7.

Pesik MT, Otten EJ. Severe rhabdomyolysis following a viral illness: a case report and review of the literature. J Emerg Med 1996; 14: 425-8.

Vanholder R, Sever MS, Ereik E, et al. Acute renal failure related to the crush syndrome: towards an era of seismo-nephrology? Nephrol Dial Transplant 2000; 15: 1517-21.

Bedry R, Baudrimont I, Defieux G, et al. Wild-mushroom intoxication as a cause of rhabdomyolysis. N Engl J Med 2001; 345: 798-802.

Bouchama A, Knochel JP. Heat stroke. N Engl J Med 2000; 346: 1978-88.

Syndrome malin des neuroleptiques

Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142: 1137-45.

Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164: 870-6.

Électrisation

Dixon GF. The evaluation and management of electrical injuries. Crit Care Med 1983; 11: 384-7.

Carleton SC. Cardiac problems associated with electrical injury. Cardiol Clin 1995; 13: 263-6.

Hypothermie

Danzel F. Accidental hypothermia. N Engl J Med 1994; 331: 1756-60.

Handrigan MT, Wright RO, Becker BM, et al. Factors and methodology in achieving ideal delivery temperatures for intravenous and lavage fluid in hypothermia. Am J Emerg Med 1997; 15: 350-3.

Lazar HL. The treatment of hypothermia. N Engl J Med 1997; 337: 1545-7.

Walpoth BH, Walpoth-Aslan BN, Mattle HP, et al. Outcome of survivors of accidental deep hypothermia and circulatory arrest treated with extracorporeal blood warming. N Engl J Med 1997; 337: 1500-5.

Goodenberger D. Cold induced illness. In: Aha SN, et al. (eds.). The Washington Manual of medical therapeutics. Lippincott Williams & Wilkins, 2001: 541-3.

Murray P, Hall J. Hypothermia. In: Hall J, et al. (eds). Principles of Critical Care. McGraw-Hill, 1998: p. 1645-55.

Maladie du caisson -- Decompression

Schröder S, Lier H, Wiese S- Der Tauchunfall. Notfallmedizinische Versorgung des schweren Tauchunfalls. In: Der Anästhesist. Springer Medizin Verlag 2004.

INTOXICATIONS

- Centre anti-poison du Québec: Tél: 1-800-563-5060; ou (418) 656-8090.
- Textbook: Tintinalli, Rothstein & Krome (ed.). Emergency medicine, a comprehensive study guide. 5th edition.
- Bulletin toxicologique (avril 1999): www.ctq.ca/avril99.pdf
- Done AK. Salicylate intoxication: significance of salicylate in blood in cases of acute ingestion. Pediatrics 1960; 26: 800-7.
- Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 1975; 55: 871-6.
- Rumack BH, Peterson RC, Koch GG, et al. Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med 1981; 141: 380-5.
- Cohen L, Kitzes R. Magnesium sulfate and digitalis-toxic arrhythmias. JAMA 1983; 249: 2808-10.
- Schwartz JA, Koenigsberg MD. Naloxone-induced pulmonary edema. Ann Emerg Med 1987; 16: 1294-6.
- Maio RF, Gaukel B, Freeman B. Intralingual injection for narcotic-induced respiratory depression. Ann Emerg Med 1987; 16: 572-3.
- Smilkstein MJ, Knapp GL, Kulig KW, et al. Efficacy of oral N-

acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). *N Engl J Med* 1988; 319: 1557-62.

Hollander JE. The management of cocaine-associated myocardial ischemia. *N Engl J Med* 1995; 333: 1267-72.

Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. *Ann Emerg Med* 1995; 26: 195-201.

Thom SR, Taber RL, Mendiguren II, et al. Delayed neurological sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. *Ann of Emerg Med* 1995; 25: 474-80.

Kind B, Krähenbühl S, Wyss PA et al. Dosierung von N-Acetylcystein bei akuter Vergiftung mit Paracetamol. *Schweiz Rdschau Med Praxis* 1996; 85: 935-8.

Ellenhorn MJ. (ed.). *Ellenhorn's Medical Toxicology*. Williams & Wilkins, 1997.

Seyffart G. (ed.). *Poison index. The treatment of acute intoxication*. 4. Edition, Pabst science publishers, 1997.

Goldfrank LR, et al. (eds.). *Goldfrank's Toxicologic Emergencies*. 6th edition, Appleton & Lange, Stanford 1998.

Hirsh J. Reversal of the anticoagulant effects of warfarin by vitamin K1. *Chest* 1998; 114: 1505-8.

Lekin JB, Paloucek FP. (eds.). *Poisoning & Toxicology Compendium*. Lexi-Comp, Hudson OH 1998.

American Academy of Clinical Toxicology (AACT), European Association of Poisons Centers and Clinical Toxicologists (EAP-CCT): Position statements: gut decontamination. *J Toxicol Clin Toxicol* 1997; 35: 695-762.

American Academy of Clinical Toxicology (AACT), European Association of Poisons Centres and Clinical Toxicologists (EAP-CCT): Position statements and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. *J Toxicol Clin Toxicol* 1999; 37: 731-51.

Olson KR. (ed.). *Poisoning and drug overdoses*. 3rd edition. Appleton & Lange, Stanford CT 1999.

Guidelines 2000 for cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 8: advanced challengers in resuscitation section 2: Toxicology in ECC. *Circulation* 2000; 102 (Suppl. 1): I223-8.

Woo OF, Mueller PD, Olson KR, et al. Shorter duration of oral N-acetylcysteine therapy for acute acetaminophen overdose. *Ann Emerg Med* 2000; 35: 363-8.

Lange RA, Hillis L. Cardiovascular complications of cocaine use. *N Engl J Med* 2001; 345: 351-8.

Meier-Abt PJ, Kupferschmidt H. Dekontamination und wichtigste Antidota. *Schweiz Med Forum* 2001; 1: 402-5.

Albertson TE, Dawson A, de Latorre F, et al. Tox-ACLS: Toxicologic-oriented advanced cardiac life support. *Ann Emerg Med* 2001; 37 (4. Suppl.): S78-90.

Wallace CI, Dargan PI, Jones AL. Paracetamol overdose: an evidence based flowchart to guide management. *Emerg Med J* 2002; 19: 202-5.

Weber JE, Shofar FS, Larkin GL, et al. Validation of a brief observation period for patients with cocaine-associated chest pain. *N Engl J Med* 2003; 348: 510-7.

Weaver LK, Valentine KJ, Hopkins RO. Carbon Monoxide Poisoning. Risk Factors for Cognitive Sequelae and the Role of Hyperbaric Oxygen. *Am J Respir Crit Care Med* 2007; 176: 491-7.

CARDIOLOGIE

ÉCG

Kossman CE. The normal electrocardiogram. *Circulation* 1953; 8: 929.

Hiss RG, Lamb LE, Allen MF. Electrocardiographic findings in 67375 asymptomatic patients. *Am J Cardiol* 1960; 6: 200.

Wasserburger RH, Alt WJ, Lloyd CJ. The normal RS-T segment elevation variant. *Am J Cardiol* 1961; 8: 184.

Warner RA. Recent advances in the diagnosis of myocardial infarction. *Cardiol Clin* 1987; 5: 381-92.

Wellens HJJ, Conover MB. (eds.). *The ECG in emergency decision making*. Philadelphia Saunders 1992.

Toubou P, Lefkiefre J, Fontaine F, et al. (eds.). In: *Les troubles du rythme cardiaque*. Editions Maloine 1993.

Chou T. (ed.). In: *Electrocardiography in Clinical Practice*. W.B. Philadelphia Saunders Company, 1996.

Scarbossa EB, Pinski SL, Barbagelata A, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 Investigators. *N Engl J Med* 1996; 334: 481-7.

Sztajzel J, Urban P. Early and late Q wave regression in the setting of acute myocardial infarction. *Heart* 2000; 83: 708-10.

Lewis GD, Holmes CH, Holmavang A et al. Q 48-year-old man with chest pain followed by cardiac arrest. *N Engl J Med* 2007; 356: 1153-62.

Syndrome du takotsubo

(cardiomyopathie de stress ou transient left ventricular apical ballooning)

Haslett C et al. *Davidson Médecine Interne, Principes et Pratique*. Maloine Editions, 2004, 1267

Miller TH, Kruse JE. Evaluation of syncope. *Am Fam Physician*. 2005; 72: 1492-500.

Bybee KA et al. Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. *Ann Intern Med* 2004; 141: 858-65.

Wittstein IS et al. Neurohumoral Features of Myocardial Stunning due to sudden emotional stress. *N Engl J Med* 2005; 352: 539-548.

Akashi YJ et al. The clinical features of takotsubo cardiomyopathy. *Q J Med* 2003; 96: 563-573.

Arythmies

Dancy M, Camm AJ. Misdiagnosis of chronic recurrent ventricular tachycardia. *Lancet* 1985; 8450: 320-3.

Stewart R, et al. Wide complex tachycardia: Misdiagnosis and outcome after emergency therapy. *Ann Int Med* 1986; 104: 766-71.

Griffith MJ, Ward DE, Linker NJ, Camm AJ. Adenosine in the diagnosis of broad complex tachycardia. *Lancet* 1988; 8587: 672-75.

Wellens HJJ, Brugada P. Treatment of cardiac arrhythmias: When, how and where? *J Am Coll Cardiol* 1989; 14: 1417-28.

Adamec R, Conti F, Zimmermann M, et al. Les arythmies. In: *Urgences Médicales*. Restellini A, et al. (eds.). Editions Médecine et Hygiène, 1997, p: 104-33.

Torsade de pointes

Vukmir BB. Torsades de pointes: a review. *Am J Emerg Med* 1991; 9: 250-5.

Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes. Mechanisms and management. *Drugs* 1994; 47: 51-65.

Roden DM. A practical approach to torsade de pointes. *Clin Cardiol* 1997; 20: 285-90.

Viskin S. Long QT syndromes and torsade de pointes. *Lancet* 1999; 354: 1625-33.

Delacretet E. Médicaments et long QT. *Forum Med Suisse* 2007; 7: 814-9.

Dissection aortique

De Baake ME, Herly WS, Cooley DA, et al. Surgical management of dissecting aneurysms of the aorta. *J Thorac Cardiovasc* 1965; 49: 130-49.

Daily PO, Trueblood HW, Stinson EB, et al. Management of acute aortic dissections. *Ann Thorac Surg* 1970; 10: 237-47.

Slater EE, DeSanctis RW. The clinical recognition of dissecting aortic aneurysm. *Am J Med* 1976; 60: 625-33.

Smith DC, Jang GC. Radiological diagnosis of aortic dissection. In: *Doroghazi RM, Slater EE (eds.). Aortic dissection*. New York: Mc Graw-Hill 1983; 71: 71-132.

Greenwood WR, Robinson MD. Painless dissection of the thoracic aorta. *Am J Emerg Med* 1986; 4: 330-3.

DeSanctis RW, Doroghazi RM, Austen WG, et al. Aortic dissection. *N Engl J Med* 1987; 317: 1060-7.

Erbel R, Engberding R, Daniel W, et al. Echocardiography in diagnosis of aortic dissection. *Lancet* 1989; 1: 457-61.

Crawford ES. The diagnosis and management of aortic dissection. *JAMA* 1990; 264: 2537-41.

Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA Guidelines for the clinical application of echocardiography. *Circulation* 1997; 95: 1686-1744.

Elefteriades JA, Lovoulos MA, Tellides G, et al. Management of descending aortic dissection. *Ann Thorac Surg* 1999; 67: 2002-5; discussion 2014-9.

Juvonen T, Ergin MA, Galla JD, et al. Risk factors for rupture of chronic type B dissections. *J Thorac Cardiovasc Surg* 1999; 117: 776-86.

Hagan PG, Nienaber CA, Isselbacher EM, et al. The international

registry of acute aortic dissection (IRAD). New insights into an old disease. *JAMA* 2000; 283: 897-903.

Pepi M, Campodonico J, Galli C, et al. Rapid diagnosis and management of thoracic aortic dissection and intramural haematoma: a prospective study of advantages of multiplane vs. biplane transoesophageal echocardiography. *Eur J Echocardiogr* 2000; 1: 72-9.

Erbel R, Alfonso F, Boileau C, et al. Diagnosis and management of aortic dissection. *Eur Heart J* 2001; 22: 1642-81.

Kawahito K, Adachi H, Yamaguchi A, et al. Preoperative risk factors for hospital mortality in acute type A aortic dissection. *Ann Thorac Surg* 2001; 71: 1239-43.

Lederle AF, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. *N Engl J Med* 2002; 346: 1437-44.

Syndrôme de BRUGADA

Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. *Am J Coll Cardiol* 1992; 20: 1391-96.

Brugada P, Brugada R, Brugada J. The Brugada syndrome. *Curr Cardiol Rep* 2000; 2: 507-14.

Brugada J, Brugada R, Antzelevitch C, et al. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. *Circulation* 2002; 105: 73-8.

Voie veineuse centrale, SWAN-GANZ

O'Quin R, Marini JJ. Pulmonary artery occlusion pressure: clinical physiology, measurement, and interpretation. *Am Rev Respir Dis* 1983; 128: 319-26.

Sharkey SW. Beyond the wedge: clinical physiology and the Swan-Ganz catheter. *Am J Med* 1987; 83: 111-22.

Perret C, Tagan D, Feihl F. (eds.). *Le cathétérisme cardiaque droit en soins intensifs*. Arnette 1993.

Sandham JD, Hull RD, Brant RF, et al.; Canadian Critical Care Clinical Trials Group. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. *N Engl J Med* 2003; 348: 5-14.

Syndrôme coronarien aigu

The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised, placebo-controlled international trial. *Eur Heart J* 1985; 6: 199-226.

Yusuf S, Peto R, Lewis J, Collins R, et al. Beta blockade during and after myocardial infarction: an overview of the randomised trials. *Prog Cardiovasc Dis* 1985; 27: 335-71.

ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. *Lancet* 1986; ii: 57-66.

Findings from aspirin component of the ongoing Physicians' Health Study. *N Engl J Med* 1988; 318: 262-4.

ISIS-2 (second International Study of Infarct Survival). Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. *Lancet* 1988; 2: 349-60.

The Steering Committee of the Physicians' Health Study Research Group. Preliminary report. Findings from the aspirin component of the ongoing Physicians' Health Study. *N Engl J Med* 1988; 318: 262-4.

Braunwald E. Unstable angina: a classification. *Circulation* 1989; 80: 410-4.

ACC/AHA Guidelines for early management of patients with acute myocardial infarction. *Circulation* 1990; 82: 664-707.

GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. *Lancet* 1990; 336: 65-71.

ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. *Lancet* 1992; 339: 753-70.

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; 344: 1383-89.

Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. *J Am Coll Cardiol* 1995; 26: 313-8.

White HD et al. (for the GUSTO I Investigators). Age and outcome with contemporary thrombolytic therapy: results from the GUSTO I Trial. *Circulation* 1996; 94: 1826-33.

Braunwald E. (ed.). *Heart disease: a textbook of cardiovascular medicine*. Philadelphia W.B. Saunders Company, 1997.

Cohen M, Demers CH, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. *N Engl J Med* 1997; 337: 447-52.

Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). (Abstr.) *Am J Cardiol* 1997; 79: 115-19.

The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatid in patients with acute coronary syndromes. *N Engl J Med* 1998; 339: 436-43.

The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limiting by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina pectoris and non-Q-wave myocardial infarction. *N Engl J Med* 1998; 338: 1488-97. [Erratum: *N Engl J Med* 1998; 339: 414].

The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. *N Engl J Med* 1998; 338: 1498-505.

ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. *Lancet* 1999; 354: 716-22.

Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 1999; 34: 890-911.

Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. *Circulation* 1998; 97: 1195-1206.

Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis infarction (TIMI) 11 B trial. *Circulation* 1999; 100: 1602-8.

FRAGmin and fast revascularisation during instability in coronary artery disease investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. *Lancet* 1999; 354: 708-15.

FRAXIS study group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction. *Eur Heart J* 1999; 20: 1553-62.

The ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. *Lancet* 1999; 354: 716-22.

Zijlstra F, Hoornstje JCA, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. *N Engl J Med* 1999; 341: 1413-9.

Gan SC, Beaver SK, Houck PM, et al. Treatment of acute myocardial infarction and 30-day mortality among women and men. *N Engl J Med* 2000; 343: 8-15.

Hamm CW, Braunwald E. A classification of unstable angina revisited. *Circulation* 2000; 102: 118-22.

Monrad ES. Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction. *Am J Cardiol* 2000; 85: 2C-9C.

Scull GS, Martin JS, Weaver WD, et al. Early angiography versus conservative treatment in patients with non-ST elevation acute myocardial infarction: MITI Investigators. *Myocardial Infarction Triage and Intervention*. *J Am Coll Cardiol* 2000; 35: 895-902.

Yeghiazarians Y, Braustein JB, Askari A, Stone P. Unstable Angina pectoris. *N Engl J Med* 2000; 342: 101-14.

Yusuf S, et al. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on death from cardiovascular events in high-risk patients. *N Engl J Med* 2000; 342,145-53.

Hamm C, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines. *Lancet* 2001; 358: 1533-8.

Ohman EM, Harrington RA, Cannon CP, et al. Intravenous thrombo-

- lysis in acute myocardial infarction. *Chest* 2001; 119 (Suppl): 253S-277S.
- Schwartz GG, Oliver MF, Ezekowitz MD, et al. Effects of Atorvastatin on early ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled study. *JAMA*; 2001; 285: 1711-8.
- Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. *Lancet* 2001; 357: 1915-24.
- The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. *Lancet* 2001; 358: 605-13.
- The Clopidogrel in unstable angina to prevent recurrent events trial investigators (CURE). Effects of Clopidogrel in addition to Aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001; 345: 494-502.
- Avlives RJ, Askari AT, Lindahl B, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. *N Engl J Med* 2002; 346: 2047-52.
- Fox KAA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations on practice and outcome. *Eur Heart J* 2002; 23: 1177-89.
- Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST segment elevation. The Task Force on the management of acute coronary syndromes of the European Society of Cardiology. *Eur Heart J* 2002; 23: 1809-40.
- Braunwald E, Antman EM, Beasley JW et al. ACC/AHA 2002 Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002. *Circulation* 2002; 106: 1893-900 (<http://www.acc.org/clinical/guidelines/unstable/unstable.pdf>).
- Budaj A, Yusuf S, Mehta SR, et al. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. *Circulation* 2002; 106: 1622-6.
- Steinhebel SR, Berger PB, Mann JF for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. *JAMA* 2002; 288: 2411-20.
- Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. *N Engl J Med* 2003; 349: 733-42.
- Brennan M-L, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. *N Engl J Med* 2003; 349: 1595-604.
- Fox K. The EUROPA trial. *Lancet* 2003; 362: 1936-7.
- Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. *Circulation* 2003; 108: 1560-6.
- Pfeffer MA, McMurray JVV, Velazquez EJ, et al. Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003; 349: 1893-906.
- Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 2003; 348: 1309-1321.
- Van de Werf F, Ardissino D, Betriu A, et al. The Task Force of Management of acute myocardial infarction of the European society cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of acute myocardial infarction of the European Society of cardiology. *Eur Heart J* 2003; 24: 28-66.
- Cannon CH, Braunwald E, McCabe C, et al. Comparison of moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004; 350: 1495-504.
- Nallamothu BK, Bradley EH, Krumholz HM. Time to Treatment in Primary Percutaneous Coronary Intervention. *N Engl J Med* 2007; 357:1631-1638.
- The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. *Eur Heart J* 2008; 29, 2909-45.
- Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. *N Engl J Med* 2009;361: 1045-57.
- Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2011; 32: 2999-3054.
- Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* 2011; 364: 11-21.
- Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). *Eur Heart J* 2012; 33: 2569-619.

Tachycardie à QRS fin

- Kastor JA. Multifocal atrial tachycardia. *N Engl J Med* 1990; 322: 1713-1717.
- Murgatroyd FD, Camm AJ. Atrial Fibrillation for the clinician. In: Camme AJ, (ed.). Clinical approaches to tachyarrhythmias. Volume 4. Futura Publishing Company Inc, Armonk, NY, 1995.
- Schläpfer J, Goy JJ. Urgences rythmiques. *Praxis* 1995; 84: 1314-20.
- Saoudi N, Cosio F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases. *European Heart Journal* 2001; 22: 1162-82.
- Bloomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—executive summary. *Circulation* 2003; 108: 1871-909. (<http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-SVA-FT.pdf>)

Fibrillation atriale

- Dunn M, Alexander J, de Silva R, Hildner F. Antithrombotic therapy in atrial fibrillation. *Chest* 1989; 95 (Suppl.): 118S-127S.
- Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. *Lancet* 1989; 1: 175-9.
- Weinberg DM, Mancini J. Anticoagulation for cardioversion of atrial fibrillation. *Am J Cardiol* 1989; 63: 745-6.
- The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *N Engl J Med* 1990; 323: 1505-11.
- Laupacis A, Albers G, Dunn M, et al. Antithrombotic therapy in atrial fibrillation. *Chest* 1992; 102 (Suppl. 4): 426S-433S.
- Pritchett ELC. Management of atrial fibrillation. *N Engl J Med* 1992; 326: 1264-71.
- The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. In: clinical features of patients at risk. *Ann Intern Med* 1992; 116: 1-5.
- Gage BF, Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. *JAMA* 1995; 274: 1839-45.
- Prytowsky EN, Benson JR, Fuster V, et al. Management of patients with atrial fibrillation. *Circulation* 1996; 93: 1262-77.
- Van Gelder IC, Crijns HJGM, Tieleman RG, et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. *Arch Intern Med* 1996; 156: 2585-92.
- Kaufmann W, (ed.). Internistische Differenzialdiagnostik. Entscheidungsprozesse in Flussdiagrammen. Schattauer, 4. Auflage 1997.
- Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. *Ann Intern Med* 1997; 126: 615-20.
- Zimmermann M. Les traitements de la fibrillation auriculaire. *Med Hyg* 1997; 55: 445-9.
- Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. *Circulation* 1998; 98: 946-52.
- Hart RG, Benavente O, McBride R et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med* 1999; 131: 492-501.
- Steeds RP, Birchall AS, Smith N, et al. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. *Heart* 1999; 82: 170-

Hart RG, Pearce LA, Rothbart RM et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. *J Am Coll Cardiol* 2000; 35: 183-7.

Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. *N Engl J Med* 2000; 342: 913-20.

Singh S, Zoble RG, Yellen L, et al. Efficacy and safety on oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. *Circulation* 2000; 102: 2385-90.

Fuster V, Rydén LE, Asinger RW, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. *J Am Coll Cardiol* 2000; 35: 183-7.

ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: executive summary. *Eur Heart J* 2001; 22: 1852-923.

Falk RH. Atrial fibrillation. *N Engl J Med* 2001; 344: 1067-87.

Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA* 2001; 285: 2864-70.

Klein AL, Grimm RA, Murray RD et al. Use of transeptal echocardiography to guide cardioversion in patients with atrial fibrillation. *N Engl J Med* 2001; 344: 1411-20.

The assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT)-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. *Lancet* 2001; 358: 605-13.

Stewart S, Hart CL, Hole DJ et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am J Med* 2002; 113: 359-64.

Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med* 2002; 347: 1825-33.

Levy S, Camm AJ, Saksena S et al. International consensus on nomenclature and classification of atrial fibrillation: A collaborative project of the Working Group on Arrhythmias and the Working Group of Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *J Cardiovasc Electrophysiol* 2003; 14: 443-5.

Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. *Circulation* 2004; 109: 1973-80.

De Denus S, et al. Rate vs. Rhythm Control in Patients with Atrial Fibrillation. *Arch Intern Med* 2005; 165: 258-262.

Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus Sotalol for Atrial Fibrillation. *N Engl J Med* 2005; 352: 1861-72.

Fuster V et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: Executive Summary. *Circulation* 2006; 114: 700-52.

January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2014 Mar 28. pii: S0735-1097(14)01739-2. doi: 10.1016/j.jacc.2014.03.021.

Meier B, Blaauw Y, Khattab AA et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. *Europace* 2014; 16: 1397-416.

Tachycardie ventriculaire, QRS larges

Wellens HJJ, Bar FWHM, Lie KI. The value of the electrocardiogram in the differential diagnosis of tachycardia with a widened QRS complex. *Am J Med* 1978; 64: 27-33.

Wellens HJJ, Bar FW, Vanagt FJ, et al. The differentiation between ventricular tachycardia and supraventricular tachycardia with aberrant conduction: the value of the 12-lead electrocardiogram. In: Wellens HJJ, Kulbertus HE (eds). What's New in Electrocardiography. Boston: Nijhoff 1981; p: 184-99.

Wellens HJJ, Brugada P. Diagnosis of ventricular tachycardia from the 12-lead electrocardiogram. *Cardiol Clin* 1987; 5: 511-25.

Tchou P, Young P, Mahmud R, et al. Useful clinical criteria for the diagnosis of ventricular tachycardia. *Am J Med* 1988; 84: 53-6.

Josephson ME, Wellens HJJ. Differential diagnosis of supraventricular tachycardia. *Cardiol Clin* 1990; 8: 411-42.

Burgada P, Brugada J, Mont LL, et al. A new approach to the differential diagnosis of regular tachycardia with a wide QRS complex. *Circulation* 1991; 83: 1649-59.

Wyse DG. Pharmacologic therapy in patients with ventricular tachyarrhythmias. *Cardiol Clin* 1993; 11:65-83.

Ganz LI, Friedmann P. Supraventricular tachycardia. *N Engl J Med* 1995; 332: 162-73.

Vukmir RB. Cardiac arrhythmia therapy. *Am J Emerg Med* 1995; 13: 459-70.

Intervalle QT - Long QT syndrome

Bazett HC. An analysis of the time relations of electrocardiograms. *Heart* 1920; 7: 353-70.

Hodges M, Salerno D, Erlen D. Bazett's QT correction reviewed. Evidence that a linear QT correction for heart ist better [Abstract]. *J Am Coll Cardiol* 1983; 1: 694.

Schwartz PJ. Idiopathic long QT syndrome: progress and questions. *Am Heart J* 1985; 109: 399-411.

Campbell CJC, Yusuf K, Moore M, et al. Importance of lead selection in QT interval measurement. *Am J Cardiol* 1988; 61: 83-87.

Day CP, James OF, Budler TJ, et al. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. *Lancet* 1993; 341: 1423-8.

Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome. An Update. *Circulation* 1993; 88: 782-4.

Roden DM, Lazzara R, Rosen M, et al. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps and future directions. *Circulation* 1996; 94: 1996-2012.

Reilly JG, Aiyis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. *Lancet* 2000; 355: 1048-52.

Delacretet E. Médicaments et long QT. *Forum Med Suisse* 2007; 7: 814-9.

Syndromes de préexcitation

Wolff L, Parkinson J, White PD. Bundle-branch block with short P-R interval in healthy young people prone to paroxysmal tachycardia. *Am Heart J* 1930; 5: 685-704.

Campbell RW, Smith RA, Gallagher JJ, et al. Atrial fibrillation in the preexcitation syndrome. *Am J Cardiol* 1977; 40: 514-20.

Gallagher JJ, Smith WM, Kasell JH, et al. Role of Mahaim fibers in cardiac arrhythmias in man. *Circulation* 1981; 64: 176-89.

Bardy GH, Packer DL, German LD, et al. Preexcited reciprocating tachycardia in patients with Wolff-Parkinson-White syndrome: incidence and mechanisms. *Circulation* 1984; 70: 377-91.

Guize L, Soria R, Chauat JC, et al. Prevalence and course of Wolff-Parkinson-White syndrome in a population of 138,048 subjects. *Ann Med Interne (Paris)* 1985; 136: 474-8.

Waspe LE, Brodman R, Kim SG, et al. Susceptibility to atrial fibrillation and ventricular tachyarrhythmia in the Wolff-Parkinson-White syndrome: role of the accessory pathway. *Am Heart J* 1986; 112: 1141-52.

Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. *N Engl J Med* 1991; 324: 1605-11.

Gaita F, Giustetto C, Riccardi R, et al. Wolff-Parkinson-White syndrome. Identification and management. *Drugs* 1992; 43: 185-200.

Gallay P, Grolleau R, Nicolai P. Les préexcitations ventriculaires. In: Touboul P, et al. (eds). Les troubles du rythme cardiaque. Paris Editions Maloine 1993, p: 141-54.

Oren JW IV, Beckman KJ, McClelland JH, et al. A functional approach to the preexcitation syndromes. *Cardiol Clin* 1993; 11: 121-149.

Ganz L, Friedman PL. Supraventricular tachycardia. *N Engl J Med* 1995; 332: 162-73.

Basson CT. A molecular basis for Wolff-Parkinson-White Syndrome. *N Engl J Med* 2001; 344: 1861-4.

Gollob MH, Green MS, Tang ASL, et al. Identification of a gene responsible for familial Wolff-Parkinson-White Syndrome. *N Engl J Med* 2001; 344: 1823-31.

Pappone C, Santinelli V, Manguso F, et al. A randomized of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. *N Engl J Med* 2003; 349: 1803-11.

Bloc atrio-ventriculaire

Wagner GS, Waugh RA, Ramo NW. (eds.). In: Cardiac arrhythmias. Churchill Livingstone 1983, p: 217-30.

Wagner GS. (ed.). In: Marriot's Practical electrocardiography, 9th ed. Williams & Wilkins 1994, p: 388-94.

Péricardite et tamponnade

- Spodick DH. Differential diagnosis of acute pericarditis. *Prog Cardiovasc Dis* 1971; 14: 192-209.
- Marini PV, Hull AR. Uremic pericarditis: a review of incidence and management. *Kidney Int Suppl* 1975; 2: 163-6.
- Spodick DH. Arrhythmias and pericardial disease. *Am J Cardiol* 1984; 53: 285.
- Spodick DH. Pericarditis, pericardial effusion, cardiac tamponade and constriction. *Crit Care Clin* 1989; 5: 455-76.
- Battle RW, Le Wintler MM. The evaluation and management of pericardial disease. *Curr Opin Cardiol* 1990; 5: 331-9.
- Spodick DH. Pericardial disease. *Mayo Clin Proc.* 1992; 67: 201-2.
- Zayas R, Anguita M, Torres F, et al. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. *Am J Cardiol* 1995; 75: 378-82.
- Marinella MA. Acute pericarditis. *Am Fam Phys* 1998; 57: 702-4.
- Adler Y, Finkelstein Y, Guindo J, et al. Colchicine treatment for recurrent pericarditis. A decade of experience. *Circulation* 1998; 97: 2183-5.
- Longo M, Jaffe CC. Electric alternans. *N Engl J Med* 1999; 341: 2060.
- Spodick DH. Acute cardiac tamponade. *N Engl J Med* 2003; 349: 684-90.
- Lange RA, Hillis LD. Clinical practice. Acute pericarditis. *N Engl J Med* 2004; 351:2195.
- Maisch B, Seferovic PM, Ristic AD, et al. Guidelines on the diagnosis and management of pericardial disease: The task force on the diagnosis and management of pericardial disease of the European Society of Cardiology. *European Heart Journal* 2004; 25:587.
- Imazio M, Bobbio M, Cecchi Enrico et al. Colchicine in addition to conventional therapy for acute pericarditis. Results of the Colchicine for acute Pericarditis (COPE) trial. *Circulation* 2005; 112: 2012-2016.
- Imazio M, Bobbio M, Cecchi Enrico et al. Colchicine as first-choice therapy for recurrent pericarditis; results of the CORE (Colchicine for Recurrent pericarditis) trial. *Arch Intern Med.* 2005; 165: 1987-1991.

Maladie thromboembolique veineuse - MTEV (TVP, EP)

- Hughes GRV. Thrombosis, abortion, cerebral disease and the lupus anti-coagulant. *BMJ* 1983; 287: 1088-9.
- Hughes GRV, Harris EN, Gharavi AE. The anticardiolipine syndrome. *J Rheumatol* 1986; 13: 486-9.
- Bernard C, de Moerloose P. Anticorps anticardiolipine et thrombose. *Med Hyg* 1990; 48: 166-9.
- Bounameaux H, Chevrollet JC. Le rôle de la thrombolyse dans le traitement de l'embolie pulmonaire. *Schweiz Med Wschr* 1991; 121: 1654-7.
- Stein PD, Perrin ML, Hales CA, et al. Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. *Chest* 1991; 10: 598-603.
- Lutter K, Kerr T, Roedersheimer L, et al. Superficial thrombophlebitis diagnosed by duplex scanning. *Surgery* 1991; 10: 42-6.
- Perrier A, Bounameau H, Morabia A, et al. Contribution of Plasma D-dimer and lower limb venous ultrasound to the diagnosis of pulmonary embolism: a decision analysis. *Am Heart J* 1994; 127: 624-35.
- Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. *N Engl J Med* 1994; 330: 518-22.
- Ginsberg JS, Wells PhS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. *Blood* 1995; 86: 3685-91.
- Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. *Arch Intern Med* 1995; 155: 601-7.
- Bounameaux H, de Moerloose Ph, Sarasin FP. Optimal duration of oral anticoagulation therapy following deep vein thrombosis of lower limbs. *Blood Coag Fibrinol* 1996; 7: 507-14.
- Cavenagh JD, Colvin BT. Guidelines for the management of thrombophilia. *Postgrad Med J* 1996; 72: 87-94.
- Ginsberg JS. Management of venous thromboembolism. *N Engl J Med* 1996; 335: 1816-28.
- Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. *N Engl J Med* 1996; 334: 677-81.
- Perrier A, Bounameaux H, Morabia A, et al. Diagnosis of pulmonary embolism by a decision analysis-based strategy including clinical probability D-dimer levels, and ultrasonography: a management study. *Arch Intern Med* 1996; 156: 531-6.
- Büller HR, Gent M, Gallus AS, et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. *N Engl J Med* 1997; 337: 657-62.
- Dalen JE, Alpert JA. Thrombolytic therapy for pulmonary embolism: is it effective? is it safe? *Arch Intern Med* 1997; 157: 2550-6.
- Schulman S, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. *N Engl J Med* 1997; 336: 393-8.
- Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. *Lancet* 1997; 350: 1795-8.
- Büller H, ten Cate JW. Primary venous thromboembolism and cancer screening. *N Engl J Med* 1998; 338: 1221-2.
- Hyers TN, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. *Chest* 1998; 114(Suppl.): 561S-78S.
- Sorensen HT, Møllemlær L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. *N Engl J Med* 1998; 338: 1169-74.
- Bounameaux H, Beer J, Blättler W, et al. Le traitement ambulatoire de la thrombose veineuse profonde: prise de position d'un comité d'experts. *Bull Med Suisses* 1999; 80: 405-6.
- Huisman MV, Rosendaal RF. Thrombophilia. *Curr Opin Hematol* 1999; 6: 291-7.
- Perrier A, Desmarais S, Miron MJ, et al. Non-invasive diagnosis of venous thromboembolism in outpatients including clinical probability, D-dimer and ultrasonography. *Lancet* 1999; 353: 190-5.
- Wells PS, Anderson DR, Ginsberg J. Assessment of deep vein thrombosis or pulmonary embolism by the combined use of clinical model and noninvasive diagnostic tests. *Semin Thromb Hemost* 2000; 26: 643-56.
- Bounameaux H, de Moerloose Ph, Perrier A. Diagnostic de la thrombose veineuse profonde et de l'embolie pulmonaire. *Med Hyg* 2000; 58: 161-9.
- Perrier A, Bounameaux H. Cost-effective diagnosis of deep vein thrombosis and pulmonary embolism. *Thromb Haemost* 2001; 86: 475-87.
- Sixth ACCP Consensus Conference on antithrombotic therapy. *Chest* 2001; 119 (Suppl. 1): 1S-336S.
- Wicki J, Perreger TV, Junod AV, et al. Assessing clinical probability of pulmonary embolism in the emergency ward: a simple score. *Arch Intern Med* 2001; 161: 92-7.
- Goldhaber SZ. Thrombolysis for pulmonary embolism. *N Engl J Med* 2002; 347: 1131-2.
- Konstantinides S, Geibel A, Heusel G. Heparin plus Alteplase compared with heparin alone in patients with submassive pulmonary embolism. *N Engl J Med* 2002; 347: 1143-50.
- Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. *N Engl J Med* 2003; 348: 1425-34.
- Kearon C, Ginsberg JS, Kovacs M, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. *N Engl J Med* 2003; 349: 631-9.
- Crowther MA, Ginsberg JS, Math JJ, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with antiphospholipid antibody syndrome. *N Engl J Med* 2003; 349: 1133-8.
- Fedullo PF, Tapson VF. The evaluation of suspected pulmonary embolism. *N Engl J Med* 2003; 349: 1247-56.
- Superficial thrombophlebitis treated by enoxaparin Study Group. A pilot randomised double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. *Arch Intern Med* 2003; 163: 1657-63.
- Wells PA, Anderson DR, Rodger M, et al. Evaluation of d-dimer in the diagnosis of suspected deep-vein thrombosis. *N Engl J Med* 2003; 349: 1227-35.
- The Matise Investigators. Subcutaneous Fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. *N Engl J Med* 2003; 349: 1695-702.
- Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. *N Engl J Med* 2004; 351: 268-77.
- Kyrle P, Minar E, Bialonczyk C et al. The risk of recurrent venous thromboembolism in men and women. *N Engl J Med* 2004; 350: 2558-63.

- Antithrombotische und thrombolytische Behandlung: Internationale EBM-Guidelines, kommentiert von Schweizer Experten. The 7th ACCP Conference on Antithrombotic and thrombolytic therapy. Swiss Med Forum 2005 (Suppl 27):1-48S.
- Perrier A, Roy P-M, Sanchez O, et al. Multidetector-Row Computed Tomography in Suspected Pulmonary Embolism. *N Engl J Med* 2005; 352: 1760-8.
- Traitement antithrombotique et thrombolytique: Commentaires des experts suisses concentrant les «EBM-guidelines» internationales. 7th Conference on antithrombotic and thrombolytic therapy. Swiss Med Forum 2005 (Suppl 28): 1-48S.
- Jeanerret Ch, Baidi Th, Jenelten R. Die oberflächliche Thrombophlebitis: ein Überblick. *Schweiz Med For* 2006; 6: 190-195.
- The van Gogh Investigators. Idraparinux versus Standard Therapy for Venous Thromboembolic Disease. *N Engl J Med* 2007: 357: 1094-1104.
- The van Gogh Investigators. Extended Prophylaxis of Venous Thromboembolism with Idraparinux. *N Engl J Med* 2007: 357: 1105-12.
- Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-based clinical practice guidelines (8th Editions). *Chest* 2008; 133 (suppl): 1-968S.
- Guyatt GH, Oxman, AD, Vist GE et al. for the GRADE working group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; 336: 924-6.
- Righini M, Perrier A, De Moerloise P, et al. D-Dimer for venous thromboembolism diagnosis: 20 years later. *J Thromb Haemost* 2008; 6: 1059- 71.
- Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians Evidence-based clinical practice guidelines (8th Edition). *Chest* 2008; 133 (Suppl):234-56.S.
- Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012 ;141 (2 Suppl):e419S-94S.
- Meyer G, Vicaut E, Danays T et al. PEITHO Investigators. Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. *N Engl J Med* 2014; 370:1402-11.
- Hypertension artérielle**
- NET (mise à jour: Luc Lanthier, Sherbrooke): www.hypertension.qc.ca
- Strandgaard S, Olesen J, Skinhoj E, et al. Autoregulation of brain circulation in severe arterial hypertension. *BMJ* 1973; 1: 507-10.
- Messerli FH, Ventura HO, Amedeo C. Osler's maneuver and pseudo-hypertension. *N Engl J Med* 1985; 312: 1548-51.
- Dahlhof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). *Lancet* 1991; 338: 1281-5.
- Melbourne Diabetic Nephropathy Study Group: comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. *BMJ* 1991; 302: 210-6.
- Phillips SJ. Pathophysiology and management of hypertension in acute ischemic stroke. *Hypertension* 1994; 23: 131-6.
- Laragh JH, Brenner BM (eds.). In: Hypertension: Pathophysiology, diagnosis, and management. New York: Raven Press, 1995.
- Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. *JAMA* 1996; 276: 1886-92.
- Elliott J. ALLHAT: The largest and most important clinical trial in hypertension ever done in the USA. Antihypertensive and lipid lowering treatment to prevent heart attack trial. *Am J Hypertension* 1996; 9: 409-11.
- Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet* 1997; 349: 747-52.
- The Sixth Report of the Joint National Committee on Detection, Evaluation, and Diagnosis of High Blood Pressure. *Arch Intern Med* 1997; 157: 2413-46.
- Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *N Engl J Med* 1998; 338: 645-52.
- Frisman WH, Nalamati J. Carvedilol: a new alpha- and beta-adrenergic blocker for heart failure and hypertension. *N Engl J Med* 1998; 339: 1759-65.
- Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. *Lancet* 1998; 351: 1755-62.
- Recommendations of the Second Joint Task Force of European and other Societies on coronary Prevention. *Eur Heart J* 1998; 19: 1434-1503.
- Tati P, Pahor M, Byington RP, et al. Fosinopril Amlodipine Cardiovascular Events Trial. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomised trial (FACET) in patients with hypertension and NIDDM. *Diabetes Care* 1998; 21: 597-603.
- UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ* 1998; 317: 703-13.
- UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ* 1998; 317: 713-20.
- Hansson L, Lindholm LH, Ekborn T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet* 1999; 354: 1751-6.
- Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. *Lancet* 1999; 353: 611-6.
- Ramsay LE, Williams B, Johnston D, et al. British Hypertension Society guidelines for hypertension management 1999: summary. *BMJ* 1999; 319: 630-5.
- Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. *N Engl J Med* 1999; 340: 677-84.
- 1999 World Health Organization-International Society of Hypertension. Guidelines for the management of hypertension. *J Hypertens* 1999; 17: 905-83.
- Campbell NR, McKay DW. Accurate blood pressure measurement: why does it matter? *Can Med Assoc* 1999; 161: 277-8.
- Dickerson JF, Hingorani HG, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. *Lancet* 1999; 353: 2008-13.
- ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA* 2000; 283: 1967-75.
- Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). *Lancet* 2000; 356: 366-72.
- Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet* 2000; 356: 359-65.
- Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-microalbuminuria (CALM) study. *BMJ* 2000; 321: 1440-4.
- Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. *Lancet* 2000; 355: 1582-7.
- The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. *N Engl J Med* 2000; 342: 145-53.
- Van den Hoogen PCW, Feskens EJM, Nagelkerke NJD, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. *N Engl J Med* 2000; 342: 1-8.
- American Diabetes Association. Aspirin therapy in diabetes. Position statement. *Diabetes Care* 2001; 24: S62-S63.
- Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001; 345: 861-9.
- Brown M. Hypertension: Matching the right drug to the right patient

- in essential hypertension. *Heart* 2001; 86: 113-120.
- Cohn JN, Tognoni G, et al. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. *N Engl J Med* 2001; 345: 1667-75.
- Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 2001; 345: 851-60.
- Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 2001; 345: 870-8.
- PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. *Lancet* 2001; 358: 1033-41.
- Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and Dietary Approaches to Stop Hypertension (DASH) diet. *N Engl J Med* 2001; 344: 3-10.
- Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. *Heart* 2001; 85: 265-71.
- The canadian recommendations for the management of hypertension: Part 1 - Therapy. *Can J Cardiol* 2001; 17: 543-59.
- The canadian recommendations for the management of hypertension: Part 2 - Diagnosis and assessment of people with high blood pressure. *Can J Cardiol* 2001; 17: 1249-63.
- Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N Engl J Med* 2001; 345: 1291-7.
- American Diabetes Association: clinical practice recommendations 2002. *Diabetes Care* 2002; 25 (Suppl.1): S1-S147.
- Antithrombotic Trialists' Collaborator. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002; 324: 71-86.
- Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; 359: 995-1003.
- Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of Losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention For Endpoint Reduction (LIFE) Substudy. *JAMA* 2002; 288: 1491-8.
- Lauer MS. Aspirin for primary prevention of coronary events. *N Engl J Med* 2002; 346: 1468-74.
- Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; 359: 1004-10.
- McAlister FA, Zarnke KB, Campbell NR, et al. The 2001 canadian recommendations for the management of hypertension: Part 2-therapy. *Can J Cardiol* 2002; 18: 625-41.
- Wallis EJ, Ramsay LE, Jackson PR. Cardiovascular and coronary risk estimation in hypertension management. *Heart* 2002; 88: 306-12.
- Société québécoise de l'hypertension artérielle. Guide thérapeutique 2002 (ISBN 2-9806257-1-X); mise à jour: www.hypertension.qc.ca
- The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA* 2002; 289: 30-309-42.
- Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and treatment of high blood pressure. *JAMA* 2003; 289: 2560-72.
- U.S. Preventive Services Task Force (Chair: Berg AO). Aspirin for the prevention of cardiovascular events: recommendation and rationale. *Ann Intern Med* 2002; 136: 157-60.
- August P. Initial treatment of hypertension. *N Engl J Med* 2003; 348: 610-17.
- Imoberdorf R. Tous les diabétiques devraient-ils prendre de l'aspirine? *Forum Med Suisse* 2003; 7: 149-54.
- Wing LMH, Reid CM, Ryan PH, et al. (ANBP2). A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. *N Engl J Med* 2003; 348: 583-92.
- Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003; 361: 1149-58.
- Adrogué HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. *N Engl J Med* 2007; 356: 1966-78.

Urgence hypertensive

- McGregor E, Isles CG, Jay JL, et al. Retinal changes in malignant hypertension. *Br Med J* 1986; 292: 233-4.
- O'Mallia JJ, Sander GE, Giles TD. Nifedipine-associated myocardial ischemia or infarction in the treatment of hypertensive urgencies. *Ann Intern Med* 1987; 107: 185-6.
- Emergency Cardiac care Committee and subcommittees, American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiac care: Part IV. special resuscitation situations: stroke. *JAMA* 1992; 268: 2242-50.
- Kaplan NM. (ed.) Hypertensive crisis. In: *Clinical Hypertension*. Baltimore: Williams & Wilkins, 1994, p: 281-97.
- Kaplan NM. Management of hypertensive emergencies. *Lancet* 1994; 344: 1335-8.
- Hirschl MM. Guidelines for the drug treatment of hypertensive crises. *Drugs* 1995; 50: 991-1000.
- Ram CVS. Immediate management of severe hypertension. *Cardiol Clin* 1995; 13: 579-91.
- Varon J, Marik PE. The diagnosis and management of hypertensive crises. *Chest* 2000; 118: 214-27.
- Vaughan CJ, Delanty N. Hypertensive emergencies. *Lancet* 2000; 356: 411-7.
- Vidt DG. Emergency room management of hypertensive urgencies and emergencies. *J Clin Hypertens* 201; 3: 158-64.
- Elliott WJ. Hypertensive emergencies. *Crit Care Clin* 2001; 17: 435-51.
- Elliott WJ. Clinical features and management of selected hypertensive emergencies. *J Clin Hypertens (Greenwich)* 2004; 6: 587-92.

Hypotension orthostatique

- Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. *Arch Neurol* 1960; 2: 511-27.
- Thomas JE, Schirger A, Fealey RD, Sheps SG. Orthostatic hypotension. *Mayo Clin Proc* 1981; 56: 117-25.
- Weidmann P. Orthostatic hypotension. *Schweiz Med Wochenschr* 1984; 114: 246-60.
- Lipsitz LA. Orthostatic hypotension in the elderly. *N Engl J Med* 1989; 321: 952-7.
- Freistuhler M, et al. The Shy-Drager syndrome. *Dtsch Med Wochenschr* 1992; 117: 1146-8.
- Rutan GH, Hermanson B, Bild DE, Kittner SJ, LaBaw F, Tell GS. Orthostatic hypotension in older adults. The Cardiovascular Health Study. *CHS Collaborative Research Group Hypertension* 1992; 19: 508-19.
- Bula C. Orthostatic hypotension in the elderly. *Schweiz Rundsch Med Prax* 1996; 85: 145-9.
- Consensus statement. The definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. *J Auton Nervous Syst* 1996; 58: 123-4.
- Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine. A randomised, placebo-controlled, crossover trial. *Neurology* 1999; 53: 2151-7.

Syncope

- Franke H. Über das Karotissinus-Syndrom und den sogenannten hyperaktiven Karotissinus-Reflex. Stuttgart: Schlatler-Verlag, 1963: 149.
- Kapoor WN, et al. A prospective evaluation and follow-up of patients with syncope. *N Engl J Med* 1983; 309: 197-204.
- Hoefnagels WAJ, Padberg GW, Overweg J, et al. Transient loss of consciousness: the value of the history for distinguishing seizure from syncope. *J Neurol* 1991; 238: 39-43.
- Sra JS, Jazayeri MR, Avitall B, et al. Comparison of cardiac pacing with drug therapy in the treatment of neurocardiogenic (vasovagal) syncope with bradycardia or asystole. *N Engl J Med* 1993; 328: 1085-90.
- Linzer M, Yang EH, Estes NA, et al. Diagnosing syncope Part 1. Value of history, physical examination, and electrocardiography. *Ann Intern Med* 1997; 126: 989-96.

- Linzer M, Yang EH, et al. Diagnosing syncope Part 2. Unexplained syncope. *Ann Intern Med* 1997; 127: 76-86.
- Jeong HOH, Hanusa BH, Kapoor WN. Do symptoms predict cardiac arrhythmias and mortality in patients with syncope? *Arch Intern Med* 1999; 159: 375-80.
- Pruvot E, Vasallei G, Kappenberger L. De l'approche diagnostic au traitement de la syncope. *Med Hyg* 1999; 57: 1182-9.
- Kapoor WN. Syncope. *N Engl J Med* 2000; 343: 1856-62.
- Brignole M, Alboni P, Benditt D, et al. Task force on syncope, European Society of Cardiology, Part 1. The initial evaluation of patients with syncope. *Europace* 2001; 3: 253-60.
- Brignole M, Alboni P, Benditt D, et al. Task force on syncope, European Society of Cardiology, Part 2. Diagnostic tests and treatment: summary of recommendations. *Europace* 2001; 3: 261-8.
- Brignole M, Alboni P, Benditt D, et al. Guidelines on management (diagnosis and treatment) of syncope. *Eur Heart J* 2001; 22: 1256-1306.
- Sarasin FP, Louis-Simonet M, Carballo D, et al. Prospective evaluation of patients with syncope: a population-based study. *Am J Med* 2001; 111: 177-84.
- Sarasin FP, Louis-Simonet M, Carballo D, et al. Prevalence of orthostatic hypotension among patients presenting with syncope in the ED. *A J Emerg Med* 2002; 20: 497-501.
- Sarasin FP, Junod AV, Carballo D, et al. Role of echocardiography in the evaluation of syncope: a prospective study. *Heart* 2002; 88: 363-7.
- Kapoor WN. Current evaluation and management of syncope. *Circulation* 2002; 106: 1606-9.
- Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope - Update 2004. *Eur Heart J* 2004; 25: 2054-72.
- Sarasin FP, Pruvot E, Louis-Simonet M, et al. Stepwise evaluation of syncope: A prospective population-based controlled study. *Int J Cardiol* 2008; 127: 103-11.
- Moya A, Sutton R, Ammirati F, et al. ESC Guidelines. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). *Eur Heart J* 2009; 30: 2631-71.
- Insuffisance cardiaque, OAP**
- Criteria Committee, New York Heart Association. Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis. 6th ed. Boston, Little Brown and Co. 1964, p. 114.
- Killip T, et al. *Am J Cardiol* 1967; 20: 257-64.
- Campeau L. Grading of angina pectoris. *Circulation* 1975; 54: 522.
- Constant J. (ed.). The jugular pulse. In: *Bedside Cardiology*. Little Brown and Company; 1976; p. 69-75.
- The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med* 1987; 316: 1429-35.
- Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). *Circulation* 1990; 82: 1724-9.
- Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N Engl J Med* 1991; 325: 303-10.
- Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. *N Engl J Med* 1991; 325: 293-302.
- Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. *N Engl J Med* 1992; 327: 685-91.
- Pfeffer MA, Braunwald E, Moy LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. *N Engl J Med* 1992; 327: 669-77.
- Goldsmith SR, Dick C. Differentiating systolic from diastolic heart failure: Pathophysiologic and therapeutic considerations. *Am J Med* 1993; 95: 645-55.
- Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subject. *Circulation* 1993; 88: 107-15.
- ACC/AHA Task Force Report. Guidelines for the evaluation and management of heart failure. *Circulation* 1995; 92: 2764-84.
- Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. *J Am Coll Cardiol* 1995; 26: 438-45.
- Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. *JAMA* 1995; 273: 1450-6.
- Singh SN, Fletcher RD, Fisher SG, et al. Amilorone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. *N Engl J Med* 1995; 333: 77-82.
- Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. *Circulation* 1996; 94: 2807-16.
- Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med* 1996; 334: 1349-55.
- Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. *N Engl J Med* 1996; 335: 1107-14.
- The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). *Am J Cardiol* 1996; 78: 902-7.
- Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-Heft III. *Circulation* 1997; 96: 856-63.
- Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet* 1997; 349: 747-52.
- The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med* 1997; 336: 525-33.
- Tsuyuki RT, Yusuf S, Rouleau JL, et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. *Can J Cardiol* 1997; 13: 1166-74.
- European study group on diastolic heart failure. How to diagnose diastolic heart failure. *Eur Heart J* 1998; 19: 990-1003.
- Recommendations of the Second Joint Task Force of European and other Societies on coronary Prevention. Prevention of coronary heart disease in clinical practice. *Eur Heart J* 1998; 19: 1434-1503.
- Van Veldhuisen DJ, Genth-Zoltz S, Brouwer J, et al. High- versus low-dose ACE inhibition in chronic heart failure. *J Am Coll Cardiol* 1998; 32: 1811-8.
- Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons. *JAMA* 1998; 279: 839-46.
- Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. *Eur Heart J* 1999; 20: 1182-90.
- Baruch L, Anand I, Cohen IS, et al. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. *Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation* 1999; 99: 2658-64.
- Brunner-La Rocca HP, Weilenmann D, Kiowski W, et al. Within-patient-comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. *Am Heart J* 1999; 138: 654-62.
- Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. *Am J Cardiol* 1999; 83: 1-38.
- Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. *ATLAS Study Group. Circulation* 1999; 100: 2312-8.
- Stevenson LW. Tailored therapy to hemodynamic goals for advanced heart failure. *Eur J Heart Failure* 1999; 1: 251-7.
- Swedberg K, Pfeffer M, Granger C, et al. Candesartan in heart failure-reassessment of reduction in mortality and morbidity (CHARM): rationale and design. *Charm-Programme Investigators. J Card Fail* 1999; 5: 276-82.
- De Vries RJ, van Veldhuisen DJ, Dunselman PH. Efficacy and safety of calcium channel blockers in heart failure: focus on

- recent trials with second-generation dihydropyridines. *Am Heart J* 2000; 139: 185-94.
- Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. *Lancet* 2000; 355: 1582-7.
- Suter TM, Eberli FR, Hess OM. Herzinsuffizienz im neuen Millennium – welche Rolle spielen die Angiotensin-II-Antagonisten? *Kardiovasc Med* 2000; 3:467-75.
- Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. *Circulation* 2000; 105: 1503-08.
- Yusuf S, Sleight P, Pogue J, et al. Effect on angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000; 342: 145-53.
- ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American college of cardiology/American heart association task force on practice guidelines. *Circulation* 2001; 104: 2996-3007. Also published in: *J Am Coll Cardiol* 2001; 38: 2101-13.
- Cohn JN, Tognoni G, et al. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. *N Engl J Med* 2001; 345: 1667-75.
- Packer M, Coats AJS, Fowler MB, et al. Effects of Carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001; 344: 1651-8.
- Remme WJ, Swedberg K. Guidelines for diagnosis and treatment of chronic heart failure. Task Force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. *Eur Heart J* 2001; 22: 1527-60.
- Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? *Circulation* 2001; 104: 779-82.
- Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. *Eur J Heart Fail* 2002; 4:507-13.
- Hess OM (Arbeitsgruppe für Herzinsuffizienz der schweizerischen Gesellschaft für Kardiologie). Empfehlungen zur Diagnose und Behandlung der chronischen Herzinsuffizienz. *Schweizerische Ärztezeitung* 2002; 83: 1233-42.
- Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. *JAMA* 2002; 288: 1491-8.
- Lubien E, DeMaria A, Krishnaswamy P, Clopton P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with doppler velocity recordings. *Circulation* 2002; 105: 595-601.
- Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. *Circulation* 2002; 105: 1387-93.
- Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. *Circulation* 2002; 105: 1503-8.
- Funder JW. The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure. *Expert Opin Investig Drugs* 2003; 12: 1963-9.
- Jessup M, Brozena S. Heart failure. *N Engl J Med* 2003; 348: 2007-18.
- Pfeffer MA, McMurray JVV, Velazquez EJ, et al. Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003; 349: 1893-906.
- Pfeffer M, Swedberg K, Granger C, et al. Effect of Candesartan on mortality and morbidity in patients with chronic heart failure. The CHARM-Overall Programme. *Lancet* 2003; 362: 759-66.
- Yusuf S, Pfeffer M, Swedberg K et al. Effects of Candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet* 2003; 362: 777-81.
- Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004; 350: 2140-50.
- Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle. *N Engl J Med* 2004; 350: 1953-9.
- Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. *N Engl J Med* 2004; 351: 585-92.
- Kjekshus J., Apetrei E, Barrios V et al. Rosuvastatin in Older Patients with Systolic Heart Failure. *N Engl J Med* 2007; 357: 2248-61.
- Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac-Resynchronization Therapy in Heart Failure with Narrow QRS Complexes. *N Engl J Med* 2007; 357: 2461-71.
- Moya A, Sutton R, Ammirati F, et al. Guidelines for de diagnosis and management of syncope (2009). *Eur Heart J* 2009 ; 30: 2631-71.
- ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. McMurray JJ, Adamopoulos S, Anker SD et al. *Eur J Heart Fail* 2012;14:803-69.

Cardiomyopathie

- Abelmann WH. Classification and natural history of primary myocardial disease. *Prog Cardiovasc Dis* 1984; 27: 73-94.
- Packer DL, Bardsy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. *Am J Cardiol* 1986; 57: 563-70.
- Lampert MB, Lang RM. Peripartum cardiomyopathy. *Am Heart J* 1995; 130: 860-70.
- Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy. *Am J Cardiol* 1992; 69: 1458-66.
- Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. *N Engl J Med* 1994; 331: 1564-75.
- Richardson R, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of the cardiomyopathy. *Circulation* 1996; 93: 841-2.
- Felker CM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med* 2000; 342: 1077-84.
- Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. *J Am Coll Cardiol* 2001; 15: 1701-6.
- Frustaci A, Cucco L, Chimenti C, et al. Celiac disease associated with autoimmune myocarditis. *Circulation* 2002; 105: 2611-8.
- Felker GM, Thompson RE, Joshua M, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med* 2000; 342: 1077-84.
- Bhagwadeen R, Woo A, Ross J, et al. Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral center. *Can J Cardiol* 2003; 19: 912-7.
- Nielsen CD, Killip D, Spencer WH 3rd. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: short-term results in 50 consecutive procedures. *Clin Cardiol* 2003; 26: 275-9.
- Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004; 350: 2140-50.
- Kadish A, Dyer A, Dauber JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. *N Engl J Med* 2004; 350: 2151-8.

Stimulateur cardiaque

- Javier RP, Maramba LC, Hildner FJ, et al. Temporary cardiac pacing: technique and indications. *Chest* 1971; 59: 498-500.
- Goy JJ. La stimulation cardiaque: indication et évolution actuelle. *Rev Med Suisse Rom* 1986; 106: 359-63.
- ACC/AHA Guidelines for early management of patients with acute myocardial infarction. *Circulation* 1990; 82: 664-707.
- Dreifuss LS, Fisch C, Griffin JC, et al. Guidelines for implantation of cardiac pacemakers and antiarrhythmic devices. *Circulation* 1991; 84: 455-67.
- Jafri SM, Kruse JA. Temporary transvenous cardiac pacing. *Crit Care Clin* 1992; 8: 713-25.
- Report of the joint American College of Cardiology/ American Heart Association task force on assessment of cardiovascular procedures (subcommittee on pacemaker implantation): Guidelines for permanent cardiac pacemaker implantation. *JACC* 1994; 4: 433-42.
- Kusumoto FM, Goldschlager N. Cardiac pacing. *N Engl J Med* 1996; 332: 89-98.
- Committee on pacemaker implantation. ACC/ AHA Guidelines for implantation of cardiac pacemakers and antiarrhythmic devices: executive summary. *Circulation* 1998; 97: 1325-35.

Valvulopathie, auscultation cardiaque

- Folland ED, Krieger BJ, Hermderson WG, et al. Implication of third heart sounds in patients with valvular heart disease. *N Engl J Med* 1992; 327: 458-62.
- Carabello BA, Crawford FA. Valvular heart disease. *N Engl J Med* 1997; 337: 32-41.
- Bonow RO et al. ACC/AHA guidelines for the management of patients with valvular heart disease. *Circulation* 1998; 98: 1949-84. Also published in: *J Heart Valve Dis* 1998; 7: 672-707 and *JACC* 1998; 32: 1486-588.
- Quinones MA. Management of mitral regurgitation. *Cardiology Clinics* 1998; 16: 421-35.
- Braunwald E, Zipes DP, Libby P. (eds.). Valvular heart disease. In: *Heart disease: a textbook of cardiovascular medicine*. W.B. Saunders Company. 2001; p. 1643-1704.
- Khot UN, Novaro GM, Popovic Z, et al. Nitroprussiate in critically ill patients with left ventricular dysfunction and aortic stenosis. *N Engl J Med* 2003; 348: 1756-63.
- Christen T, Lercha R., Trindadea PT. Die Aortenklappenstenose beim Erwachsenen. *Schweiz Med Forum* 2006; 6:647-651.

Pouls

- Spodick DH. Acute cardiac tamponade: pathologic physiology, diagnosis and management. *Prog Cardiovasc Dis* 1967; 10: 64-96.
- Gubermann BA, Fowler NO, Engel PJ, et al. Cardiac tamponade in medical patients. *Circulation* 1982; 64: 633-40.

Anticoagulation

- Sixth ACCP Consensus Conference on antithrombotic therapy. *Chest* 2001; 119 (Suppl. 1): 1S-336S.
- The Warfarin Antiplaquet Vascular Evaluation Trial Investigators. Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. *N Engl J Med* 2007; 357: 217-27.

Stratific. risque périop. coronarien

- Palda VA, Detsky AS. Perioperative assessment and management of risk on coronary artery disease. *Ann Intern Med* 1997; 127: 131-28.
- Fleisher LA, Eagle K. Lowering cardiac risk in noncardiac surgery. *N Engl J Med* 2001; 345: 1677-82.

Voie veineuse centrale

<http://content.nejm.org/cgi/content/short/357/24/e26?query=TOC>

PNEUMOLOGIE

Auscultation pulmonaire

- Forcas P. (ed.). Lung sounds. Baillière Tindall, 1978.
- Zellweger JP. Anamnesis and physical examination in pneumology. *Praxis* 1992; 81: 278-81.
- Maitre B, Similowski T, Derenne JP, et al. Physical examination of the adult patient with respiratory diseases: inspection and palpation. *Eur Respir J* 1995; 8: 1584-93.
- Marquet P. Les bruits d'origine ventilatoire. *Rev Mal Resp* 1995; 12: 87-101.
- Meslier N, Charbonneau G, Racineux JL, et al. Wheezes. *Eur Respir J* 1995; 8: 1942-8.
- Sharma OP. Symptoms and signs in pulmonary medicine: old observations and new interpretations. *Disease-A-Month* 1995; 41: 577-638.
- Breitenstein E, Aubert JD. Signes cliniques en pneumologie: faut-il encore les rechercher ? *Med Hyg* 1996; 54: 2231-3.

Asthme

- NET: www.ginasthma.com
- McFadden ER, Lyons HA. Arterial blood gas tension in asthma. *N Engl J Med* 1968; 278: 1027-32.
- McFadden ER, Gilbert IA. Asthma. *N Engl J Med* 1992; 327: 1928-37.
- Corbridge TC, Hall JB. The assessment and management of adults with status asthmaticus. *Am J Respir Crit Care Med* 1995; 151: 1296-1316.
- McFadden ER, Hejal R. Asthma. *Lancet* 1995; 345: 1215-20.
- Schaller MD, Tagan D, Perret C. Asthme aigu grave. *Encycl Med Chir (Elsevier, Paris)*, Anesthésie-réanimation, 36-970-A-10, 1996.
- Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of low-

- dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. *N Engl J Med* 1997; 337: 1412-8.
- O'Byrne PM, Israel E, Drazen JM. Antileucotrienes in the treatment of asthma. *Ann Intern Med* 1997; 127: 472-80.
- The British Thoracic Society. Guidelines and asthma management. *Thorax* 1997; 52 (Suppl.1): S1-S21.
- Van der Molen T, et al. Effects of the long acting β -agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. *Thorax* 1997; 52: 535-9.
- Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. *N Engl J Med*, 1998; 339: 147-52.
- Li JT, et al. Algorithm for the diagnosis and management of asthma: a practice parameter update: Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. *Ann Allergy Asthma Immunol* 1998; 81: 415-20.
- Nelson JA, Strauss LS, et al. Effect of long-term salmeterol treatment on exercise-induced asthma. *N Engl J Med* 1998; 339: 141-6.
- Pralong G, Leuenberger Ph. Les β -2 stimulants à longue durée d'action dans le traitement de l'asthme: utiles ou dangereux ? *Med Hyg* 1998; 56: 2322-6.

BPCO - COPD - PPOC

- Medical Research Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. *Lancet* 1965; i: 775-9.
- Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxic chronic obstructive lung disease. *Ann Intern Med* 1980; 93: 391-8.
- Medical Research Council. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. *Lancet* 1981; 1: 681-6.
- Antonissen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987; 106: 196-204.
- American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. *Am Rev Respir Dis* 1991; 144: 1202-18.
- Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. *Ann Intern Med* 1991; 114: 216-23.
- Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1992; 146: 1067-83.
- Curtis JR, et al. Emergent assessment and management of acute respiratory failure in COPD. *Clin in Chest Med* 1994; 3: 481-500.
- American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. *Am J Resp Crit Care Med* 1995; 152: 77-120.
- Brochard L, Maneebo J, Wysocky M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 1995; 333: 817-22.
- Kramer N, Meyer TJ, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. *Am J Respir Crit Care Med* 1995; 151: 1799-1806.
- Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary diseases exacerbations. A meta-analysis. *JAMA* 1995; 273: 957-60.
- Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. *Eur Respir J* 1995; 8: 1398-1420.
- Tarpy SP, Celli BR. Long-term oxygen therapy. *N Engl J Med* 1995; 333: 710-4.
- Aboussouan LS. Acute exacerbations of chronic bronchitis. *Postgrad Med* 1996; 99: 89-103.
- Leuenberger Ph, Anderhub HP, Brändli O, et al. Management 1997 of chronic obstructive pulmonary disease. *Schweiz Med Wochenschr* 1997; 127: 766-82.
- McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. *Chest* 1997; 111: 732-43.
- O'Donohue WJ. Home oxygen therapy. *Clin Chest Med* 1997; 18: 535-45.
- Maurer JR, Frost AE, Estenne M, et al. International guidelines for the selection of lung transplant candidates. The international society for heart and lung transplantation, the american thoracic

society. *Transplantation* 1998; 66: 951-6.

Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. *Lancet* 1999; 354: 456-60.

Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 1999; 340: 1941-7.

Vincken W, Greefhorst APM, Westbroek J, et al. Once daily tiotropium is more efficacious than q.i.d. ipratropium as maintenance treatment of COPD. *Eur Resp J* 1999; 14 (Suppl. 30): S20S.

Barnes PJ. Chronic obstructive pulmonary disease. *N Engl J Med* 2000; 343: 269-80.

Lancaster T, Stead L, Silagy C, et al. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. *BMJ* 2000; 321: 355-8.

Niewoehner DE, Collins D, Erbland ML. Relation of FEV1 to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000; 161: 1201-5.

Rice KL, Rubins JB, Lebahn F, et al. Withdrawal of chronic systemic corticosteroids in patients with COPD; a randomized trial. *Am J Respir Crit Care Med* 2000; 162: 174-8.

Fitting JW, Rochat Th. Corticostéroïdes dans la broncho-pneumopathie obstructive chronique. *Réhabilitation respiratoire. Med Hyg* 2000; 58: 60-4.

McCorry DC, Brown C, Gelfand SE, et al. Management of acute exacerbations of COPD. *Chest* 2001; 119: 1190-1209.

Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseases. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med* 2001; 163: 1256-76.

Snow V, Lascher S, Mottur-Pilson C. The evidence base for management of acute exacerbations of COPD: clinical practice guideline. *Chest* 2001; 119: 1185-9.

Donohue JA, van Noord JA, Bateman ED, et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. *Chest* 2002; 122: 47-55.

Casbari R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. *Eur Respir J* 2002; 19: 217-24.

Aron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. *N Engl J Med* 2003; 348: 2618-25.

Irwin RS, Madison M. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 2003; 348: 2679-81.

National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. *N Engl J Med* 2003; 348: 2059-73.

Tashkin DP, Celli B, Senn S, et al. UPLIFT Study Investigators. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. *N Engl J Med* 2008; 359: 1543-54.

Leuppi DJ, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. *JAMA* 2013; 5; 309(21):2223-31. doi: 10.1001/jama.2013.5023.

Fonction pulmonaire, spirométrie

Weinberger SE. Principals of pulmonary medicine. Philadelphia, Saunders, 1986.

West JB. (ed.). *Physiologie respiratoire*. 2ème édition. MEDSI, Paris, 1986.

Gold WM, Boushey HA. Pulmonary function testing. Murray JF, Nadel JA (eds.). In: *Textbook of respiratory medicine*. Philadelphia, Saunders, 1988, p: 611-82.

Altose MD. Practical aspects of pulmonary function testing. In: Baum GL, Wolinsky E. (eds.). *Textbook of Pulmonary Disease*. Little Brown and Company, 1989, p: 101-3.

Clausen JL. Pulmonary testing. In: Kelly WN, et al. (eds.). *Textbook of Internal Medicine*, Philadelphia, JB. Lippincott, 1992, p: 182.

Débit de pointe (Peak flow)

Gregg I, Nunn AJ. Peak expiratory flow on normal subjects. *BMJ* 1973; 3: 282-4.

Nunn AJ, Gregg I. New regression equations for predicting peak expiratory flow in adults. *BMJ* 1989; 298: 1068-70.

Pneumothorax

Miller AC, Harvey JE on behalf of Standards of Care Committee, British Thoracic Society. Guidelines for the management of spontaneous pneumothorax. *Br Med J* 1993; 307: 114-6.

Jantz MA, Pierson DJ. Pneumothorax and barotrauma. *Clin Chest Med* 1994; 15: 75-91.

Light RW. Tension pneumothorax. *Intensive Care Med* 1994; 20: 468-9.

Light RW. *Pleural diseases*. 3rd edition. Baltimore, Williams and Wilkins 1995.

Wyser C, Ullmer E, Bolliger CT. Pneumothorax. *Bulletin des Médecins Suisses*. 1998; 79: 28-31.

Sahn SA, Hefner JE. Spontaneous pneumothorax. *N Engl J Med* 2000; 342: 868-74.

Baumann HM, Strange C, Hefner HE, et al. Management of spontaneous pneumothorax: an American College of Chest Physician Delphi consensus statement. *Chest* 2001; 119: 590-602.

Noppen M, Alexander P, Driesen P, et al. Manual aspiration versus chest tube drainage in first episodes of primary spontaneous pneumothorax: a multicentre, prospective, randomized pilot study. *Am Respir Crit Care Med* 2002; 165: 1202-3.

Henry M, Arnold T, Harvey J, et al. BTS guidelines for the management of spontaneous pneumothorax. *Thorax* 2003; 58 (Suppl. II): ii39-ii52.

Test aux stéroïdes

Leuenberger Ph, Anderhub HP, Brändli O, et al. Management 1997 of chronic obstructive pulmonary disease. *Schweiz Med Wochenschr* 1997; 127: 766-82.

Fitting JW, Rochat Th. Corticostéroïdes dans la broncho-pneumopathie obstructive chronique. *Réhabilitation respiratoire. Med Hyg* 2000; 58: 60-4.

Pneumonie

Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. *British J Hosp Med* 1993; 49: 346-50.

Marrie TJ. Community-acquired pneumonia. *Clin Infect Dis* 1994; 18: 501-15.

American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. *Am J Respir Crit Care Med* 1996; 153: 1711-25.

Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcome of patients with community-acquired pneumonia. A meta-analysis. *JAMA* 1996; 275: 134-41.

Fine JM, Auble TE, Yealy DM, Hanusa BH, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 1997; 336: 243-50.

Mellay JP, Kapoor WN, Fine JM. Does this patient have community-acquired pneumonia? *JAMA* 1997; 278: 1440-5.

Bartlett JG, Breiman RF, Mandell LA, File TM. Guidelines for the infectious diseases society of America. Community-acquired pneumonia in adults: guidelines for management. *Clin Infect Dis* 1998; 26: 811-38.

ESOCAP committee: management of adult community-acquired lower respiratory tract infections. *Eur Respir J* 1998; 61: 391-426.

Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalised with community-acquired pneumonia. Implications for practice guidelines. *JAMA* 1998; 279: 1452-7.

Nathwani D. Sequential switch therapy for lower respiratory tract infections. *Chest* 1998; 113: 2115-2185.

Fine MJ, Stone RA, Singer DE, et al. Process and outcomes of care for patients with community-acquired pneumonia. *Arch Intern Med* 1999; 159: 970-80.

Lamy O, Zanetti G, Bille J, et al. Diagnostic et traitement de la pneumonie acquise à domicile de l'adulte. *Rev Suisse Rom* 1999; 119: 403-27.

Mandell LA, Marrie TJ, Grossman RF, et al. Summary of canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the canadian infectious disease and the canadian thoracic society. *Can Respir J* 2000; 7: 371-82.

Guthrie R. Community-acquired lower respiratory tract infections. *Etiology and treatment. Chest* 2001; 120: 2021-34.

McCorry DC, Brown C, Gelfand SE, et al. Management of acute exacerbation of COPD. *Chest* 2001; 119: 1190-1209.

Halm EA, Teirstein AS. Management of community-acquired pneumonia. *N Engl J Med* 2002; 347: 2039-45.

Épanchement pleural

- Yam LT. Diagnostic significance of lymphocytes in pleural effusions. *Ann Intern Med* 1967; 66: 972-82.
- Light RW, et al. Pleural effusions: the diagnostic separation of transudates and exudates. *Ann Intern Med* 1972; 77: 507-13.
- Ocana IM, et al. Adenosine deaminase in pleural fluids. *Chest* 1983; 84: 51-53.
- Seneff MG, et al. Complications associated with thoracentesis. *Chest* 1986; 90: 97-100.
- Rodríguez-Panadero, Lopez Mejías J. Low glucose and pH levels in malignant pleural effusions. *Am Rev Respir* 1989; 139: 663-7.
- Light RW. *Pleural diseases*. 3rd ed. Baltimore, Williams and Wilkins 1995.
- Marel M, et al. Diagnosis of pleural effusions. *Chest* 1995; 107: 1598-1603.
- Hamm H, Light RW. Parapneumonic effusion and empyema. *Eur Respir J* 1997; 10: 1150-6.
- Light RW. Diagnostic principles in pleural disease. *Eur Respir J* 1997; 10: 476-81.
- Trachiotis GD, Vricella LA, Aaron BL, et al. Reexpansion pulmonary edema. *Ann Thorac Surg* 1997; 63: 1206-7.
- Nicod LP. Epanchement parapneumoniques: evaluation et traitement. *Med Hyg* 1997; 55: 2312-5.
- Aleman C, Alegre J, Armadans L, et al. The value of chest roentgenography in the diagnosis of pneumothorax after thoracentesis. *Am J Med* 1999; 107: 340-3.
- Light RW. Pleural effusion. *N Engl J Med* 2002; 346: 1971-7.
- Thomsen TW, DeLaPena J, Setnik GS. Thoracentesis. *N Engl J Med* 2007; 355: e16

Pneumopathies interstitielles

- Dunkalek E. Interstitielle (diffuse) Lungenerkrankungen. In: Kaufmann W. (ed.) *Internistische Differenzialdiagnostik*. Schattauer Verlag, 1997, p. 80-99.
- Siegenthaler W, Kaufmann W, Hornbostel H, et al (eds.). In: *Lehrbuch der inneren Medizin*. Thieme, 1997.

Fibrose pulmonaire idiopathique

- Katzenstein ALA, Myers JL. Idiopathic pulmonary fibrosis - clinical relevance of pathologic classification. *Am J Respir Crit Care Med* 1998; 157: 1301-15.
- Mason RJ, Schwarz MI, Hunninghake GW, et al. Pharmacological therapy for idiopathic pulmonary fibrosis: past, present, future. *Am J Respir Crit Care Med* 1999; 160: 1771-7.
- King TE, Costabel U, Cordier JE, et al. ATS/ETS. Idiopathic pulmonary fibrosis: Diagnosis and treatment. *Am J Respir Crit Care Med* 2000; 161: 646-64.
- Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. *Am J Respir Crit Care Med* 2000; 161: 646-64.
- Gross TG, Hunninghake GW. Idiopathic pulmonary fibrosis. *N Engl J Med* 2001; 345: 517-25.
- Travis WE, King TE, Bateman ED, et al. ATS/ETS international multidisciplinary consensus classification of idiopathic interstitial pneumonias. General principles and recommendations. *Am J Respir Crit Care Med* 2002; 165: 277-304.
- Noble P, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. *Lancet* 2011; 377: 1760-9.
- Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. *N Engl J Med* 2011; 365: 1079-87.
- King TE, Bradford WZ, CastroBernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis (ASCEND). *N Engl J Med* 2014; 370: 2083-92.
- Richeldi L, du Bois R, Ragu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis (INPULSIS). *N Engl J Med* 2014; 370: 2071-82.

Hypertension pulmonaire

- Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. *Ann Intern Med* 1987; 107: 216-23.
- Rich S, Chomka E, Hasara L, et al. The prevalence of pulmonary hypertension in the United States. Adult population estimates obtained from measurements of chest roentgenograms from the NHANES II Survey. *Chest* 1989; 96: 236-41.
- Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV infection. *Chest* 1991; 100:1268-71.
- Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. *N Engl J Med* 1992; 327: 76-81.
- Rubin LJ. ACCP consensus statement: primary pulmonary hypertension. *Chest* 1993; 104: 236-50.
- Rich S, Kaufmann P, Lew PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. *N Engl J Med* 1992; 327: 76-81.
- Abenheim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. *N Engl J Med* 1996; 335: 609-16.
- Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. *N Engl J Med* 1996; 334: 296-301.
- Gainé SP, Rubin LJ. Primary pulmonary hypertension. *Lancet*; 1998; 352: 719-25.
- Rich S, (ed). Primary pulmonary hypertension: executive summary from the world symposium. Geneva: World Health Organization, 1998.
- Benigni A, Ramuzzi G. Endothelin antagonists. *Lancet* 1999; 353: 133-8.
- Sanchez O, Humbert M, Sitbon O, et al. Treatment of pulmonary hypertension secondary to connective tissue disease. *Thorax* 1999; 54: 274-7.
- Hoepfer MM, Schwarze M, Eherlerding St, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. *N Engl J Med* 2000; 342: 1866-70.
- Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet* 2001; 358: 1119-23.
- Hoepfer MM, Galie N, Simonneau G, et al. New treatments for pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2002; 165: 1209-16.
- Kim NHS, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonist in the management of pulmonary artery hypertension. *J Cardiovasc Pharmacol Therapeut* 2002; 7: 9-19.
- Prakash A, Perry CM. Bosentan. *Am J Cardiovasc Drugs* 2002; 2: 335-42.
- Olschewski H, G Simonneau, Galie N, et al. Inhaled Iloprost for severe pulmonary hypertension. *N Engl J Med* 2002; 347: 322-9.
- Rubin LJ. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. *Am J Respir Crit Care Med* 2002; 166: 1308-9.
- Rubin LJ, Badesch DB, Barst R, et al. Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med* 2002; 346: 896-903.
- Barst RJ, McGoan M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. *J Am Coll Cardiol* 2003; 41: 2119-25.
- Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. *Eur Respir J* 2003; 21: 155-76.
- Barst RJ, McGoan M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. *J Am Coll Cardiol* 2004; 43 (12 Suppl): S40-7.
- Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. *J Am Coll Cardiol* 2004; 43 (12 Suppl): S25-32.
- Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2004; 43 (12 Suppl): S5-12.
- Pengo V, Lensing AWA, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med* 2004; 350: 2257-64.
- Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galie N, Hoepfer MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gainé S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J* 2009; 34: 1219-63.
- Hoepfer MM, Bogaard HJ, Condliffe R et al. Definitions and diagnosis of pulmonary hypertension. *J Am Coll Cardiol* 2013; 62(25 Suppl): D42-50.
- Simonneau G, Gatzoulis MA, Adatia I et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2013; 62 (25 Suppl): D34-41.

Sarcoïdose

Panel of the world association of sarcoidosis and other granulomatous disease. Consensus conference: activity of sarcoidosis. *Eur*

Resp J 1994; 7: 624-7.

Peckham DG, Spiteri MA. Sarcoidosis. *Postgrad Med J* 1996; 72: 196-200.

Newman LS, Rose CS, Maier LA. Sarcoidosis. *N Engl J Med* 1997; 336: 1224-34.

American Thoracic Society, European Respiratory Society, World Association of Sarcoidosis and other Granulomatous Disorders. Statement on sarcoidosis. *Am J Respir Crit Care Med* 1999; 160: 736-55.

Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. *N Engl J Med* 2007; 357: 2153-65.

Rhinite

Laursen LC, Faurschou P, Pals H, et al. Intramuscular betamethasone dipropionate vs. oral prednisolone in hay feverpatients. *Allergy* 1987; 42: 168-72.

Brogden RN, McTavish D. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. *Ann Allergy* 1991; 67: 541-7.

Naclerio RM. Allergic rhinitis. *N Engl J Med* 1991; 325: 860-9.

Brooks CD, Karl KJ, Francom SF. Oral methylprednisolone acetate (Medrol tablets) for seasonal rhinitis: examination of dose and symptom response. *J Clin Pharmacol* 1993; 33: 816-22.

International Rhinitis Management Working Group. International consensus report on the diagnosis and management of rhinitis. *Allergy* 1994; 49 (Suppl. 9): S5-S34.

Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. *Am J Respir Crit Care Med* 1995; 151: 969-74.

Bernstein IL, Storm WW. Practice parameters for allergy diagnostic testing. Joint task force on practice parameters for the diagnosis and treatment of asthma. The American academy of allergy, asthma and immunology. *Ann Allergy Asthma Immunol* 1995; 75: 43-625.

Desager JP, Horsmans Y. Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. *Clin Pharmacokinet* 1995; 28: 419-32.

Small P, Hule PA, et al. A comparison of triamcinolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis. *J Allergy Clin Immunol* 1997; 100: 592-5.

Stern MA, Dahl R, et al. A comparison of aqueous suspensions of budesonide nasal spray and fluticasone propionate nasal spray in the treatment of adult patients with seasonal allergic rhinitis. *Am J Rhinol* 1997; 11: 323-30.

Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. *J Allergy Clin Immunol* 1998; 102: 558-562.

Dykewicz MS, et al. Joint Task Force Algorithm and Annotations for Diagnosis and Management of Rhinitis. *Ann Allergy Asthma Immunol* 1998; 81: 469-73.

Dykewicz MS, et al. Joint Task Force summary statements on Diagnosis and Management of Rhinitis. *Ann Allergy Asthma Immunol* 1998; 81: 463-8, et 474-7.

Dykewicz MS, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. *Ann Allergy Asthma Immunol* 1998; 81: 478-518.

Lundbäck B. Epidemiology of rhinitis and asthma. *Clin Exp Allergy* 1998; 28: 3-10.

Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. *N Engl J Med* 1999; 341: 468-75.

Howarth PH. A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis. *Allergy* 2000; 62: 6-11.

Van Cauwenberge P, Bachert P, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European academy of allergology and clinical immunology. *Allergy* 2000; 55: 116-34.

Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. *J Allergy Clin Immunol* 2001; 101 (Suppl. 5): S147-S334.

Kaszuba SM, Barody FM, deTineo M, et al. Superiority of an intranasal corticoid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. *Arch Intern Med* 2001; 161: 2581-7.

Pullerits T, Praks L, Ristioja V, et al. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. *J Allergy Clin Immunol* 2002; 109: 949-55.

Toux

Pratter MR, Bartter Th, Akers St, et al. An algorithmic approach to chronic cough. *Ann Intern Med* 1993; 119: 977-83.

O'Connell F, Thomas VE, Pride NB, et al. Capsaicin cough sensitivity decreases with successful treatment of chronic cough. *Am J Respir Crit Care Med* 1994; 150: 374-80.

Patrick H, Patrick F. Chronic cough. *Med Clin North Am* 1995; 79: 361-72.

Chung KF, Lalloo UG. Diagnosis and management of chronic persistent dry cough. *Postgrad Med J* 1996; 72: 594-8.

Lawler WR. An office approach to the diagnosis of chronic cough. *Am Fam Physician* 1998; 58: 2015-22.

Smymios NA, Irwin RS, Curley FJ, et al. From a prospective study of chronic cough. *Arch Intern Med* 1998; 158: 1222-8.

Palombini BC, Villanova CAC, Araújo E, et al. A pathogenic triad in chronic cough. *Chest* 1999; 116: 279-84.

Pratter MR, Bartter Th, Lotano R. The role of sinus imaging in the treatment of chronic cough in adults. *Chest* 1999; 116: 1287-91.

Irwin RS, Madison JM. The diagnosis and treatment of cough. *N Engl J Med* 2000; 343: 1715-21.

Irwin RS, Madison JM. Diagnosis and treatment of chronic cough due to gastro-esophageal reflux disease and postnasal drip syndrome. *Pulm Pharmacol Ther* 2002; 15: 261-6.

Madison JM, Irwin RS. Pharmacotherapy of chronic cough. *Expert Opin Pharmacother* 2003; 4: 1039-48.

Morice AH, Fontana GA, Sovijarvi AR, et al. The diagnosis and management of chronic cough. *Eur Respir J* 2004; 24:481-92.

Kastelik JA, Aziz I, Ojoo JC et al. Investigation and management of chronic cough using a probability-based algorithm. *Eur Respir J* 2005; 25: 235-43.

Hoquet chronique

Kolodzki PW, Eilers MA. Hiccups (singultus): review and approach to management. *Ann Emerg Med* 1991; 20: 565-73.

Launcois S, Bizce JL, Whitelaw WA, et al. Hiccup in adults: an overview. *Eur Respir J* 1993; 6: 563-75.

Friedgood CE, Ripstein CB. Chlorpromazine (Thorazine) in the treatment of intractable hiccups. *JAMA* 1995;157:309-10.

Friedman NL. Hiccups: a treatment review. *Pharmacotherapy*. 1996; 16: 986-95.

Federspil PA, Zenk J. Singultus. *HNO*. 1999; 47: 867-75.

Syndrome de l'apnée du sommeil

American Thoracic Society: Indications and standards for cardiopulmonary sleep studies. *Am Rev Respir Dis* 1989; 139: 559-68.

Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 1991; 14: 540-5.

Bradley TD, Phillipson EA. Central sleep apnea. *Clin Chest Med* 1992; 13: 493-505.

Douglas N, Thomas S, Jan M. Clinical value of polysomnography. *Lancet* 1992; 339: 347-50.

Guilleminault C, Stoohs R, Clerk A, et al. A cause excessive daytime sleepiness. The upper airway resistance syndrome. *Chest* 1993; 104: 781-7.

McNamara SG, Grunstein RR, Sullivan CE. Obstructive sleep apnoea. *Thorax* 1993; 48: 754-64.

Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med* 1993; 328: 1230-5.

Flemons WW, Whitelaw WA, Brant R, et al. Likelihood ratios for a sleep apnea clinical prediction rule. *Am J Respir Crit Care Med* 1994; 150: 1279-85.

Maurice JC, Marc I, Series F. Efficacy of auto-CPAP in the treatment of obstructive sleep apnea/hypopnea syndrome. *Am J Respir Crit Care Med* 1996; 153: 794-8.

Series F. Auto CPAP in the treatment of sleep apnea hypopnea syndrome. *Sleep* 1996; 19 (10 Suppl): S281-3.

Young T, Peppard P, Palta M, et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. *Arch Intern Med* 1997; 157: 1746-52.

Naughton MT. Heart failure and central apnea. *Reviews. Sleep Medicine* 1998; 2: 105-16.

Worsnop CJ, Naughton MT, Barter CE, et al. The prevalence of obstructive sleep apnea in hypertensives. *Am J Respir Crit Care Med* 1998; 157: 111-5.

Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The report of an american academy of sleep medicine task force. *Sleep* 1999; 22: 667-89.

- Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. *N Engl J Med* 2000; 342: 1378-84.
- Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. *J Hypertens* 2001; 19: 2271-7.
- Kohnlein T, Welle T, Tan LB et al. Central sleep apnoea syndrome in patients with chronic heart disease: a critical review of the current literature. *Thorax* 2002; 57: 547-54.
- Series F. Interpretation of home oxymetry tracings. *Chest* 2002; 121: 1006-7.
- Brack Th. Therapie der Cheyne-Stokes-Atmung bei Herzinsuffizienz.

phagusvarizen. Forum Med Suisse 2001; 12: 313-9.
Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. N Engl J Med 2001; 345: 669-81.
Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with Nadolol and Isosorbid Mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345: 647-55.

Diverticulite

Brodribb AJM. Treatment of symptomatic diverticular disease with a high fibre diet. Lancet 1977; 1: 664-5.
Almy TP, Howel DA. Diverticular disease of the colon. N Engl J Med 1980; 302: 324-31.
Konvolinka CW. Acute diverticulitis under age of forty. Am J Surg 1994; 167: 562-5.
Roberts PL, Veidemheimer MC. Current management of diverticulitis. Adv Surg 1994; 27: 189-208.
Vignati PV, Welch JP, Cohen JL. Long-term management of diverticulitis in young patients. Dis Colon Rectum 1995; 38: 627-9.
Ambrosetti P, Grossholz M, Becker C, et al. Computed tomography in acute left colonic diverticulitis. Br J Surg 1997; 84: 532-4.
Cunningham MA, Davis JW, Kaups KL. Medical versus surgical management of diverticulitis in patients under age 40. Am J Surg 1997; 174: 733-6.
Stollman NH, Raskin JB. Diagnosis and management of diverticular disease of the colon in adults. Am J Gastroenterol 1999; 94: 3110-21.
Jacobs DO. Diverticulitis. N Engl J Med 2007; 357: 2057-66.

Troubles fonctionnelles intestinales - Côlon irritable

Otte JJ, Larsen L, Anderson JR. Irritable bowel syndrome and symptomatic diverticular disease-different diseases? Am J Gastroenterol 1986; 81: 529-31.
Drossmann DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999; 45: 1-5.
Drossmann DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-90.
Track J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-79.

Diarrhées aiguës

Fine KD et al. In: Sleisenger MH, Fordtran JS, Gastrointestinal Disease 1989; p: 290-316.
Bandres JC, DuPont H. Approach to the patient with diarrhea. In: Gorbach SL, et al. (eds.). Infectious Diseases. Philadelphia: Saunders, 1992; p: 572-575.
Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-62.
Ruppin H, Soergel KH. Diagnostic guidelines in diarrhea. Ther Umsch 1994; 51: 166-71.
Ruppin H. Therapeutic guidelines in diarrhea. Ther Umsch 1994; 51: 172-6.
Powell DW. Approach to the patient with diarrhea. In: Yamada T, et al. (eds.). Textbook of Gastroenterology. Philadelphia JB Lippincott, 1995: 813-31.
Praz JO, Stalder H. Les diarrhées aiguës. Med Hyg 1996; 54: 1719-22.
DuPont HL. Guidelines on acute infectious diarrhea in adults. The practice parameters committee of the American College of Gastro-entology. Am J Gastroenterol 1997; 92: 1962-75.
Mensa J, Gatell JM, et al. Guia de Terapèutica Antimicrobiana. Masson, S.A., 1997.
Aranda-Michel J, Giannella RA. Acute diarrhea: a practical review. Am J Med 1999; 106: 670-7.
Furness BW, Beach MJ, Roberts JM. Giardiasis surveillance - United States. 1992-1997. MMWR CDC Surveill Summ 2000; 49: 1-13.
Haque R, Huston C, Hughes M, et al. Amebiasis. N Engl J Med 2003; 348: 1565-73.

Diarrhées chroniques

Rambaud JC. Diarrhée chronique: orientation diagnostique et conduite à tenir. Rev Prat (Paris) 1989; 39: 1809-16.
Descos L. Diarrhée chronique sans malabsorption intestinale du grêle. Etiologie, diagnostic, évolution et pronostic, principes de traitement. Rev du Prat 1990; 9: 846-8.
Greenberger NJ. Diagnostic approach to the patient with a chronic diarrhea disorder. Dis Mon 1990; 36: 131-79.
Cerf M. Stratégie diagnostique devant une diarrhée chronique de

l'adulte. Gastroenterol Clin Biol 1992; 16: T12-T21.
Donowitz M, Kokke FT, Saidi R. Evaluation of patients with chronic diarrhea. N Engl J Med 1995; 332: 725-9.
Fine KD. Diarrhea. In: Feldman M, et al. (eds.). Sleisenger and Fordtran's Gastrointestinal and hepatic disease: pathophysiology, diagnosis, management. Philadelphia: Saunders WB 1998, p: 126-52.
Marteau Ph. Les diarrhées chroniques. Gastroenterol Clin Biol 1999; 23: 73-95.
Fine KD, Schiller LR. American Gastroenterological Association Medical position statement: Guidelines for the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116: 1461-3.
Binder HJ. Causes of Chronic Diarrhea. N Engl J Med 2006; 355: 236-9.

Pancréatite

Ranson JHC et al. Computed tomography and the prediction of pancreatic abscess in acute pancreatitis. Ann Surg 1985; 201: 656-65.
Reynaert MS, Dugernier T, Kestens PJ. Current therapeutic strategies in severe acute pancreatitis. Intensive Care Med 1990; 16: 352-62.
Ros E, Navarro S, Bru C, et al. Occult microlithiasis in " idiopathic " acute pancreatitis: prevention of relapses by cholecystectomy or ursodeoxycholic acid therapy. Gastroenterology 1991; 101: 1701-9.
Tenner SM, Steinberg W. The admission serum lipase: amylase ratio differentiates alcoholic from nonalcoholic acute pancreatitis. Am J Gastroenterol 1992; 12: 1755-8.
Steinberg W, Tenner S. Acute Pancreatitis. N Engl J Med 1994; 330: 1198-1210.
Delcenserie R, Yzet T, Ducroix JP. Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis. Pancreas 1996; 13: 198-201.
Sainio V, Kempanian E, Poulakkainen P et al. Early antibiotic treatment in acute necrotising pancreatitis. Lancet 1995; 346: 663-7.
Gaillard Ph, Restellini A, Malé PJ, et al. Pancréatite aiguë. In: Urgences Médicales, Restellini A et al. (eds.). Médecine et Hygiène, 1997, p: 267-72.
Bassi C, Falconi M, Talamini G, et al. Controlled clinical trial of pefloxacin versus imipenem in severe acute pancreatitis. Gastroenterology 1998; 115: 1513-7.
Pitchumoni CS. Chronic pancreatitis, pathogenesis and management of pain. J Clin Gastroenterol 1998; 27: 101-7.
Nathens AB, Curtis R, Beale RJ, et al. Management of the critically ill patient with severe acute pancreatitis. Crit Care Med 2004; 32: 2524-36.

Cirrhose biliaire primitive (CBP)

Angulo P, Lindor KD. Primary biliary cirrhosis and primary sclerosing cholangitis. Clin Liver Dis 1999; 3: 529-70.
Leuschner M, Maier KP, Schlichtling J, et al. Oral budesonide and ursodeoxycholic acid treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999; 117: 918-25.
Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the study of liver diseases practice guidelines. Hepatology 2000; 31: 1005-13.
Holtmeier J, Leuschner U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Digestion 2001; 64: 137-50.
Floreani A. Preventive therapy in primary biliary cirrhosis. Clin Liver Dis 2003; 7: 911-21.
Levy C, Lindor KD. Management of primary biliary cirrhosis. Curr Treat Options Gastroenterol 2003; 6: 493-8.
Talwalker JA, Lindor KD. Primary biliary cirrhosis. Lancet 2003; 362: 53-61.
Pares A, Cisneros L, Salmeron JM, et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 1105-10.
Bressler B, Pinto R, El-Ashry D, Heathcote EJ. Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection? Gut 2005; 54: 407-10.

Sclérose biliaire primitive (SBP)

Angulo P, Lindor KD. Primary biliary cirrhosis and primary sclerosing cholangitis. Clin Liver Dis 1999; 3: 529-70.

Stiehl A, Benz C, Sauer P. Primary sclerosing cholangitis. *Can J Gastroenterol* 2000; 14: 311-5.

Holtmeier J, Leuschner U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. *Digestion* 2001; 64: 137-50.

Zein CO, Lindor KD. Primary sclerosing cholangitis. *Semin Gastrointest Dis* 2001; 12: 103-12.

Foetor ex ore

Rosenberg M, Kozlovsky A, Gelemler I, et al. Self-estimation of oral malodor. *J Dent Res* 1995; 74: 1577-82.

Rosenberg M. Clinical assessment of bad breath: currents concepts. *J Am Dent Assoc* 1996; 127: 475-82.

Rosenberg M. The science of bad breath. *Sci Am* 2002; 286: 72-9.

Quiryenen M, Zhao H, van Steenberghe D. Review of the treatment strategies for oral malodour. *Clin Oral Invest* 2002; 6: 1-10.

Filippi A, Meyer J. Halitosis - Ursachen, Diagnose, Therapie. *Schweiz Med Forum* 2004; 4: 585-9.

Hépatite auto-immune

Bieri-Tehovnik S, Marbert U, Bertschinger P. Autoimmune hepatitis in Switzerland. *Schweiz Med Wochenschr* 1998; 128: 850-2.

Alvarez F, Berg PA, Bianchi L, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. *J Hepatol* 1999; 31: 929-38.

Manns MP. Autoantibodies to soluble liver antigen: specific marker of autoimmune hepatitis. *J Hepatol* 2000; 33: 326-8.

Al-Khalidi JA, Czaja AJ. Current concepts in the diagnosis, pathology, and treatment of autoimmune hepatitis. *Mayo Clin Proc* 2001; 76: 1237-52.

Czaja AJ. Autoimmune hepatitis. *Clin Liver Dis* 2002; 6: xi-xii.

Czaja AJ, Freese DK; American Association for the study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. *Hepatology* 2002; 36: 479-97.

McFarlane IG. Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. *Clin Liver Dis* 2002; 6: 317-33.

Strassburg CP, Manns MP. Autoantibodies and autoimmune hepatitis. *Semin Liver Dis* 2002; 22: 339-52.

NASH (nonalcoholic steatohepatitis)

Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an evolving diagnosis. *Can J Gastroenterol* 2000; 14: 321-6.

Farrell GC. Drugs and steatohepatitis. *Semin Liver Dis* 2002; 22: 185-94.

Brunt EM. Nonalcoholic steatohepatitis. *Semin Liver Dis* 2004; 24: 3-20.

Cirrhose hépatique - Ascite

Goldberg BB, Goodman GA, Clearfield HR. Evaluation of ascites by ultrasound. *Radiology* 1970; 96: 15-22.

Rocco VK, Ware AJ. Cirrhotic ascites: Pathophysiology, diagnosis and management. *Ann Intern Med* 1986; 105: 573-85.

Runyon BA. Low protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. *Gastroenterology* 1986; 91: 1343-6.

Ariza J, Xiol X, Esteve M, et al. Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients. *Hepatology* 1991; 14: 91-8.

Gines P, Arroyo V, et al. Paracentesis with intravenous infusion of albumin compared with peritoneovenous shunting in cirrhosis with refractory ascites. *N Engl J Med* 1991; 325: 829-35.

Garcia-Pagan JC, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. *Hepatology* 1994; 19: 1095-99.

Runyon BA. Care of patients with ascites. *N Engl J Med* 1994; 330: 337-42.

Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. *Hepatology* 1996; 23: 164-76.

Gines A, Fernández-Esparrach G, Monesillo A, et al. Randomized trial comparing albumin, Dextran-70 plus polygeline in cirrhotic patients with ascites treated with paracentesis. *Gastroenterol* 1996; 111: 1002-10.

Batalier R, Gines P, Arroyo V. Practical recommendations for the treatment of ascites and its complications. *Drugs* 1997; 54: 571-80.

Gines P, Fernández-Esparrach G, Arroyo V, et al. Pathogenesis of ascites in cirrhosis. *Semin Liver Dis* 1997; 17: 175-89.

Arroyo V, Cardenas A. TIPS in the treatment of refractory ascites. In: Arroyo V. et al. (ed.). Treatment of liver diseases. 1999, Masson.

Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. *Gastroenterology* 2000; 119: 1637-48.

Cardenas A, Batalier R, Arroyo V. Mechanisms of ascites formation. *Clin Liver Dis* 2000; 4: 447-65.

Rössle M, Ochs A, Veit G, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. *N Engl J Med* 2000; 342: 1701-7.

Ginès P, Cardenas A, Arroyo V, Rodés J. Management of Cirrhosis and Ascites. *N Engl J Med* 2004; 350:1646-54.

Péritonite bactérienne spontanée

Runyon BA, Hoefs JC. Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis. *Hepatology* 1984; 4: 1209-11.

Yang CY, Liaw YF, Chu CM, et al. White count, pH and lactate in ascites in the diagnosis of spontaneous bacterial peritonitis. *Hepatology* 1985; 5: 85-90.

Titó L, Rimola A, Ginès P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. *Hepatology* 1988; 8: 27-31.

Ginès P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind placebo-controlled trial. *Hepatology* 1990; 12: 716-24.

Arroyo V, Navasa M, Rimola A. Spontaneous bacterial peritonitis in liver cirrhosis: treatment and prophylaxis. *Infection* 1994; 22 (Suppl.3): S1-8.

Gilbert JA, Kamath PS. Spontaneous bacterial peritonitis: An update. *Mayo Clin Proc* 1995; 70: 365-70.

Ginès P, Navasa M. Antibiotic prophylaxis for spontaneous bacterial peritonitis: how and whom? *J Hepatology* 1998; 29: 490-94.

Rimola A, Garcia-Tsao G, Navasa M, et al. (and the International Ascites Club). Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. *J Hepatol* 2000; 32: 142-53.

Wu JC, Chan FK. Esophageal bleeding disorders. *Curr Opin Gastroenterol* 2004; 20: 386-90.

Syndrôme hépatorenal

Arroyo A, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. *Hepatology* 1996; 23: 164-73.

Angeli P, Volpin R, Gerunda G, et al. Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. *Hepatology* 1999; 29: 1690-7.

Cardenas A, Uriz J, Gines P, et al. Hepatorenal syndrome. *Liver Transpl* 2000; 6 (4 Suppl. 1): S63-71.

Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. *J Hepatol* 2000; 33: 43-8.

Batalier R, Ginès P, Arroyo V, et al. Hepatorenal syndrome. *Clin Liver Dis* 2000; 4: 487-507.

Insuffisance hépatocellulaire

Trey C, Burns DG, Saunders SJ. Treatment of hepatic coma by exchange blood transfusion. *N Engl J Med* 1966; 274: 473-81.

Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transsection of the oesophagus for bleeding oesophageal varices. *Brit J Surg* 1973; 60: 646-9.

Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. *N Engl J Med* 1989; 321: 1014-22 et 1092-9.

Chapman RW, Forman D, Peto R, Smallwood R. Liver transplantation for acute hepatic failure? *Lancet* 1990; 1: 32-5.

Caraceni P, van Thiel DH. Acute liver failure. *Lancet* 1995; 345: 163-9.

Giostra E, Mentha G, Malé PJ, et al. Insuffisance hépatocellulaire (IHC) aiguë et hépatite fulminante. In: Urgences Médicales, Restellini A et al. (eds.). Editions Médecine et Hygiène, 1997, p: 278-83.

Lebrec D. Pharmacological treatment of portal hypertension: present and future. *J Hepatol* 1998; 28: 869-907.

Itctère

Zimmermann HJ, Deschner KW. Differential diagnosis of jaundice. *Hosp Practice (Off Ed)* 1987; 22: 99-103.

Reisman Y, Gips CH, Lavelle SM, Wilson JHP. Clinical presentation of (subclinical) jaundice. The Eumetrics project in the Netherlands. *Hepato-Gastroenterology* 1996; 43: 1190-5.

Insuffisance pancréatique exocrine

- Steer ML, Waxman I, Feedman S. Chronic pancreatitis. *N Engl J Med* 1995; 332: 1482-90.
- Pitchumoni CS. Chronic pancreatitis, pathogenesis and management of pain. *J Clin Gastroenterol* 1998; 27: 101-7.

Hépatite: A, B, C. Vaccins

- Bernau J, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. *Hepatology* 1986; 6: 648-51.
- Bismuth H, Samuel D, Gugenheim J, et al. Emergency liver transplantation for fulminant hepatitis. *Ann Int Med* 1987; 107: 337-41.
- Malé PJ. Hépatites virales. *Rev Med Suisse Rom* 1989; 109: 889-99.
- Tormans G, Van Damme P, Van Doorslaer E. Recommendations for prevention of hepatitis A based on a effectiveness analysis. *J Travel Med* 1994; 1: 127-135.
- Swiss Association for the Study of the Liver; Groupe d'Experts Suisses pour les Hépatites Virales; Société Suisse de Gastro-entérologie et d'Hépatologie. Recommendations pour le traitement par l'interféron de l'hépatite C chronique. *Bulletin des Médecins Suisses* 1996; 43: 1746-7.
- Lee WM. Hepatitis B virus infection. *N Engl J Med* 1997; 337: 1733-44.
- Hoofnagle JH, Di Bisceglie AM. The treatment of chronic hepatitis. *N Engl J Med* 1997; 336: 347-56.
- Poynard T, Bedossa P, Opolon P, et al. Natural history of liver fibrosis progression with chronic hepatitis C. *Lancet* 1997; 349: 825-32.
- Koff RS. Hepatitis A. *Lancet* 1998; 351: 1643-9.
- Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine of chronic hepatitis B. *N Engl J Med* 1998; 339: 61-8.
- Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. *N Engl J Med* 1998; 339: 1493-9.
- McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. *N Engl J Med* 1998; 339: 1485-92.
- Niederer C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. *Hepatology* 1998; 28: 1687-95.
- Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. *BMJ* 1998; 317: 437-40.
- Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. *N Engl J Med* 1998; 338: 286-90.
- Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med* 1999; 341: 1256-63.
- EASL International Consensus Conference on Hepatitis C. *J Hepatol* 1999; 31 (Suppl.1): 3-8.
- Jack AD, Hall AJ, Maine N, et al. What level of hepatitis B antibody is protective? *J Infect Dis* 1999; 179: 489-92.
- Marcellin P. Hepatitis C: the clinical spectrum of the disease. *J Hepatol* 1999; 31 (Suppl.1): 9-16.
- Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. *Gastroenterology* 1999; 116: 378-86.
- Jaekel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with Interferon alpha 2b. *N Engl J Med* 2001; 345: 1452-7.
- Lauer GM, Walker BD. Hepatitis C virus infection. *N Engl J Med* 2001; 345: 41-52.
- Penilo R, Schiff ER, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. *Hepatology* 2000; 32: 129-34.
- Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2001; 34: 1225-41.
- Alberti A, Boccardo S, Vario A, et al. Therapy of acute hepatitis C. *Hepatology* 2002; 36 (suppl 1): S195-S200.
- Conjeevaram HS, Lok AS. Management of chronic hepatitis B. *J Hepatol* 2003; 38 (Suppl 1): S90-103. Erratum in: *J Hepatol* 2003; 38: 876.
- Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. *Gastroenterology* 2003; 125: 80-88.
- Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipi-

- voxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. *N Engl J Med* 2003; 348: 800-7.
- Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. *Gastroenterology* 2003; 125: 1714-22.
- Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. *N Engl J Med* 2003; 348: 808-16.
- Lin KW, Kirchner JT. Hepatitis B. *Am Fam Physician* 2004; 69: 75-82.
- Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus Ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *N Engl J Med* 2004; 351: 438-50.
- Wiegand J, Jeckel E, Cornberg M, et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. *Hepatology* 2004; 40: 98-107.
- Lok AS. New treatment of chronic hepatitis B. *Semin Liver Dis* 2004; 24 (Suppl 1): 77-82.
- Lok AS, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. *Hepatology* 2004; 39: 857-61.
- Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. *Gastroenterology* 2004; 126: 1015-23.

Hépatite alcoolique

- Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. *Gastroenterol* 1978; 75: 193-9.
- Carithers RL, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. *Ann Intern Med* 1989; 110: 685-90.
- Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. *N Engl J Med* 1992; 326: 507-12.
- Salaspuro M. Biological state makers of alcohol abuse. *Alcohol Health Res World* 1994; 18: 131-5.
- Lieber CS. Medical disorders of alcoholism. *M Engl J Med* 1995; 333: 1058-65.
- Stauber RE, Stepan V, Trauner M, et al. Evaluation of carbohydrate-deficient transferrin for detection of alcohol abuse in patients with liver dysfunction. *Alcohol Alcohol* 1995; 30: 171-6.
- Lesch OM, Walter H. A new "state" marker for the detection of alcoholism. *Alcohol Alcohol* 1996; 31 (Suppl.1): 59-62.
- Mathurin P, Duchatelle V, Ramond MJ, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. *Gastroenterol* 1996; 110: 1847-53.
- Naveau S. Les indications de la ponction-biopsie hépatique chez les sujets alcooliques. *Hepato Gastro* 1999; 1: 11-5.
- Spahr L, Burckhardt B, Hadengue A. La maladie alcoolique du foie. *Med Hyg* 2000; 8: 262-6.

Troubles intestinaux fonctionnels

- Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. *BMJ* 1978; 2: 653-4.
- Lennard-Jones JE. Functional gastrointestinal disorders. *N Engl J Med* 1983; 308: 431-5.
- Camilleri M, Prather CM. The irritable bowel syndrome: mechanisms and a practical approach to management. *Ann Intern Med* 1992; 116: 1001-8.
- Culliford GL, Coffey JF, Carr-Locke DL. Irritable bowel syndrome: can the patient's response colonoscopy help with diagnosis. *Digestion* 1992; 52: 209-13.
- Accarino AM, Azizov F, Malagelada JR. Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. *Gastroenterology* 1998; 108: 636-43.
- Agréus L, Svärdsudd K, Nyren O, et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lock of stability over time. *Gastroenterology* 1995; 109: 671-80.
- Drossmann DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. *Gastroenterology* 1997; 112: 2120-37.
- Aziz A, Thompson DG. Brain-gut axis in health and disease. *Gastroenterol* 1998; 114: 559-78.
- Farthing JMG. New drugs in the management of the irritable bowel syndrome. *Drugs* 1998; 56: 11-21.
- Camilleri M. Review article: clinical evidence to support therapies of irritable bowel syndrome. *Aliment Pharmacol Therap Ther* 1999; 13: 48-53.
- Hammer J, Talley NJ. Diagnostic criteria for the irritable bowel syn-

drome. *Am J Med* 1999; 107: 5S-11S.

Thompson WG. Irritable bowel syndrome: a management strategy. *Baillière's clinical Gastroenterology* 1999; 13: 453-60.

Drossmann DA. The functional gastrointestinal disorders, their diagnosis, and the Rome II process. In: Drossmann DA, Corazzini E, Talley NJ, et al. (eds.). *Rome II. The functional gastrointestinal disorders: diagnosis, pathophysiology and treatment: a multinational consensus*. McLean VA: Degnon Associates, 2000: 1-36.

De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. *Drugs* 2001; 61: 317-32.

Camilleri M. Management of the irritable bowel syndrome. *Gastroenterology* 2001; 120: 652-68.

Intolérance au lactose

Bayless TM, et al. A racial difference in incidence of lactase deficiency: a survey of milk intolerance and lactase deficiency in healthy adult males. *JAMA* 1966; 197: 968-72.

Bayless TM, et al. Lactose and milk intolerance: clinical implications. *N Engl J Med* 1975; 292: 1156-9.

Newcomer AD, McGill DB, Thomas PJ, et al. Prospective comparison of indirect methods for detecting lactase deficiency. *N Engl J Med* 1975; 293: 1232-6.

Rosade JL, Solomons NW. Sensitivity and specificity of the hydrogen breath-analysis test for detecting malabsorption of physiological doses of lactose. *Clin Chem* 1983; 29: 545-8.

Hammer HF, Petrich W, Pristautz H et al. Assessment of the influence of hydrogen nonexcretion on the usefulness of the hydrogen breath test and lactose tolerance test. *Wien Klin Wochenschr* 1996; 108: 137-41.

Shaw AD, Davies GJ. Lactose intolerance: problems in diagnosis and treatment. *J Clin Gastroenterol* 1999; 28: 208-16.

Högenauer C, Hammer HF, Mellitzer K et al. Evaluation of a new DNA test compared with the lactose hydrogen breath test for the diagnosis of lactase non-persistence. *Eur J Gastroenterol Hepatol* 2004; 17: 371-6.

Kubli M, Tuitan R, Fried M et al. Chronische Diarrhoe - Fallgruppe Laktasemangel. *Forum Med Schweiz* 2007; 7: 422-4.

Maladie de WHIPPLE

Galperin C, Gershwin ME. Immunopathogenesis of gastrointestinal and hepatobiliary diseases. *JAMA* 1997; 278: 1946-55.

Feldman M, Scharnschmidt BF, Sleisenger MH (eds.). In: *Sleisenger and Fordtran's gastrointestinal and liver diseases*. W Saunders Company, 1998.

Malabsorption

De la Morena ES, Chantar R. Malabsorción intestinal. In: *Rodés J, et al. (eds.). El Manual de Medicina*. Masson, S.A., 1993, p: 539-61.

Falk R, Comenzo RL, Skinner M. The systemic amyloidoses. *N Engl J Med* 1997; 337: 898-909.

Feldman M, Scharnschmidt BF, Sleisenger MH (eds.). *Sleisenger and Fordtran's gastrointestinal and liver diseases*. W. Saunders Company, 1998.

Furness BW, Beach MJ, Roberts JM. Giardiasis surveillance - United States, 1992-1997. *MMWR CDC Surveill Summ* 2000; 49: 1-13.

Coeliakie - Sprue

Trier JS. Celiac sprue and refractory sprue. *Gastroenterology* 1978; 75: 307-16.

Revised criteria for diagnosis of coeliac disease: report of working group of European society of paediatric gastroenterology and nutrition. *Arch Dis Child* 1990; 65: 909-11.

Dietrich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. *Nat Med* 1997; 3: 797-801.

Greco L, Romino R, Coto I et al. Their first large population based twin study of coeliac disease. *Gut* 2002; 50: 624-8.

Farrell RJ, Kelly CP. Celiac sprue. *N Engl J Med* 2001 ; 346: 180-8.

Green PHR, Cellier Ch. Celiac Disease. *N Engl J Med* 2007; 357: 1731-43.

Maladie de CROHN

Best WR, Beckett JM, Singleton JW, et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. *Gastroenterology* 1976; 70: 439-44.

Best WR, Beckett JM, Singleton JW, et al. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). *Gastroenterology* 1979; 77: 843-6.

Hodgson HJF, Mazlam MZ. Assessment of drug therapy in inflammatory bowel disease. *Aliment Pharmacol Ther* 1991; 5: 555-84.

Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. *N Engl J Med* 1994; 331: 842-5.

Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. *Ann Intern Med* 1995; 123: 132-42.

Hanauer SB. Inflammatory bowel disease. *N Engl J Med* 1996; 334: 841-8.

Guyot J, Hess J, Fasel J. Maladies inflammatoires intestinales. *Med Hyg* 1999; 57: 199-206.

Podolsky DK. Inflammatory bowel disease. *N Engl J Med* 2002; 347: 417-29.

Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab Pegol for the Treatment of Crohn's Disease. *N Engl J Med* 2007; 357: 228-38.

Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance Therapy with Certolizumab Pegol for Crohn's Disease. *N Engl J Med* 2007; 357: 239-50.

Rectocolite ulcéro-hémorragique

Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. *BMJ* 1955; 2: 1041-8.

Hanauer SB. Inflammatory bowel disease. *N Engl J Med* 1996; 334: 841-8.

Guyot J, Hess J, Fasel J. Maladies inflammatoires intestinales. *Med Hyg* 1999; 57: 199-206.

Podolsky DK. Inflammatory bowel disease. *N Engl J Med* 2002; 347: 417-29.

Constipation

Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. *Gut* 1999; 45: 43-7.

Lembo A, Camilleri M. Chronic constipation. *N Engl J Med* 2003; 349: 1360-8.

Reflux gastro-oesophagien, oesophagite

El-Serag HB, Sonnenberg A. Associations between different forms of gastro-oesophageal reflux disease. *Gut* 1997; 41: 594-9.

Ferraris R, Bonelli L, Conio M, et al. Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme. *Eur J Gastroenterol Hepatol* 1997; 9: 881-5.

Dent J. Gastro-oesophageal reflux disease. *Digestion* 1998; 59: 433-45.

Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 1999; 340: 825-31.

Jornod Ph, Blum AL, Armstrong D. Oesophagite par reflux: classification. In: Dupas JL, Fléjoux (eds.). *Maladies de l'oesophage, de l'estomac et du duodénum*. Editions Arnette, 1999.

Jornod Ph, Vuillaume D, Blum AL. Oesophagite peptique. *Med Hyg* 2000; 58: 209-15.

Spechler SJ. Barrett's esophagus. *N Engl J Med* 2002; 2002: 346: 836-42.

Vakil N, van Zanten SV, Kahrilas P, et al. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006; 101: 1900-20; quiz 1943.

Helicobacter pylori

NIH Consensus development conference. *Helicobacter pylori* in peptic ulcer disease. *JAMA* 1994; 272: 65-9.

Lind T, et al. Eradication of *Helicobacter pylori* using one-week triple therapies combining omeprazole with two antimicrobials: the Mach I study. *Helicobacter* 1996; 1: 138-44.

Soil AH. Medical treatment of peptic ulcer disease. *Practice guidelines*. *JAMA* 1996; 275: 622-9. [Erratum: *JAMA* 1996; 275: 1314].

Dominguez-Munoz, et al. A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of *Helicobacter pylori* infection. *Gut* 1997; 40: 459-62.

The European *Helicobacter Pylori* Study Group (EHPG). Current European concepts in the management of *H. pylori* infection. The Maastricht consensus report. *Gut* 1997; 41: 8-13.

HuntRH, Thompson ABR. Canadian *Helicobacter pylori* consensus conference. *Can J Gastroenterol* 1998; 12: 314-41.

Hunt RH, Fallone CA, Thomson AB. Canadian *Helicobacter pylori* consensus conference update: infections in adults. *Can J*

Gastroenterol 1999; 13: 213-7.
Viani F, Blum AL, Koelz HR, Pantoflickova D. Helicobacter pylori, ulcère gastro-duodénal et AINS. Med Hyg 2000; 58: 216-24.
Harris A, Misiewicz JJ. ABC of the upper gastrointestinal tract. Management of helicobacter pylori infection. BMJ 2001; 323: 1047-50.
Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
Vulliamoz D, Viani F, Jornod P, et al. Maladies peptiques. Rev Med Suisse 2005; 1: 200-8.

ZOLLINGER-ELLISON Syndrome

Jensen RT, Fraker DL. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma. JAMA 1994; 271: 1429-35.
Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Ann Rev Med 1995; 46: 395-411.
Wolfe MM, Jensen RT. Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med 1997; 317: 1200-9.
Norton JA, Fraker DL, Surgery, Alexander R, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 635-44.
Wells SA, Jr. Surgery for the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 689-90.

Dumping syndrome

Lev-Ran A, Anderson RW. The diagnosis of postprandial hypoglycemia. Diabetés 1981; 30: 996-9.
Parardi J, Havrankova J, Lepage R, et al. Blood glucose measurement during symptomatic episodes in patients with suspected postprandial hypoglycemia. N Engl J Med 1989; 321: 1421-5.

NEUROLOGIE

Textbook

Biller J. (ed.). Practical Neurology. Lipincott-Raven Publishers 1997.

Hémorragie cérébrale

Anderson CS, Heeley E, Huang Y, et al. INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013; 368: 2355-65.

Accident cérébro-vasculaire (AVC)

Goldstein M, Bolis CL, (eds.). Cerebrovascular disorders: a clinical and research classification. Geneva: World Health Organization, 1978. (WHO offset publication no 43.)
Bogousslavsky J. Embolies cérébrales d'origine cardiaque: quand anticoaguler? Schweiz Med Wschr 1985; 115: 1381-6.
Garcia JH, et al. Physiopathology of cerebral ischemia. Crit Rev Neurobiol 1989; 4: 303-24.
Farrell B, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-54.
North american symptomatic carotid endarterectomy trial collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325: 445-53.
Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991; 84: 527-39.
The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-6.
Sieber FE, Traystman RJ. Special issues: glucose and brain. Crit Care Med 1992; 20: 104-14.
European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62.
Powers WJ. Acute hypertension after stroke. Neurology 1993; 43: 461-7.
Adams HPJ, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994; 25: 1901-14.
Feinberg WM, Albers GW, Barnett HJM, et al. Guidelines for the management of transient ischemic attacks. Stroke 1994; 25:

1320-35.
Matchar DB, McCrory DC, Barnett HJM, et al. Guidelines for medical treatment for stroke prevention. Ann Intern Med 1994; 121: 54-5.
Blecic S, Bogousslavsky J. General management of patients with ischemic stroke: Clinical features and epidemiology. Curr Opin Neurol 1995; 8: 30-7.
Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. N Engl J Med 1995; 333: 1392-1400.
Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421-8.
Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European cooperative acute stroke study (ECASS). JAMA 1995; 274: 1017-25.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.
Berger JP. Petits débits cérébraux, attaques d'ischémie transitoire et syncopes. Rev Med Suisse Rom. 1996; 116: 597-604.
CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events. Lancet 1996; 348: 1329-39.
Dewarrat A, Bogousslavsky J. Antithrombotiques et prevention des accidents vasculaires cérébraux. Rev Med Suisse Rom 1996; 116: 629-34.
Fisher M, Garcia JH. Evolving stroke and the ischemic penumbra. Neurology 1996; 47: 884-8.
CAST Collaborative Group. CAST: Randomized placebo-controlled trial of early aspirin use in 20000 patients with acute ischemic stroke. Lancet 1997; 349: 1641-9.
International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischemic stroke. Lancet 1997; 349: 1569-81.
Barnett HJM, Taylor DW, Eliasziw M, et al. for the North American Symptomatic Carotid-Endarterectomy Trial Collaborators (NAS-CET). Benefit of carotid endarterectomy in patients with symptomatic moderate to severe stenosis. N Engl J Med 1998; 339: 1415-25.
Christ M, Diener HC, Kurth T, et al. Sekundärprävention atherosklerotischer Erkrankungen in der täglichen Praxis. Internist 1998; 39: 1080-97.
European Carotid Surgery Trialists' Cooperative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351: 1379-87.
Kidwell CS, Saver JL, Schubert GB, et al. Design and retrospective analysis of the Los Angeles prehospital stroke screen (LAPSS). Prehosp Emerg Care 1998; 2: 267-73.
Schrader J, Rothenmeyer M, Luders S, et al. Hypertension and stroke - rationale behind the ACCESS trial. Acute candesartan cilexetil evaluation in stroke survivors. Bas Res Cardiol 1998; 93 (Suppl. 2): 69-78.
Broderick JP et al. Am.Stroke Assoc. Guidelines for intracerebral hemorrhage: Stroke 1999; 30:905-15.
Kappelle LJ, Eliasziw M, Fox AJ, et al. for the North American Symptomatic Carotid-Endarterectomy Trial Group. Importance of intracranial atherosclerotic disease in patients with symptomatic stenosis of the internal carotid artery. Stroke 1999; 30: 282-6.
Kothari RU, Panciolo A, Liu T, et al. Cincinnati Prehospital Stroke Scale: reproducibility and validity. Ann Emerg Med 1999; 33: 373-8.
Brott Th, Bogousslavsky J. Treatment of acute ischemic stroke. N Engl J Med 2000; 343: 710-22.
Inzitari D, Eliasziw M, Gates P, et al. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. N Engl J Med 2000; 342: 1693-700.
Kidwell CS, Starkman S, Eckstein M, et al. Identifying stroke in the field: prospective validation of the Los Angeles Prehospital Stroke Screen (LAPSS). Stroke 2000; 31: 71-6.
Kistler JP, Furie KL. Carotid endarterectomy revisited. N Engl J Med 2000; 342: 1743-45.
Steiner Th, Hennes HJ, Kretz R, et al. Akute klinische Schlaganfallbehandlung. Anaesthesist 2000; 49: 2-8.
Zerebrovaskuläre Arbeitsgruppe der Schweiz (ZAS) und Schweizerische Herzstiftung (SHS). Sekundärprävention nach ischämischem Schlaganfall. Schweiz Aerztezeitung 2000; 81: 1105-15.

Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Sixth ACCP Consensus Conference on antithrombotic therapy. *Chest* 2001; 119 (Suppl. 1): 300S-320S.

Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke. A statement for healthcare professionals from the stroke council of the american heart association. *Stroke* 2001; 32: 280-99. Or in: *Circulation* 2001; 103: 163-82.

Sacco RL. Extracranial carotid stenosis. *N Engl J Med* 2001; 345: 1113-8.

Barnett HJM, Meldrum HE, Eliasziw M, et al. The appropriate use of carotid endarterectomy. *CMAJ* 2002; 166: 1169-79.

Schrader J, Luders S, Kulschewski A, et al. ACCESS study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors [Abstract]. *Am J Hypertension* 2002; 15: 17A.

Adams HP et al. Am.Stroke Assoc. Guidelines for ischemic stroke. *Stroke* 2003; 34: 1056-83.

Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet* 2004; 364: 331-37.

Toni D et al. European Stroke Initiative recommendations. *Cerebrovasc Dis* 2004; 17 Suppl 2:30-46.

Adams H, Adams R, del Zoppo G, et al. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update: AHA/ASA. *Stroke* 2005; 36: 916-32.

AHA Part 9: Adult Stroke. *Circulation* 2005; 112: 111-20.

Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke (AHA). *Stroke* 2007; 38: 1655-711 (Erratum *Stroke* 2007; 38: e38).

Bart von der Worp H, Gijn J. Acute ischemic stroke. *N Engl J Med* 2007; 357: 572-9.

Paciaroni M, Agnelli G, Micheli S, et al. Efficacy and safety of anti-coagulation treatment in acute cardioembolic stroke; a meta-analysis of randomized controlled trials. *Stroke* 2007; 38: 423-30.

Thrombolyse de l'AVC

The national institute of neurological disorders and stroke, rt-PA stroke study group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med* 1995; 333: 1581-7.

Bogousslavsky J. Thrombolysis in acute stroke. *BMJ* 1996; 313: 640-1.

Bogousslavsky J, Buettner UW, Hess K, et al. Thrombolyse intraveineuse par rt-PA (recombinant tissue plasminogen activator) dans le traitement aigu des accidents vasculaires cérébraux. *Bull Médecins Suisses* 1998; 79: 114-5.

Fifth consensus conference on antithrombotic therapy (1998): summary recommendations. *Chest* 1998; 114 (Suppl.): 439S-769S.

Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australian Acute Stroke Study Investigators. *Lancet* 1998; 352: 1245-51.

Norris JW, Buchman A, Cote, et al. Canadian guidelines for intravenous thrombolytic treatment in acute stroke. *Can J Neurol Sci* 1998; 25: 257-9.

Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. *JAMA* 1999; 282: 2019-26.

Furlan A et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomised controlled trial. *Prolyse in acute cerebral thromboembolism*. *JAMA* 1999; 282: 2003-11.

Hallan S et al. A decision analysis of thrombolytic therapy compared with standard therapy in acute ischemic stroke. *J Intern Med* 1999; 246: 549-59.

Ueda T et al. Multivariable analysis of predictive factors related to outcome at 6 month after intra-arterial thrombolysis for acute ischemic stroke. *Stroke* 1999; 30: 2360-5.

Brott TH, Bogousslavsky J. Treatment of ischemic stroke. *N Engl J Med* 2000; 343: 710-22.

Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. *Chest* 2001; 119 (Suppl.): 300S-320S.

ANAES Recommandations pour la pratique clinique. Prise en charge initiale des patients adultes atteints d'accident vasculaire cérébral. Aspects médicaux. Septembre 2002, p. 1.127.

AHA Part 9: Adult Stroke. *Circulation* 2005; 112: 111-20.

Aphasie

Geschwind N. Aphasia. *N Engl J Med* 1971; 284: 654-6.

Damasio AR. Aphasia. *N Engl J Med* 1992; 326: 531-8.

Mesulam MM. Primary progressive aphasia - a language-based dementia. *N Engl J Med* 2003; 349: 1535-42.

Trombose veineuse cérébrale

Stam J. Thrombosis of the Cerebral Veins and Sinuses. *N Engl J Med* 2004; 352: 1791-8.

Dystonie aiguë - Dyskinésies tardives

De Gowin EL, De Gowin RL (eds.). *Diagnostic au lit du malade*. Doin Editions-Paris, 1980, p. 808-18.

Marschen D, Fahn S. (eds.). *Movement disorders 1, 2, 3*.

Butterworth Heinenmann, 1996.

Van Harten P, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. *BMJ* 1999; 319: 623-6.

Céphalée, migraine

NET: Guidelines/Headache/www.aan.com/professionals / 1-25. 2005.

Bruyn GW. Intracranial arteriovenous malformation and migraine. *Cephalalgia* 1984; 4:191-207.

Mitchell CS, Osborn RE, Grosskreutz SR. Computed tomography in the headache patient: is routine evaluation really necessary? *Headache* 1993; 33:82-86.

Frishberg BM. The utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations. *Neurology* 1994; 44:1191-1197.

Akpek S, Arac M, Atilla S, Onal B, Yucel C, Isik S. Cost-effectiveness of computed tomography in the evaluation of patients with headache. *Headache* 1995; 35:228-230.

Weiller C, May A, Limmoth V, Juptner M, Kaube H, Schayck RV, Coenen HH, Diener HC. Brain stem activation in spontaneous human migraine attacks. *Nat Med* 1995; 1:658-660.

Dde Bruijn SF, Stam J, Kappelle LJ. Thunderclap headache as first symptom of cerebral venous sinus thrombosis. *CVST Study Group*. *Lancet* 1996; 348:1623-1625.

Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. *Cell* 1996; 87:543-552.

Frishberg BM. Neuroimaging in presumed primary headache disorders. *Semin Neurol* 1997; 17:373-382.

Morgenstern LB, Luna-Gonzales H, Huber JC, Jr, Wang SS, Uthman MO, Gurian JH, Castillo PR, Shaw SG, Frackowiak RF, Grotta JC. Worst headache and subarachnoid hemorrhage: prospective, modern computed tomography and spinal fluid analysis. *Ann Emerg Med* 1998; 32:297-304.

Newman LC, Lipton RB. Emergency department evaluation of headache. *Neurol Clin* 1998; 16:285-303.

Sommer-Bühler J, Sztajzel R, Le Floch-Rohr J, et al. Les céphalées. *Med Hyg* 2000; 58: 788-96.

Bahra A, Matharu MS, Buechel C, Frackowiak RS, Goadsby PJ. Brainstem activation specific to migraine headache. *Lancet* 2001; 357:1016-1017.

Goadsby PJ. Neuroimaging in headache. *Microsc Res Tech* 2001; 53:179-187.

Morgenstern LB, Huber JC, Luna-Gonzales H, Saldin KR, Grotta JC, Shaw SG, Knudson L, Frankowski RF. Headache in the emergency department. *Headache* 2001; 41:537-541.

Van GJ, Rinkel GJ. Subarachnoid haemorrhage: diagnosis, causes and management. *Brain* 2001; 124:249-278.

Dodick DW. Thunderclap headache. *Headache* 2002; 42:309-315.

Ekbom K, Hardebo JE. Cluster Headache aetiology, diagnosis and management. *Durges* 2002; 62: 61-9.

Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. *Lancet Neurol* 2002; 1:251-257.

Goadsby PJ, Lipton RB, Ferrari MD, et al. Migraine - current understanding and treatment. *N Engl J Med* 2002; 346: 257-70.

Mattie HP, Sturzenegger M, Meyer C. Céphalée symptomatiques. *Forum Med Suisse* 2002; 5: 93-9.

Medina L, D'Souza B, Vasconcellos E. Adults and children with headache: evidence-based diagnostic evaluation. *Neuroimaging Clin N Am* 2003; 13:225-235.

Ramadan, N. M. Headache update. Headache update. Continuum lifelong learning in neurology from the american academy of neurology 9, 9-24. 2003. Lippincott, Williams, Wilkins.

Cortelli P, Cevisi S, Nonino F, Baronciani D, Magrini N, Re G, De BG, Manzoni GC, Querzani P, Vandelli A. Evidence-based dia-

gnosis of nontraumatic headache in the emergency department: a consensus statement on four clinical scenarios. *Headache* 2004; 44:587-595.

Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria criteria for headache disorders, cranial neuralgias, and facial pain. *Cephalalgia Suppl* 1, S1-S160. 2004.

Lipton RB, Bigal ME, Steiner TJ, Silberstein SD, Olesen J. Classification of primary headaches. *Neurology* 2004; 63:427-435.

Olesen J, Lipton RB. Headache classification update 2004. *Curr Opin Neurol* 2004; 17:275-282.

Swartz RH, Kern RZ. Migraine is associated with magnetic resonance imaging white matter abnormalities: a meta-analysis. *Arch Neurol* 2004; 61:1366-1368.

Sempere A, Porta-Etessam J, Medrano V, Garcia-Morales I, Concepcion L, Ramos A, Florencio I, Bermejo F, Botella C. Neuroimaging in the evaluation of patients with non-acute headache. *Cephalalgia* 2005; 25:30-35.

Epilepsie

Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical classification and electroencephalographic classification of epileptic seizures. *Epilepsia* 1981; 22: 489-501.

Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical classification and epileptic syndromes. *Epilepsia* 1989; 30: 389-99.

De Lorenzo. Status epilepticus in children, adult and the elderly. *Epilepsia* 1992; 33 (Suppl.4): S15- S25.

Greenberg MK, Barsan WG, Starkman S. Neuroimaging in the emergency patient presenting with seizure. *Neurology* 1996; 47: 26-32.

Despland PA, Foletti G. Strategies therapeutiques dans l'etat de mal epileptique. Les urgences neurologiques. Les 60 premières minutes. *Med Hyg* 1997; 55: 1073-7.

Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: A systematic review of their efficacy and tolerability. *Epilepsia* 1997; 38: 859-80.

Lowenstein DH, Alldredge BK. Status epilepticus. *N Engl J Med* 1998; 338: 970-6.

Markand ON. Epilepsie in adults. In: Biller J. (ed.). *Practical Neurology*. Lippincott-Raven Publishers 1997, pages 418-36.

Bleck TP. Management approaches to prolonged seizures and status epilepticus. *Epilepsia* 1999; 40: Suppl. 1:S59-S63.

Allredge BK, Gelb AM, Isaacs SM, et al. A comparison of Lorazepam, Diazepam and placebo for the treatment of out-of-hospital status epilepticus. *N Engl J Med* 2001; 345: 631-7.

Browne TR, Holmes GL. Epilepsy. *N Engl J Med* 2001; 344: 1145-51.

Chang BS, Lowenstein DH. Epilepsy. *N Engl J Med* 2003; 349: 1257-66.

Engl J Med 1995; 333: 1415-7.
Hughes RA, Hadden RD, Gregson NA, et al. Pathogenesis of Guillain-Barre syndrome. J Neuroimmunol 1999; 100: 74-97.
Willison HJ, O'Hanlon GM. The immunopathogenesis of Miller Fisher syndrome. J Neuroimmunol 1999; 100: 3-12.
Mori M, Kuwabara S, Fukutate T, et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001; 56: 1104-6.
Van der Meche FG, Van Doorn PA, Meulstee J, et al. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol 2001; 45: 133-9.
Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012; 366: 2294.

Hypertension intracrânienne, oedème cérébral

Bruns FJ, Fraley DS, Haigh J, et al. Control of organ blood flow. In: Snyder JV, Pinsky MR (eds.). Oxygen transport in the critically ill. Chicago: Year Book Medical Publishers 1987; 87-124.
Drummond JC, Shapiro HM. Cerebral physiology. In: Miller RD (ed.). Anesthesia. Churchill Livingstone, 1990, p. 625.
Lang EW, Chesnut RM. Intracranial pressure and cerebral perfusion pressure in severe head injury. New Horiz 1995; 3: 400-9.
Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996; 335: 1124-32.
Chesnut RM. The management of severe traumatic brain injury. Emerg Med Clin North Am 1997; 15: 581-604.
Lam CH, Villemure JG. Comparison between ventriculoatrial and ventriculoperitoneal shunting in the adult population. Br J Neurosurg 1997; 11: 43-8.
Corkill RG, Cadoux-Hudson TA. Normal pressure hydrocephalus: developments in determining surgical prognosis. Curr Opin Neurol 1999; 12: 671-7.
Zemack G, Romner B. Seven years of clinical experience with the programmable Codman Hakim valve: a retrospective study of 583 patients. J Neurosurg 2000; 92: 941-8.

Hydrocéphalie normotensive

Berg K, Wood-Dauphinee S, Williams JI. The Balance Scale: Reliability assessment for elderly residents and patients with an acute stroke. Scand J Rehab Med 1995; 27: 27-36.
Berg K, Wood-Dauphinee S, Williams JI, Maki, B. Measuring balance in the elderly: Validation of an instrument. Can. J. Pub. Health 1992; Suppl. 2: S7-11.
Wood-Dauphinee S, Berg K, Bravo G, Williams JI. The Balance Scale: Responding to clinically meaningful changes. Canadian Journal of Rehabilitation 1997; 10: 35-50.
Hebb AO, Cusimano MD. Idiopathic normal pressure hydrocephalus: a systematic review of diagnosis and outcome. Neurosurgery 2001; 49: 1166-86.

Syndrôme lombo-vertébral aigu

Calin A, Porta J, Fries JF, et al. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977; 237: 2613-4.
Weber H. Lumbar disc herniation. A controlled, prospective study with ten years of observation. Spine 1983; 8: 131-40.
Deyo RA, Tsui-Wu JY. Descriptive epidemiology of low-back pain and its related care in the United States. Spine 1987; 12: 264-8.
Kosteljanetz M, Bang F, Schmidt-Olsen S. The clinical significance of straight-leg-raising (Lasegue's sign) in the diagnosis of prolapsed lumbar disc. Spine 1988; 13: 393-5.
McCombe PF, Fairbank JCT, Cockersole BC, et al. Reproducibility of physical signs in low-back pain. Spine 1989; 14: 908-18.
Boden SD, Davis DO, Dina TS, et al. Abnormal magnetic resonance scans of the lumbar spine in asymptomatic subjects. J Bone Joint Surg Am 1990; 72: 403-8.
Deyo RA, Rainville J, Kent DL. What can the history and the physical examination tell us about low back pain? JAMA 1992; 268: 760-5.
Leuba Manueddu B, Stalder H. Lumbalgie aiguë. Med Hyg 1995; 54: 1745-9.
Malmivaara A, Häkkinen U, Aro T, et al. The treatment of acute low back pain - bedrest, exercises, or ordinary activity. N Engl J Med 1995; 332: 351-5.

Syndromes extrapyramidal, pyramidal, cérébelleux. Réflexes

Babinski J. tournay A. Symptômes des maladies du cerveau. Rev Neurol 1993; 18: 306-22.
De Gowing EL, De Gowing RL (eds.). Diagnostic au lit du malade. Doin Editions-Paris, 1980, p. 808-18.

Marschen D, Fahn S. (eds.). Mouvement disorders 1, 2, 3. Butterworth Heinemann, 1996.

Syndrôme d'impatience des membres inférieurs à l'éveil (RLS) Restless legs syndrome

Walters AS. Toward a better definition of the restless legs syndrome: the international restless legs syndrome study group. Mov Disord 1995; 10: 634-42.
Rothdach AJ, Trenkwalder C, Haberkost J, et al. Prevalence and risk factors of RLS in an elderly population. Neurology 2000; 54: 1064-8.
Mathis J. Das restless legs Syndrom und periodische Beinbewegungen im Schlaf. Med Hyg 2003; 61: 106-7.
Comella CL. Restless legs syndrome: treatment with dopaminergic agents. Neurology 2002; 58 (Suppl. 4): S87-S92.
Odin P, Mrowka M, Shing M. Restless legs syndrome. Eur J Neurol 2002; 9 (Suppl 3): S59-S67.
Stiasny K, O'Pertel WH, Trenkwalder C. Clinical symptomatology and treatment of restless legs syndrome and periodic limb movement disorder. Sleep Med Rev 2002; 6: 253-65.
Mathis J. Das Restless Legs Syndrom in der Praxis. Swiss Medical Forum 2002; 4: 67-71.
Garcia-Borreguero D et al.. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med 2013; 14: 675-684.

Tremblement

Elbe RJ, Koller WC. Tremor. Johns Hopkins University Press, Baltimore 1990.
Ghika J, Kuntzer R, Regli F. Les tremblements. Revue Suisse de medecins (Praxis). 1993; 82: 759-68.
Findly LJ, Koller WC. (eds.). Handbook of tremor disorders. Marcel Dekker, 1999.
Habib-ur-Rehman. Diagnosis and management of tremor. Arch Intern Med 2000; 160: 2438-44.
Habib-ur-Rehman. Arch Intern Med 2000; 160: 2438-44.
Sullivan KL, Hauser RA, Siewicz TA. Essentiel tremor. Epidemiology, diagnosis, and treatment. Neurologist 2004; 10: 250-8.
Practice parameter. Therapies for Essential Tremor. Neurology 2005; 64: 2008-20.

Parkinsonisme — M. PARKINSON

Calne DB. Treatment of parkinson's disease. N Engl J Med 1993; 329: 1021-7.
Ghika J, Regli F. Nouvelles acquisitions thérapeutiques dans la maladie de Parkinson. Med Hyg 1995; 53: 32-6.
Dooley M, Markham A. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. Drugs & Aging 1998; 12: 495-514.
Groupe de travail de la commission de therapie de la Societe suisse de neurologie (SNN). Recommandations pour le traitement du syndrôme de Parkinson idiopathique. Bulletin des Medecins Suisses 1998; 79: 425-7.
Lang AE, Lozano AM. Parkinson's disease, first of two parts. N Eng J Med 1998; 339: 1044-53.
Lang AE, Lozano AM. Parkinson's disease, second of two parts. N Eng J Med 1998; 339: 1130-43.
Dewey RB Jr, Hutton JT, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58: 1385-92.
Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349: 1925-34.
Groupe de travail de la commission de therapie de la Societe suisse de neurologie. Archives de Suisses de Neurologie et de Psychiatrie 2004; 155: 74-8.
Burkhard PR, Villemure JG, Vingerhoets FJG. Traitement actuel de la maladie de Parkinson: difficultés et controverses. Rev Med Suisse 2005; 1: 1214-9.
Nutt JG, Wooten GF. Diagnosis and initial management of Parkinson's Disease. N Engl J Med 2005; 353: 1021-7.

Drop attack

Brust JCM, Plank CR, Heaton EB, et al. The pathology of drop attacks: a case report. Neurology 1979; 29: 786-790.

Lipsitz LA. The drop attack: a common geriatric symptom. *J Am Geriatric Soc* 1983; 31: 617-20.

Meissner I, Wiebers DO, Swanson JW, et al. The natural history of drop attacks. *Neurology* 1986; 36: 1029-34.

Baloh RW, Jacobson K, Winder T. Drop attacks with Meniere's syndrome. *Ann Neurol* 1990; 28: 384-7.

Morillo CA, Villar JC. Neurocardiology. Neurogenic syncope. *Baillieres Clin Neurol* 1997; 6: 357-80.

Shaw FE, Kenny RA. The overlap between syncope and falls in the elderly. *Postgrad Med J* 1997; 73: 635-9.

Encéphalopathie de (GAYET)-WERNICKE, KORSKOFF

Reuler JB, Girard DE, Cooney TG. Wernicke's encephalopathy. *N Engl J Med* 1985; 312: 1035-9.

Lindberg MC, Oylar RA. Wernicke's encephalopathy. *Am Fam Physician* 1990; 41: 1205-9.

Heye N, Terstege K, Sirtl C, et al. Wernicke's encephalopathy - causes to consider. *Intensive Care Med* 1994; 20: 282-6.

Kril JJ. Neuropathology of thiamine deficiency disorders. *Metab Brain Dis* 1996; 11: 9-17.

Preuss UW, Soyka M. Wernicke-Korsakoff syndrome: clinical aspects, pathophysiology and therapeutic approaches. *Fortschr Neurol Psychiatr* 1997; 65: 413-20.

Zubaran C, Fernandes JG, Rodnigh R. Wernicke-Korsakoff syndrome. *Postgrad Med J* 1997; 73: 27-31.

Ponction lombaire, LCR

Kuntz KM, Kokmen E, Stevens JC, et al. Post-lumbar puncture headaches: experience in 501 consecutive procedures. *Neurology* 1992; 42: 1884-7.

Broadley SA, Fuller GN. Lumbar puncture needn't be a headache. Use blunt needles and no bed rest. *BMJ* 1997; 315: 1324-5.

Hasbun R, Abraham J, Jekel J, et al. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. *N Engl J Med* 2001; 345: 1727-33.

SLA/ALS - Sclérose latérale amyotrophique

Swash M, Leish N. Criteria for diagnosis of familial amyotrophic lateral sclerosis: European FALS Collaborative Group. *Neuromuscul Disord* 1992; 2: 7-9.

Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial «Clinical limits of amyotrophic lateral sclerosis» workshop contributors. *J Neurol Sci* 1994; 124, Suppl.: 96-107.

Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. *Neuropathol Appl Neurobiol* 1998; 24: 104-17.

Brooks BR, Miller RG, Swash M, et al. Revised Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. A Consensus Conference held at Airlie House, Warrenton, Virginia April 2-4, 1998.

Brooks BR, Miller RG, Swash M, Munat TL. World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revised: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2000; 1: 293-9.

De Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. *Clin Neurophysiol* 2008; 119: 497-503.

Sclérose en plaque - MS

Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". *Ann Neurol* 2005; 58: 840-6.

Ransohoff RM. Natalizumab for Multiple Sclerosis. *N Engl J Med* 2007; 356: 2622-9.

Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol* 2011; 69: 292-302.

Christian P, Kamm CP, Uitendhaag BM, Polman CH et al. Multiple Sclerosis: Current Knowledge and Future Outlook *Eur Neurol* 2014; 72: 132-41.

Insuffisance rénale aiguë

Humes HD. Aminoglycosides nephrotoxicity. *Kidney Int* 1988; 33: 900-8.

Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent decreases in renal function induced by radiocontrast agents. *N Engl J Med* 1994; 331:1416-20.

Brady HR, Singer GG. Acute renal failure. *Lancet* 1995; 346: 1533-40.

Thadani R, Pascual M, Bonventre JV. Acute renal failure. *N Engl J Med* 1996; 334: 1448-60.

Mindell JA, Chertow GM. A practical approach to acute renal failure. *Med Clin North Am* 1997; 81: 731-48.

NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation. *Am J Kidney Dis.* 1997; 30 (Suppl 2): S15-66.

Schrier RW, Gottschalk CW (eds). *Diseases of the kidney*. 6th edition, Little Brown & Co 1997.

Halperin ML, Goldstein MB, (ed). *Fluid, electrolyte, and acid-base physiology: a problem-based approach*, 3rd edition. W.B. Saunders Company, 1999.

Tepel M, Van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. *N Engl J Med* 2000; 343: 180-4.

Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. *Crit Care Med* 2001; 29: 1526-31.

Hoste EAJ, Clermont G, Kersten A et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. *Crit Care* 2006; 10: R73.

IRA sur produit de contraste

Barrett BJ. Contrast nephrotoxicity. *J Am Soc Nephrol* 1994; 5: 25-37.

Gutterer NV, Diaz A, Timmis GC, O'Neill WW, et al. Determinants of serum creatinine trajectory in acute contrast nephropathy. *J Interv Cardiol* 2002; 15: 349-54.

Barrett BJ, Parfrey S. Preventing Nephropathy Induced by Contrast Medium. *N Engl J Med* 2006; 354:379-86.

Marenzi G, Assanelli E, Marana I, et al. N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty. *N Engl J Med* 2006; 354: 2773-82.

Dialyse

Gillum DM, Dixon BS, Yanover MJ, et al. The role of intensive dialysis in acute renal failure. *Clin Nephrol* 1986; 25: 249-55.

Conger JD. Interventions in clinical acute renal failure: what are the data? *Am J Kidney Dis* 1995; 26:565-76.

Clark WR, Mueller BA, Kraus MA, Macias WL. Extracorporeal therapy requirements for patients with acute renal failure. *J Am Soc Nephrol* 1997; 8:804-12.

Insuffisance surrénalienne

Werbel SS, Ober KP. Acute adrenal insufficiency. *Endocrinol Metab Clin North Am* 1993; 22: 303-28.

Howlett TA. An assessment of optimal hydrocortisone replacement therapy. *Clin Endocrinol* 1997; 46: 263-8.

Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. *N Engl J Med* 2003; 348: 727-34.

Hamrahian AH, Oseni TS, Arafah BM. Measurements of Serum Free Cortisol in Critically Ill Patients. *N Engl J Med* 2004; 350: 1629-38.

Colique néphrétique, néphrolithiase

Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. *N Engl J Med* 1986; 315: 1386-9.

Consensus Conference. Prevention and treatment of kidney stones. *JAMA* 1988; 260: 977-81.

Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. *N Engl J Med* 1992; 327: 1141-52.

Curhan GC, Willet WC, Speizer FE, et al. Beverage use and risk for kidney stones in women. *Ann Intern Med* 1998; 128: 534-40.

Dobbins JM, Rao PM, Novelline RA, Bush JA. Unenhanced helical computed tomography for suspected urinary tract stones: current state of the art. *Em Radiol* 1998; 5: 97-102.

Hess B, Jost C, Zipperle L, et al. High calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. *Nephrol Dial Transplant* 1998; 13: 2241-7.

Borghli L, Schianchi T, Meschi T, et al. Comparison of two diets for

the prevention of recurrent stones in idiopathic hypercalcaemia. *N Engl J Med* 2001; 346: 77-84.

Sodium

- Berl T, Schrier RW. Water metabolism and the hypo-osmolar syndrome. In: Brenner BM, Stein JH (eds). *Sodium and Water Homeostasis*. Churchill Livingstone, New York, 1978.
- Ayus JC, Krothapalli RK, Arieff AI. Changing concepts in treatment of severe symptomatic hyponatremia. *Am J Med* 1985; 78: 897-902.
- Rose BD. New approach to disturbances in the plasma sodium concentration. *Am J Med* 1986; 81: 1033-40.
- Weisberg LS. Pseudohyponatremia. *Am J Med* 1989; 86: 315-18.
- Clutimans FH, Meinders AE. Management of severe hyponatremia: rapid or slow correction? *Am J Med* 1990; 88: 161-6.
- Schrier RW, Briner A. The differential diagnosis of hyponatremia. *Hosp Pract* 1990; 30: 29-37.
- Lauriat SM, Berl T. The hyponatremic patients: Practical focus on therapy. *J Am Soc Nephrol* 1997; 8: 1599-1607.
- Kumar S, Berl T. Sodium. *Lancet* 1998; 352: 220-8.
- Adrogué HJ, Madias NE. Hyponatremia. *N Engl J Med* 2000; 342: 1493-9.
- Adrogué HJ, Madias NE. Hyponatremia. *N Engl J Med* 2000; 342: 1581-9.
- Singer GG. Fluid and electrolyte management. In: Ahya SN, et al. (eds.). *The Washington Manual of medical therapeutics*. Lippincott Williams & Wilkins, 2001; p. 43-75.

Potassium

- Milne FJ, Gear JS, Laidley L, Ritchie M, et al. Spot urinary electrolyte concentrations and 24 hour excretion. *Lancet* 1980; 2: 1135.
- Blumberg A, Weidmann P, Ferrari P. Effect of prolonged intravenous bicarbonate administration on plasma potassium in terminal renal failure. *Kidney Int* 1992; 41: 369-74.
- Wallach J, (ed.) *Interpretation of Diagnostic Tests*. Little Brown, 1996.
- Gennari FJ. Hypokalemia. *N Engl J Med* 1998; 339: 451-8.
- Cohn JN, Kowey PR, Whelton PK, et al. New Guidelines for potassium replacement in clinical practice. *Arch Intern Med* 2000; 160: 2429-36.

Calcium et magnésium

- Reinhard RA, Desbien NA. Hypomagnesemia in patients entering the ICU. *Crit Care Med* 1985; 13: 506-7.
- Whang R. Management deficiency: pathogenesis, prevalence, and clinical implications. *Am J Med* 1987; 82: 24-9.
- Arrambide K, Toto RD. Tumor lysis syndrome. *Semin Nephrol* 1993; 13: 273-80.
- Wallach J, (ed.). *Interpretation of Diagnostic Tests*. Little Brown, 1996.
- Rose BD, Post TW, (ed). *Clinical physiology of acid-base and electrolyte disorders*. 5th edition, McGraw-Hill, New York, 2001.
- Singer GG. Fluid and electrolyte management. In: Ahya SN, et al. (eds.). *The Washington Manual of medical therapeutics*. Lippincott Williams & Wilkins, 2001; p. 43-75.

Phosphate

- Newman JH, Neff TA, Ziporen P. Acute respiratory failure associated with hypophosphatemia. *N Engl J Med* 1977; 296: 1101-3.
- Kingston M, Badawi AI-Siba'i M. Treatment of severe hypophosphatemia. *Crit Care Med* 1985; 13: 16-8.
- Knochel JP. Hypophosphatemia and rhabdomyolysis. *Am J Med* 1992; 92: 455-7.
- Brooks MJ, Melnik G. The refeeding syndrome: an approach to understanding its complications and preventing its occurrence. *Pharmacotherapy* 1995; 15: 713-26.
- Weisinger JR, Bellorin-Font E. Magnesium and phosphorus. *Lancet* 1998; 352: 391-6.
- Subramanian R, Khadori R. Severe hypophosphatemia. *Medicine (Baltimore)* 2000; 79: 1-8.
- Crook MA, Hally V, Pantelli JV. The importance of the refeeding syndrome. *Nutrition* 2001; 17: 632-7.

Insuff. rénale chron., urémie

- NET (Adaptations des posologies en cas d'IR) www.med.uni-heidelberg.de/med/klimpfarm/Nierebck.htm
- Smith HW. *The kidney: structure and function in health and disease*. Oxford University Press, New York 1951, 231-238.
- Berlyne G. Endogenous creatinine clearance and glomerular filtration

on rate. *Lancet* 1964; II: 874-6.

- Lubowitz H, Slatopolsky E, Shankel S, et al. Glomerular filtration rate. Determination in patients with chronic renal disease. *JAMA* 1967; 199: 252-6.
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; 16: 31-41.
- Brenner B, Meyer T, Hostetter T. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. *N Engl J Med* 1982; 307: 652-9.
- Fine LG. El síndrome uremico: mecanismos de adaptación y tratamiento. *Hosp Pract (Ed España)*; 1988; 3: 9-19.
- Caravaca F, Santos I, Cubero JJ. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. *Nephron* 1992; 60:423-7.
- Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. *Clin Chem* 1992; 38: 1933-53.
- Van Acker BA, Koomen GC, Koopman MG, et al. Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. *Lancet* 1992; 340: 1326-9.
- Klahr S, Levey AS, Beck GJ, et al. The effect of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. *N Engl J Med* 1994; 330: 877-84.
- Llach F. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. *Am J Kidney Dis* 1995; 25: 663-79.
- Peterson JC, Adler S, Burkart JM, et al. MDRD Group: Blood pressure control, proteinuria, and the progression of renal disease: The modification of Diet in Renal Disease Study. *Ann Intern Med* 1995; 123: 754-62.
- Klahr S. Role of dietary protein and blood pressure in the progression of renal disease. *Kidney Int* 1996; 49: 1783-6.
- Kopple JD, Levey AS, Greene T, et al. Effect of dietary protein restriction on nutritional status in the modification of diet in renal disease study. *Kidney Int* 1997; 52: 778-91.
- NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. *Am J Kidney Dis* 1997; 30 (Suppl.3): S192-S240.
- The Sixth Report of the Joint National Committee on Detection, Evaluation, and Diagnosis of High Blood Pressure (JNC VI). *Arch Intern Med* 1997; 157: 2413-46.
- Cameron J, Greger R. Renal function and testing of function, in AM Davidson, JS Cameron, JP Grunfeld, et al., *Oxford textbook of clinical nephrology*. Oxford University Press Oxford 1998, 39-69.
- Gallieni M. Iron in the treatment of anemia in dialysis patients: an important support to erythropoietin. *Int J Artif Organs* 1998; 21: 681-6.
- Walser M. Assessing renal function from creatinine measurements in adults with chronic renal failure. *Am J Kidney Dis* 1998; 32: 23-31.
- Rahn KH, Heidenreich S, Bruckner D. How to assess glomerular function and damage in humans. *J Hypertens* 1999; p. 309-317.
- Halabi G, Vogel G, Wauters JP. *Hypertrophie rénale secondaire: Prévention et traitement*. *Med Hyg* 1999; 57: 432-6.
- Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999; 130: 461-70.
- Rahn KH, Heidenreich S, Bruckner D. How to assess glomerular function and damage in humans. *J Hypertens* 1999; 309-17.
- Working Party for European Management of Anaemia in patients with chronic renal failure. European best practice guidelines for the management of anaemia in patients with chronic renal failure. *Nephrol Dial Transplant* 1999; 14 (Suppl. 5): 1-50.
- Ruedin P. Nouvelles recommandations du traitement de l'anémie au cours de l'insuffisance rénale chronique. *Med Hyg* 2001; 59: 495-9.
- Eknoyan G, Levin NW, Eschbach JW, et al. Continuous quality improvement: DOQI becomes K/DOQI and is updated. National kidney foundation's dialysis outcomes quality initiative. *Am J Kidney Dis* 2001; 37: 179-94.
- Eknoyan G, Levin NW. Impact of the new K/DOQI guidelines. *Blood Purif* 2002; 20: 103-8.
- K/DOQI. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Kidney Disease Outcome Quality Initiative*. *Am J Kidney Dis*, 2002; 39: 1-246.
- National Kidney Foundation (NKF) *Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board*. K/DOQI clinical practice gui-

delines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; 39 (Suppl. 2): S1-S246.

Vervoot G, Willems HL, Wetzels JF. Assessment of glomerular filtration rate in healthy subjects and normalalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. *Nephrol Dial Transplant* 2002; 17: 1909-13.

Darbepoetin alfa: new preparation. Just a me-too: no advantage in anaemia of chronic renal failure. *Prescrire Int* 2003; 12: 14-6.

Meyer TW, Hostetter TH. Uremia. *N Engl J Med* 2007; 357: 1316-1325.

Urine: pH, protéine, «spot»

Harrington JT, Cohen JJ. Measurement of urinary electrolytes - indications and limitations. *N Engl J Med* 1975; 293: 1241-43.

Glasscock RJ. Postural (orthostatic) proteinuria: no cause for concern. *N Engl J Med* 1981; 305: 639-41.

Lenke RR, Van Dorsten JP. The efficacy of the nitrate test and microscopic urinalysis in predicting urine culture test. *Am J Obstet Gynec* 1981; 140: 427-9.

Abuelo JG. Proteinuria: diagnostic principles and procedures. *Ann Intern Med* 1983; 98: 186-91.

Ginsberg J, et al. Use of single voided urine samples to estimate quantitative proteinuria. *N Engl J Med* 1983; 309: 1543-6.

Shaw AB, Risdon P, Lewis-Jackson JD. Protein creatinine index and albustix in assessment of proteinuria. *Brit Med J* 1983; 287: 929-32.

Dufel SE. Urinary electrolytes. *Emerg Med Clin North Am* 1986; 4: 185-92.

Elseviers MM, Verpooten GA, DeBroe ME. Interpretation of creatinine clearance. *Lancet* 1987; 1: 457.

Nathan DM, Rosenbaum C, Protasowicki D. Single-void urine samples can be used to estimate quantitative microalbuminuria. *Diabetes Care* 1987; 10: 414-18.

De Torrenté A. Analyse d'urine au cabinet médical: méthodes et interprétation. *Ther Umsch* 1988; 45: 528-34.

De Torrenté A. Protéinurie isolée. *Schweiz Med Wschr* 1989; 119: 851-3.

Kamel SK, Ethier JH, Richardson RMA, et al. Urine electrolytes and osmolality: when and how to use them. *Am J Nephrol* 1990; 10: 89-102.

Watts GF, Kubal C, Chinn S. Long-term variation of urinary albumin excretion in insulin-dependent diabetes mellitus: some practical recommendations for monitoring micro-albuminuria. *Diabetes Res Clin Pract* 1990; 9: 169-77.

Pappas PG. Laboratory in the diagnosis and management of urinary tract infections. *Med Clin North Am* 1991; 75: 313-25.

Haldimann B. Electrolytes urinaires: indications et interprétation. *Rev Med Suisse Rom* 1993; 113: 1035-38.

Peterson JC, Adler S, Burkart JM, et al. MDRD Review: Blood pressure control, proteinuria, and the progression of renal disease: The modification of Diet in Renal Disease Study. *Ann Intern Med* 1995; 123: 754-762.

Parving HH, Osterby R, Anderson PW, et al. Diabetic nephropathy. In: Brenner BM (ed.). *The Kidney*. W.B. Saunders Company, 1996, p: 1864 ff.

Kaene WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE); a position paper of the National Kidney Foundation. *Am J Kidney Dis* 1999; 33: 1001-10.

Levey AS, Bosch JP, Breyer Lewis J, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. *Ann Intern Med* 1999; 130: 461-70.

Kaene WF. Proteinuria: its clinical importance and the role in progressive renal disease. *Am J Kidney Dis* 2000; 35 (Suppl. 1): S97-105.

David S, Wauters JP. Fonction rénale et protéinurie: nouveaux concepts pour vieux dosages. *Med Hyg* 2001; 59: 471-81.

NFK-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease Update 2000. *Am Kidney Dis* 2001; 37 (Suppl 1): S182-238.

Syndrôme néphrotique, syndrôme néphritique

Cameron JS, Glasscock RJ (eds.). In: *The nephrotic syndrome*. New York, Dekker, 1988.

Brenner BM (ed.). *The Kidney*. W.B. Saunders Company, 1996.

Couser WG. Glomerulonephritis. *Lancet* 1999; 353: 1509-15.

Nolin L, Courteau M. Management of IgA nephropathy: evidence-based recommendations. *Kidney Int Suppl* 1999; 70: S56-62.

Savage CO. ANCA-associated renal vasculitis. *Kidney Int* 2001; 60: 1614-27.

Hématurie microscopique

Froom P, Ribak J, Benbassat J. Significance of microhaematuria in young adults. *Br Med J* 1984; 288: 20-2.

Mohr DN, Offord KP, Owen RA, et al. Asymptomatic microhaematuria and urologic disease. A population-based study. *JAMA* 1986; 256: 224-9.

Copley JB, Hasbargen JA. Idiopathic hematuria. *Arch Intern Med* 1987 147: 434-7.

Corwin HL, Silverstein MD. The diagnosis of neoplasia in patients with asymptomatic microscopic hematuria: a decision analysis. *J Urol* 1988; 139: 1002-6.

Andres A, Praga M, Bello I, et al. Hematuria due to hypercalcemia and hyperuricemia in adult patients. *Int Kidney* 1989; 36: 96-9.

Woolhandler S, Pels RJ, Bor DH, et al. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria. *JAMA* 1989; 262: 1214-9.

Murakami S, Igarashi T, Hara S, et al. Strategies for asymptomatic microscopic hematuria: a prospective study of 1,034 patients. *J Urol* 1990; 144: 99-101.

Culclasure TF, Bray VJ, Hasbargen JA. The significance of hematuria in the anticoagulant patient. *Arch Intern Med* 1994; 154: 649-52.

Schröder FH. Microscopic haematuria. *BMJ* 1994; 309: 70-2.

Fogazzi GB, Ponticelli C. Microscopic hematuria diagnosis and management. *Nephron* 1996; 72: 125-34.

Cohen RA, Brown RS. Microscopic hematuria. *N Engl J Med* 2003; 248: 2330-8.

Gaz artériel

Goldberg M, Green SB, Moss ML, et al. Computer-based instruction and diagnosis of acid-base disorders. *JAMA* 1973; 223: 269.

Guinand O. Interprétation de la gazométrie. *Med Hyg* 1984; 42: 334-8.

Fauci A, Braunwald E, (eds.). et al. In: Harrison: Principles of Internal Medicine, 1998 McGraw Hill.

Hall JB, Schmidt GA, Wood LDH. (eds). Principles of critical care. McGraw-Hill, 1998.

Équilibre acido-basique

Textbook: Rose BD, Post TW, (ed). Clinical physiology of acid-base and electrolyte disorders. 5th edition, McGraw-Hill, New York, 2001.

Baldwin Ef, Courmand A, Richards DW. Pulmonary insufficiency III. A study of 122 cases of chronic pulmonary emphysema. *Medicine* 1948; 28: 201-37.

Oh MS, Carroll HJ. The anion gap. *N Engl J Med* 1977; 297: 814-7.

Van Dixhoorn J, Duivenvoorden HJ. Efficacy of Nijmegen questionnaire in recognition of hyperventilation syndrome. *J Psychosomatic Research* 1985; 29: 199-206.

Battle DC, Hizon M, Cohen E, et al. The use of the urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis. *N Engl J Med* 1988; 318: 594-9.

Winter SD, Pearson JR, Gabow PA, et al. The fall of the serum anion gap. *Arch Intern Med* 1990; 150: 311-3.

Paillard M, Borensztein P, Houillier P, et al. Les désordres de la balance acido-basique. *Med Hyg* 1991; 49: 794-807.

Shapiro JI, Kaehny WD. Pathogenesis and management of metabolic acidosis and alkalosis. In: Schrier RW (ed.). *Renal and Electrolyte Disorders*. Little Brown 1992, p: 161-210.

Hanson CW 3rd, Marshall BE, Frasch HF, et al. Causes of hypercarbia with oxygen therapy in patients with chronic obstructive pulmonary disease. *Crit Care Med* 1996; 24: 23-8.

Adrogué HJ, Madias NE. Management of life-threatening acid-base disorders. *N Engl J Med* 1998; 338: 26-34.

Néphropathie IgA

Catran DC, Greenwood C, Ritchie S. Long-term benefit of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. *Am J Kidney Dis* 1994; 23: 247-54.

Nolin L, Courteau M. Management of IgA-nephropathy: evidence-based recommendations. *Kidney International* 1999; 55 (Suppl 70): S56-S62.

Pozzi C, Bolasco PG, Folazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. *Lancet* 1999; 353: 883-7.

D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. *Am J Kidney Dis* 2000;

- Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. *Am J Kidney Dis* 2001; 38: 18-25.
- Appel AB, Glasscock RJ et al. Syllabus. Glomerular, vascular, tubulointerstitial, and genetic diseases. *Nephrology Self-Assessment program* 2002; 1: 12-19.
- Donadio JV, Grande JP. IgA nephropathy. *N Engl J Med* 2002; 347: 738-49.

ENDOCRINOLOGIE

Diabète / Hyperglycémie / Insuline

- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993; 329: 977-86.
- Philippe J, Marini M, Pometta D. Le diabète. Guide du praticien. Editions Médecine et Hygiène, 1994.
- Peters AL, Davidson MB, Schriger DL, et al. A clinical approach for the diagnosis of diabetes mellitus. An analysis using glycosylated hemoglobin levels. *JAMA*, 1996; 276: 1246-52.
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997; 20: 1183-97.
- A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1999. *Diabet Med* 1999; 116: 716-30.
- American Diabetes Association. Aspirin therapy in diabetes. *Diabetes Care* 1999; 22, Suppl 1: S60-61.
- Bolli GB, Di Marchi RD, Park GD et al. Insulin analogues and their potential in the management of diabetes mellitus. *Diabetologia* 1999; 42: 1151-67.
- De Fronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. *Ann Intern Med* 1999; 131: 281-303.
- Makoto T, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the funagata diabetes study. *Diabetes Care* 1999; 22: 920-4.
- UKPDS Group. Effect of intensive blood-glucose control with Metformin on complications on overweight patients with type 2 diabetes. *Lancet* 1999; 352: 1557.
- Horton ES, Clinkinbeard C, Gatlin M, et al. Nateglinid alone and in combination with Metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. *Diabetes Care* 2000; 23: 1660-5.
- Recommandation de l'association suisse du diabète. Groupe de travail SSE/ASD, 2000.
- Ruiz J, Keller U, Bullard C et al. Prévention et dépistage de la maladie coronarienne chez le patient diabétique. *Bulletin des Médecins Suisses* 2000; 81: 2596-2600.
- Troisi RJ, Cowie CC, Harris MI. Diurnal variation in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the afternoon. *JAMA* 2000; 284: 3157-9.
- Bonvin JL. Insulinothérapie dans le diabète de type 2. *Med Hyg* 2001; 59: 1321-5.
- Van den Bergh G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001; 345: 1359-67.
- Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. *JAMA* 2001; 286: 1882-5.
- American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). *Diabetes Care* 2001; 24 (Suppl. 1): S33-S43.
- American Diabetes Association: clinical practice recommendations 2002. *Diabetes Care* 2002; 25 (Suppl. 1): S1-S147.
- American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Disease. The prevention or delay of type 2 diabetes (Position statement). *Diabetes Care* 2002; 25: 724-9.
- Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. *Diabetes* 2002; 51: 2796-803.
- Chiasson JL, Josse RG, Gomis R et al. STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus. The STOP-NIDDM randomised trial. *Lancet* 2002; 359: 2072-7.
- Diabetes Preventive Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002; 346: 393-403.

- Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. *N Engl J Med* 2002; 347: 1342-9.
- American Diabetes Association: Aspirin therapy in diabetes (Position Statement). *Diabetes Care* 2003; 26 (Suppl. 1): S87-S88.
- American Diabetes Association: Diabetic nephropathy (Position Statement). *Diabetes Care* 2003; 26 (Suppl. 1): S94-S98.
- American Diabetes Association: Management of dyslipidemia in adults with diabetes (Position Statement). *Diabetes Care* 2003; 26 (Suppl. 1): S83-86.
- American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). *Diabetes Care* 2003; 26 (Suppl. 1): S33-S50.
- American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 2003; 26 (Suppl. 1): S5-S20.
- American Diabetes Association: Treatment of hypertension in adults with diabetes (Position Statement). *Diabetes Care* 2003; 26 (Suppl. 1): S80-S82.
- Barnett AH. A review of basal insulins. *Diabet Med* 2003; 20: 873-85.
- Schwab S, Stuer S, Müller B et al. Orale Antidiabetika heute - Substanzen, Indikationen, Perspektiven. *Schweiz Med Forum* 2005; 5: 993-9.
- Amori RE, Lau J, Pittas AG. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes Systematic Review and Meta-analysis. *JAMA* 2007; 298: 194-206.
- Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-Receptor Antagonist in Type 2 Diabetes Mellitus. *N Engl J Med* 2007; 356: 1517-26.
- Holman RR, Thorne KI, Farmer AJ et al. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. *N Engl J Med* 2007; 357: 1716-30.
- Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2014; 37 (Suppl 1): S81-S90.
- Standards of Medical Care in Diabetes - 2014. *Diabetes Care* 2014; 37 (Suppl 1): S14-S80.

Acidocétose diabétique, hyperosmol.

- Delaney MF, Zisman A, Ketylye WM. Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. *Endocrinol Metab Clin North Am* 2000; 29: 683-705.
- American Diabetes Association. Hyperglycemic crises in patients with diabetes mellitus. *Diabetes Care* 2001; 19: 82-90.
- Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. *Diabetes Care* 2001; 24: 131-53.
- Magee MF, Bhatt BA. Management of decompensated diabetes. Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome. *Crit Care Med* 2001; 17: 75-106.
- American Diabetes Association. Hyperglycemic crisis in patients with diabetes mellitus. *Diabetes Care* 2003; 26 (Suppl. 1): S109-S117.
- Kitabchi AE, Umpierrez GE, Murphy MB, et al. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. *Diabetes Care* 2006; 12: 2739-48.
- Kitabchi AE, Umpierrez GE, Miles JM et al. Hyperglycemic Crises in Adult Patients with Diabetes. *Diabetes Care* 2009; 32: 1335-43.
- Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2014; 37 (Suppl 1); S81-S90.
- Standards of Medical Care in Diabetes - 2014. *Diabetes Care* 2014; 37 (Suppl 1): S14-S80.

Diabète insipide

- Vokes TJ, Robertson GL. Disorders of antidiuretic hormone. *Endocrinol Metabol North Am* 1988; 17: 281-99.
- Fujii T, Kojima S, Imanishi M, et al. Different mechanisms of polyuria and natriuresis associated with paroxysmal supraventricular tachycardia. *Am J Cardiol* 1991; 68: 343-8.
- Blevins LS, Wand GS. Diabetes insipidus. *Crit Care Med* 1992; 20: 69-79.
- Buonocore CM, Robinson AG. The diagnosis and management of diabetes insipidus during medical emergencies. *Endocrinol Metab Clin North Am* 1993; 22: 411-23.
- Kumar S, Berl T. Sodium. *Lancet* 1998; 352: 220-8.
- Maghnie M, Cosi G, Genovese E, et al. Central diabetes insipidus in children and young adults. *N Engl J Med* 2000; 343: 998-1007.
- Rose BD, Post TW. Clinical physiology of acid-base and electrolyte disorders, 5th edition 2001; McGraw-Hill, New York: p. 754-8.

Hyperglycémie

- Marks V, Teale JD. Investigation of hypoglycemia. *Clin Endocrinol* 1996; 44: 133-6.
- Service FJ. Hypoglycemic Disorders. *N Engl J Med* 1995; 332: 1144-52.
- Dizon AM, Kowalsky S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinoma. *Am J Med* 1999; 106: 307-10.
- Service FJ. Classification of hypoglycemic disorders. *Endocrinol Metab Clin North Am* 1999; 28: 501-17.
- Sinnvolle Anwendung endokrinologischer Tests. Christ-Crain M, Schild U, Müller B. *Schweiz Med Forum* 2004; 4: 1113-9.
- Hirsch IB. Insulin Analogues. *N Engl J Med* 2005; 352: 174-83.

Axe hypothalamo-hypophysaire

- Livanou T, Ferriman D, James VH. Recovery of hypothalamo-pituitary-adrenal function after corticoid therapy. *Lancet* 1967;2: 856-9.
- Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate on man determined by stable isotope dilution/mass spectrometry. *J Clin Endocrinol Metabol* 1991; 72: 39-45.
- Service FJ, O'Brian PC, Kao PC, et al. C-peptid suppression test: effects of gender, age, and body mass index; implications for the diagnosis of insulinoma. *J Clin Endocrinol Metab* 1992; 74: 204-10.
- Grinspoon SK, Biller BM. Clinical review 62 : Laboratory assessment of adrenal insufficiency. *J Clin Endocrinol Metabol* 1994; 79: 923.31.
- Trainer PJ, Besser M. *The Bart's endocrine protocols*. Churchill Livingstone, 1995.
- Glowniak JV, Loriaux DL. A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency. *Surgery* 1997; 121: 123-9.
- Bangar V, Clayton RN. How reliable is the short synacthen test for the investigation of th hypothalamic-pituitary-adrenal axis? *Eur J Endocrinol* 1998; 139: 580-3.
- Vollenweider P, Waeber G. Stratégie thérapeutique lors d'un sevrage aux glucocorticoïdes. *Med Hyg* 2001; 59: 366-73.
- Cooper M, Stewart P. Corticosteroid insufficiency in acutely ill patients. *N Engl J Med* 2003; 348: 727-734.

Insuffisance surrénalienne

- Gallagher JC. Pathophysiology of osteoporosis. *Semin Nephrol* 1992; 12: 109-15.
- Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. *Ann Intern Med* 1992; 117: 1-9.
- Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. *N Engl J Med* 1993; 329: 1141-6.
- Meunier PJ. Is steroid-induced osteoporosis preventable? *N Engl J Med* 1993; 328: 1781-2 et 1745-52 (Comment).
- Peck WA, et al. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. *Am J Med* 1993; 94: 646-50.
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. *Osteoporosis Int* 1994; 4: 368-81.
- Gambert SR, Schultz BM, Hamdy RC. Osteoporosis. Clinical features, prevention and treatment. *Endocrinol Metab Clin North Am* 1995; 24: 317-71.
- Chesnut CH, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. *Am J Med* 1995; 99: 144-52.
- Liberman UA, Weiss ST, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures on postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis treatment Study Group. *N Engl J Med* 1995; 333: 1437-43.
- Reginster JY, Deroisy R, Lecart MP, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. *Am J Med* 1995; 98: 452-8.
- Osteoporose: Richtlinien der Diagnostik-Prävention-Behandlung. Schweizerische Vereinigung gegen die Osteoporose SVGO; 1996.
- Ziegler R. Osteoporosis - diagnosis and therapy. *Med Klin* 1996; 91 (Suppl.1): 29-33.
- Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women oVvVitamin D supplementatdrXXTaNWHO OSXXTaNreportges OSXXTaNntion-Beolgen NI OSXXTbNJ OSXXTaNMed OSXXTbN1995; OSXXTaN333:Y

on guidelines for use of laboratory tests in thyroid disorders. JAMA 1990; 263: 1529-32.

Nordin H, Gallo AM, Ladefoged SD, et al. The effects of propranolol and paracetamol on hyperthyroid heart symptoms and function, assessed by systolic time intervals. Acta Endocrinol (Copenh) 1993; 128: 297-300.

Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994; 330: 1731-8.

Singer PA, Cooper DA, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA 1995; 273: 808-12.

Weetman AP. Graves' disease. N Engl J Med 2000; 343: 1236-48.

Portmann L. Approches thérapeutiques de l'hyperthyroïdie. Med Hyg 2001; 59: 350-6.

Cooper DS. Subclinical Hyperthyroidism. N Engl J Med 2001; 345: 260-5.

Weetman AP. Graves' disease. N Engl J Med 2001; 235: 1236-48.

Fajfr R, Müller B, Diem P. Hyperthyreose - Abklärung und Therapie. Schweiz Forum 2003; 5: 103-8.

Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228-38.

Hypothyroïdie

Staub JJ, Althaus BU, Engler H et al. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med 1992; 92: 631-42.

Zulewski H, et al. Estimation of tissue hypothyroidism by a new clinical score: Evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab 1997; 82: 771-76.

Zulewski H, Müller B, Exer P, et al. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab 1997; 82: 771-6.

Zulewski H, Siggekkow H, Walden C, et al. Evaluation of procalcitonin III peptide as a marker of tissue hypothyroidism in long-term treated women with TSH suppressive doses of thyroxine. Exp Clin Endocrinol Diabetes 1999; 107: 190-4.

Toft AD. Subclinical Hypothyroidism. N Engl J Med 2001; 345: 512-6.

Col NF, Surks MI, Daniels GH. Subclinical thyroid disease: clinical applications. JAMA 2004; 291: 239-43.

Surks MI, Ortiz E, Daniels GH et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228-38.

Thyroïdite de HASHIMOTO

Dyan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med 1996; 335: 99-107.

Nodules thyroïdiens

American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.

Crise thyrotoïxique - Thyroid storm

Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am 1993; 22: 263.

Porphyrie

Betanocor P. Patología del metabolismo de las porfirinas. In: Rodés J, et al. (eds.). El Manual de Medicina. Masson, S.A, 1993, p: 1212-20.

Fauci A, Braunwald E, (eds.) et al. In: Harrison: Principles of Internal Medicine. 1998 Mc Graw Hill.

Cholestérol - Management

Reiner Z, Catapano AL, De Backer G, Graham I, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-818.

Brun N, Rodondi N. [How to deal with familial dyslipidemia in clinical practice?]. Rev Med Suisse 2012; 8: 494-6, 8-500.

Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Sr., Gibbons R, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American

College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation November 12, 2013.

<http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437741.48606.98 citation>

Kokkinos PF, Fasellis C, Myers J, Panagiotakos D, Doumas M.

Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet 2013; 381: 394-9.

Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. November 12, 2013.

<http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a citation>

Ioannidis JP. More Than a Billion People Taking Statins? Potential Implications of the New Cardiovascular Guidelines. JAMA 2014; 311: 463-4.

Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013; 382: 1762-5.

Nanchen D, von Eckardstein A, Riesen WF, et al. im Namen der Schweizer Arbeitsgruppe Lipide und Atherosklerose (AGLA). Cholesterin management in der kardiovaskulären Risikoprävention: amerikanische Guidelines 2013 Stellungnahme der Schweizer Arbeitsgruppe Lipide und Atherosklerose (AGLA). Schweiz Med Forum 2014; 14: 378-381.

Yates T, Haffner SM, Schulte PJ, et al. Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. Lancet 2014; 383: 1059-66.

Obésité

Ireton-Jones CS, Turner WW Jr. Actual or ideal body weight: wch should be used to predict energy expenditure? J Am Diet Assoc 1991; 91: 193-5.

Physical status: the use and interpretation of anthropometry: report of a WHO expert committee. WHO Tech Rep Ser 1995; 854: 1-452.

Bjorntorp P. Obesity. Lancet 1997; 350: 423-6.

International Obesity Task Force (IOTF). Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva, 3-5 June, 1997 (WHO/NUT/ICD/97.2).

Lean ME. Sibutramine – a review of clinical efficacy. Int J Obes Relat Metab Disord 1997; 21(Suppl. 1): S30-6; discussion S37-9.

Seidel JC, Rissanen AM. Time trends in the worldwide prevalence of obesity. In: Bray GA, Bouchard C, James WPT (eds.), Handbook of obesity. New York: Marcel Dekker 1998, p. 79-91.

Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-73.

Stevens J, Cai J, Pamuk ER, et al. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998; 338: 1-7.

Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort on U.S. adults. N Engl J Med 1999; 341: 1097-1105.

Davidson MH, Hauptmann J, Di Girolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999; 281: 235-42.

Golay A, et al. Consensus über die Behandlung der Adipositas in der Schweiz 1999. Schweiz Med Wschr 1999; 129 (Suppl.114): 4S-20S.

Golay A, et al. Consensus sur le traitement de l'obésité en Suisse 1999. Schweiz Med Wschr 1999; 129 (Suppl.114): 21S-36S.

Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286: 1331-9.

Deitel M, Shikora SA. The development of the surgical treatment of morbid obesity. J Am Coll Nutr 2002; 21: 365-71.

Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 591-602.

O'Brian PE, Dixon JB. Weight loss early and late complications - the international experience. Am J Surg 2003; 184: 42S-45S.

Syndrome des ovaires polykystiques

Stein IF, Leventhal ML. Amenorrhoe associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181-91.

Waldstreicher J. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988; 66:

- Knochenhauer E. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. *J Clin Endocrinol Metab* 1998; 83: 3078-82.
- Diamanti-Kandaraki E. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. *J Clin Endocrinol Metab* 1999; 84: 4006-11.
- Ehrmann DA. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. *Diabetes care* 1999; 22: 141-6.
- Legro RS. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. *J Clin Endocrinol Metab* 1999; 84: 165-9.
- Azziz R. Family history as a risk factor for the polycystic ovary syndrome. *J Pediatr Endocrinol Metab* 2000; 13: 1303-6.
- Azziz R. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. *J Clin Endocrinol Metab* 2001; 86: 1626-32.
- Fogel RB. Increased prevalence of obstructive sleep apnea and daytime sleepiness: role of insulin resistance. *J Clin Endocrinol Metab* 2001; 86: 1175-80.
- Hardiman P. Polycystic ovary syndrome and endometrial carcinoma. *Lancet* 2003; 362: 1082 / Balen A. Polycystic ovary syndrome and cancer. *Hum Reprod Update* 2001; 7: 522-5.
- Gopal M. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovary syndrome. *Sleep Med* 2002; 3: 401-4.
- Glueck CJ. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. *Metabolism* 2003; 52: 908-15.
- Ehrmann DA. Polycystic Ovary Syndrome. *N Engl J Med* 2005; 352: 1223-36.

Syndrôme métabolique

- Weisser B, Locher R, Vetter W. The metabolic syndrome: common etiology for distinct cardiovascular risk factors. *Schweiz Rundsch Med Prax* 1993; 82: 1339-43.
- Zimmet P, Boyko EJ, Collier GR, et al. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. *Ann NY Acad Sci* 1999; 892: 25-44.
- Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis, The Framingham offspring study. *JAMA* 2000; 283: 221-8.
- Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001; 24: 683-9.
- Ramos F, Baglivo HP, Ramirez AJ, et al. The metabolic syndrome and related cardiovascular risk. *Curr Hypertens Rep* 2001; 3: 100-6.
- Ford ES, Wayne HG, Dietz WH, et al. Prevalence of the metabolic syndrome among US adult. *JAMA* 2002; 287: 356-9.
- Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002; 288: 2709-16.
- National Cholesterol Education Program. Third report of the national cholesterol education program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report: National Publication No.-02-5215, september 2002 (www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf). And: Executive summary, National Publication No.-01-3670, mai 2001 (www.nhlbi.nih.gov/guidelines/cholesterol/atp3sum.pdf).
- Keller KB, Lemberg L. Obesity and the metabolic syndrome. *Am J Crit Care* 2003; 12: 167-70.
- Meigs JB. The metabolic syndrome. *BMJ* 2003; 327: 61-2.
- American Diabetes association. Screening for type 2 diabetes. *Diabetes Care* 2004; 27 (Suppl 1):S11-14.

Hypercholestérolémie

- Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S). *Lancet* 1994; 344: 1383-9.
- Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) trial investigators. *N Engl J Med* 1996; 335: 1001-9.
- Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations lipoprotein and coronary atherosclerosis study. *Am J Cardiol* 1997; 80: 278-86.
- Pyörälä K, Pederson TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the scandinavian simvastatin survival study (4S). *Diabetes Care* 1997; 20: 614-20.
- Haffner SM. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998; 339: 229-34.
- Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Cornary Prevention Study (WOSCOPS). *Circulation* 1998; 97: 1440-5.
- Recommendations of the Second Joint Task Force of European and other Societies on coronary Prevention. Prevention of coronary heart disease in clinical practice. *Eur Heart J* 1998; 19: 1434-1503.
- The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998; 339: 1349-57.
- Société Suisse de Cardiologie, Groupe de travail Lipides et Athérosclérose. Recommendations 1999 pour l'indication au traitement du facteur de risque "cholestérol". *Schweiz Ärztezeitung* 1999; 80: 544-8.
- Lauer MS. Aspirin for primary prevention of coronary events. *N Engl J Med* 2002; 346: 1468-74.
- Management of dyslipidemia in adults with diabetes. *Diabetes Care* 2002; 25: Suppl. 1: S74-S77.
- National Cholesterol Education Program. Third report of the national cholesterol education program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). National Publication No.-02-5215, september 2002 (www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf).
- Sudhop T, Lufjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. *Circulation* 2002; 106: 1943-8.
- Sudhop T, von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. *Drugs* 2002; 62: 2333-7.
- De Backer G, Ambrosini E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2003; 24: 1601-10.
- Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. *N Engl J Med* 2004; 350: 1505-15.
- International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Access sept 2005 (consensus 14 april 2005, Berlin) y *Rev Panam Salud Publica* 2005; 18: 451-4.
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. *N Engl J Med* 2006; 355: 549-59.
- Barter PH, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. Treating to New Targets Investigators. *N Engl J Med* 2007; 357: 1301-10.

Nutrition

- A.S.P.E.N. Board of Directors. Guidelines for the use of enteral nutrition in the adult patient. *J Parent Sci* 1987; 11: 435-9.
- Rodés J, Aguirre A, Arroyo V, et al. (eds.). *Valores nutritivos. El Manual de Medicina. Masson*, 1993, p: 3335-41.

Hyperparathyroïdie

- NIH Consensus development conference statement: diagnosis and management of asymptomatic primary hyperparathyroidism. *Ann Intern Med* 1991; 114: 593-7.
- Niederle B, Stamm L, Längle F, et al. Primary hyperparathyroidism in Austria. Results of an 8-year prospective study. *World J Surg* 1992; 16: 777-83.
- Paitou F, Huglo D, Proye C. Radionuclide scanning in parathyroid disease. *Br J Surg* 1998; 85: 1605-16.
- Marcus R. Diagnosis and treatment of hyperparathyroidism. *Rev Endocr Metab Disord* 2000; 1: 247-52.
- Keams AE, Thompson GB. Medical and surgical management of hyperparathyroidism. *Mayo Clin Proc* 2002; 77: 87-91.

Méningite

- Glauser MP. Recommendations pour la prévention de la dissémination des méningocoques. *Schweiz Aerztezeitung* 1982; 63: 279-81.
- Quagliarello VJ, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology, and progress. *N Engl J Med* 1992; 327: 864-72.
- Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults: a review of 493 episodes. *N Engl J Med* 1993; 328: 21-8.
- Lepow ML. Meningococcal vaccines. In: Plotkin SA, Mortimer EA (eds). *Vaccines*. 2nd edition Philadelphia: WB Saunders Company 1994, p: 503-15.
- Office fédéral de la santé publique. Maladies méningococciques invasives en Suisse 1988-1994. *Bull OFSP* 1995; 50: 5-11.
- Garner JS, and the Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. *Am J Infect Control* 1996; 24: 24-52.
- Centers for Disease Control and Prevention. Control and prevention of meningococcal disease and control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks. Recommendations of the Advisory Committee on Immunization Practices. *MMWR* 1997; 46: 1-21.
- Jafari HS, Perkins BA, Wenger JD. Control and prevention of meningococcal disease: practices of the advisory committee of immunization practices (ACIP). *MMWR* 1997; 46, RR-5: 1-11.
- Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. *N Engl J Med* 1997; 336: 708-16.
- Aronin SI, et al. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. *Ann Intern Med* 1998; 129: 862-9.
- Attia J, Hatala R, Cook DJ, et al. Does this adult patient have acute meningitis? *JAMA* 1999; 282: 175-81.
- Trouillet N, Rohner P, Raebler R, et al. Epidémiologie et prévention des infections dues à *Neisseria meningitidis*. *Bull Med Suisse* 1999; 80: 1375-9.
- Apicella MA, *Neisseria meningitidis*. In: GL, Bennett JE, Dolin R (eds). *Principles and practice of infectious diseases*. 5th edition New York: Churchill Livingstone 2000.
- Hasbun R, Abrahams J, Jekel J, et al. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. *N Engl J Med* 2001; 345: 1727-33.
- De Gans J, Van de Beek D. Dexamethasone in adults with bacterial meningitis. *N Engl J Med* 2002; 347: 1549-56.
- Thi Hoang Mai N, Thi Hong Chau T, Thwaites G et al. Dexamethasone in Vietnamese Adolescents and Adults with Bacterial Meningitis. *N Engl J Med* 2007; 357: 2431-40.

État fébrile

- Mackowiak PA, LeMaistre CF. Drug fever: a critical appraisal of conventional concepts. *Ann Intern Med* 1987; 106: 728-33.
- Strickland TG. Fever in travelers. In: Strickland TG. (ed.): *Hunter's Tropical Medicine*. Philadelphia: WB Saunders, 1991; 1023-31.
- Wynngaarden JB, Smith LH, Bennet JC. (eds). *Cecil, Textbook of Medicine*. W.B. Saunders Company 1992.
- Humar A, Keystone J. Evaluating fever in travellers returning from tropical countries. *BMJ* 1996; 312: 953-6.
- Norman DC, et al. Fever in the elderly. *Infect Dis Clin North Am* 1996; 10: 93-9.
- Fauci A, Braunwald E. (eds.) et al. In: *Harrison: Principles of Internal Medicine*. 1998 Mc Graw Hill.
- Magill AJ. Fever in the returned traveler. *Infect Dis Clin North Am* 1998; 12: 445-69.

Fièvre d'origine indéterminée (FOU)

- NET:
- www.fevertravel.ch
 - www.safetravel.ch
- Petersdorf RG, Beeson PB. Fever of unexplained origin. *Medicine* 1961; 40: 1-30.
- Jacoby GA, Swartz MN. Fever of undetermined origin. *N Engl J Med* 1973; 289: 1407-10
- Petersdorf RG. Fever of unknown origin. An old friend revisited. *Arch Intern Med* 1992; 152: 21-2.

- Schneider-Glig A. Unklarer Status Febrilis. *Praxis* 1986; 75: 651-5.
- Cunha BA. Fever of unknown origin. *Infect Dis Clin North Am* 1996; 10: 111-27.
- Arnoff PM, Flaherty JP. Fever of unknown origin. *Lancet* 1997; 350: 575-80.
- Hirschmann JV. Fever of unknown origin in adults. *Clin Infect Dis* 1997; 24: 291-302.

Neutropénie fébrile

- Imunocompromised Host Society. The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. *J Inf Dis* 1990; 161: 397-401.
- Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. *Antimicrob Agents Chemother* 1996; 40: 1108-15.
- Hughes WT, Armstrong D, Bodey GP, et al. Guidelines from the infectious diseases society of America. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. *Clin Infect Dis* 1997; 25: 551-73.
- Harten P, et al. Febrile neutropenia: practical aspects. *Med Klin* 1998; 93: 598-611.
- Kern WV, Cometta A, De Boek R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. *N Engl J Med* 1999; 341: 312-18.
- Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. *N Engl J Med* 1999; 340: 764-71.
- Klastersky J, Paesmans M, Rubenstein EB, et al. Te multinational association for supportive care in cancer risk index: a multinational scoring system for identify low-risk febrile neutropenic cancer patients. *J Clin Oncol* 2000; 18: 3038-51.
- Corey L, Boeckh M. Persistent fever in patients with neutropenia. *N Engl J Med* 2002; 346: 222-4.
- Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clin Infect Dis* 2002; 34: 730-51.
- Walsh TJ, Pappas P, Winston D, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. *N Engl J Med* 2002; 346: 225-34.
- Flückiger U, Marchetti O, Bille J, et al. Treatment options of invasive fungal infections in adults. *Swiss Med Wkly* 2006; 136:447-463.

Tuberculose

- NET: www.who.int
- Shaw JB, Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. *Am Rev Tuberc* 1954; 69: 724-32.
- Meijer J, Barnett GD, Kubik A, Styblo K. Identification of sources of infection. *Bull Int Union Tuberc* 1971;45:5-50.
- Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. *Bull Int Union Tuberc* 1975;50:90-106.
- Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis. *Am Rev Respir Dis* 1978; 117: 991-1001.
- Cauthen GM, Pio A, ten Dam HG. Annual risk of infection. World Health Organization Document 1988;WHO/TB/88.154:1-34.
- Rieder HL, Zimmermann H, Zwahlen M, Billio NE. Epidemiologie der Tuberkulose in der Schweiz. *Schweiz Rundschau Med Praxis* 1990; 79: 675-9.
- Association suisse contre la tuberculose et les maladies pulmonaires. Lignes directrices pour la chimiothérapie préventive de l'infection tuberculeuse. *Bull OFSP* 1991; 23: 38-9.
- Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. *Am Rev Respir Dis* 1992; 145:494-7.
- Winters R.A., Murray H.W. Malaria - The Mime Revisited: Fifteen More Years of Experience at a New York City Teaching Hospital. *The American Journal of Medicine*. 1992; 93: 243-6.
- Veen J. Microepidemics of tuberculosis: the stone-in-the-pond principle. *Tuber Lung Dis* 1992;73:73-6.
- Association suisse contre la tuberculose et les maladies pulmonaires. Lignes directrices concernant la prévention de la tuberculose dans le cadre professionnel. *Bull OFSP* 1993; annexe 3: 31-6.
- Iseman MD. Treatment of multidrug-resistant tuberculosis. *N Engl J Med* 1993; 329: 784-791.
- American Thoracic Society, CDC and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. *Am J Respir Crit Care Med* 1994; 149: 1359-74.
- Brewer MA, Edwards KM, Palmer PS, Hinson HP. Bacille Calmette

- Guerin immunization in normal healthy adults. *J Infect Dis* 1994; 170:476-9.
- Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. *JAMA* 1994; 271: 698-702.
- International Union Against Tuberculosis and Lung Disease. Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease. *Tuber Lung Dis* 1994; 75:179-80.
- Rieder HL, Zellweger JP, Raviglione MC, Keizer ST, Migliori GB. Tuberculosis control in Europe and international migration. Report of a European Task Force. *Eur Respir J* 1994; 7: 1545-53.
- Standards Committee, Canadian Thoracic Society. Essential of tuberculosis control for the practising physician. *Can Med Assoc J* 1994; 150: 1561-71.
- Schalcher C, Brändli O, Beran J, Gaze H, Howald H, Tschopp JM. Tuberkulintests bei Schulgängern in den Kantonen Bern, Neuenburg und Wallis 1992/1993. *Schweiz Med Wochenschr* 1995; 125:796-801.
- World Health Organization. Global tuberculosis programme and global programme on vaccines. Statement on BCG revaccination for the prevention of tuberculosis. *WHO Wkly Epidem Rec* 1995; 70: 229-31.
- Association suisse contre la tuberculose et les maladies pulmonaires. Lignes directrices pour le traitement de la tuberculose. *Bull OFSP* 1996; 16: 9-13.
- Sudre P, Rieder H, Bassetti S, Hirschel BJ, Ledergerber B, Malvy D, Swiss HIV Cohort Study. Infection VIH, tuberculose et test tuberculinique en Suisse. *Schweiz Med Wochenschr* 1996; 126: 2007-12.
- White NJ. The treatment of malaria. *N Engl J Med* 1996; 335:800-6. Richtlinien für den Tuberkulintest. *Bull BAG* 1997:13-14.
- Association suisse contre la tuberculose et les maladies pulmonaires ASTP Société suisse de pneumologie SSP. Lignes directrices concernant le test tuberculinique. *Bull OFSP* 1997; 16: 13-14.
- Behr MA, Hopewell PC, Paz A, Kawamura LM, Schechter GF, Small PM. Predictive value of contact investigation for identifying recent transmission of mycobacterium tuberculosis. *Am J Respir Crit Care Med* 1998; 158: 465-9.
- Maher D, Chaulet P, Spinaci S, Harries A. Global Tuberculosis Programme World Health Organization Geneva, Switzerland, 1998, p 1-81. [<http://www.who.int>]
- Markwalder K., Hatz C. Malaria-Therapie 1998. *Schweiz Med Wochenschr* 1998; 128: 1313-27.
- Trnka L, Dankova D, Zitova J, et al. Survey of BCG vaccination policy in Europe: 1994-96. *Bull World Health Organ* 1998; 76:85-91.
- Standards Committee (Tuberculosis), Canadian Thoracic Society, Canadian tuberculosis standards. 3rd ed. Ottawa: Canadian Lung Association, 1998.
- Soccal PM, Rochat Th. Diagnostic de tuberculose. *Med Hyg* 1998; 56: 2336-41.
- Bundesamt für Gesundheit. Infektionskrankheiten in der Schweiz 1997. Tuberculose. *Bull BAG/OFSP* 1999; 34-7.
- ERS TASK FORCE. Tuberculosis management in Europe. *Eur Respir J* 1999; 14: 978-92.
- Havliv DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. *N Engl J Med* 1999;340:367-73.
- Del Castillo OD, Penafiel CM, Alvarez GF, Soto Campos JG, Calderon OE, et al. Investigation of tuberculosis contacts in a nonhospital pneumology practice. *Eur J Clin Microbiol Infect Dis* 1999; 18: 790-5.
- American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. *Am J Respir Crit Care Med* 2000; 161: S221-S247.
- American Thoracic Society, CDC and prevention. Diagnostic standards and classification of tuberculosis in adults and children. *Am J Resp Crit Care Med* 2000; 161: 1376-95.
- Hopewell PC. Targeting tuberculosis prevention. *Am J Respir Crit Care Med* 2000; 162: 2017-8.
- Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. *MMWR* 2000; 49 (N° RR-6).
- Chin DP, Crane CM, Diul MY, Sun SJ, Agraz R, et al. Spread of mycobacterium tuberculosis in a community implementing recommended elements of tuberculosis control. *JAMA* 2000; 283: 2968-74.
- Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. *Am J Respir Crit Care Med* 2000; 162: 2033-8.
- Rieder HL. Epidemiologic basis of tuberculosis control. 1 ed. International Union Against Tuberculosis and Lung Disease, Paris, 1999; 1-162.
- Bundesamt für Gesundheit. Tuberculose in der Schweiz: 1995 bis 1998. *Bull BAG/OFSP* 2000;1:8-11.
- World Health Organisation. Severe Falciparum Malaria. *Trans R Soc Trop Med Hyg* 2000; 94 (S1): 1-90.
- American Thoracic Society, Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States 2001. *Am J Respir Crit Care Med* 2001; 164: 1319-20.
- Hatz C. Clinical Treatment of Malaria in Returned Travelers. In: Schliengenhauf P. (Hrsg.). *Travelers' Malaria*. BC Decker, Hamilton - London 2001; 431-45.
- Keane J, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med* 2001; 345: 1098-104.
- Lalvani A, Pathan AA, McShane H, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. *Am J Respir Crit Care Med* 2001; 163: 824-8.
- Lalvani A, Pathan AA, Durkan H, et al. Enhanced contact tracing and spatial tracking of mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. *Lancet* 2001; 357: 2017-21.
- Rieder HL. Risk of travel-associated tuberculosis. *Clin Infect Dis* 2001; 33: 1393-6.
- World Health Organization. BCG in immunization programmes. *Wkly Epidem Rec* 2001;76:33-9.
- Broekmans JF, Migliori GB, Rieder HL, Lees J, Ruutu P, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. *Eur Respir J* 2002; 19: 765-75.
- Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. A meta-analysis of the effect of bacille Calmette Guerin vaccination on tuberculin skin test measurements. *Thorax* 2002;57:804-9.
- American Thoracic Society, CDC, and infectious disease of America. Treatment of tuberculosis. *MMWR* 2003; 52 (N° RR-11).
- Barnes PF, Cave MD. Molecular epidemiology of tuberculosis. *N Engl J Med* 2003; 349: 1149-56.
- Lalvani A. Spotting latent infection: the path to better tuberculosis control *Thorax* 2003; 58:916-8.
- Pai M, Riley LW, Coford JM. Interferon-g assays in the immunodiagnosis of tuberculosis: a systematic review. *Lancet Infect Dis* 2004;4:761-76.
- Whitty CJ, Lalloo D, Ustianowski A. Malaria: an update on treatment of adults in non-endemic countries. *BMJ* 2006; 333: 241-5.
- Genton B. Malaria: Prophylaxe und Therapie - ist die Mefloquin-Ära vorbei? *Schweiz Med Forum* 2001; 1: 337-44.

Borréliose (LYME-disease)

- Steere AC, Batsford WP, Weinberg M, et al. Lyme carditis: cardiac abnormalities of Lyme disease. *Ann Intern Med* 1980; 93: 8-16.
- Burgdorfer W, Barbour AG, Hayes SF, et al. Lyme disease - a tick-borne spirochete? *Science* 1982; 216: 1317-9.
- Steere AC. Lyme disease. *N Engl J Med* 1989; 321: 586-96.
- Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. *N Engl J Med* 1990; 323:1438-44.
- Rahn DW. Lyme disease: clinical manifestations, diagnosis, and treatment. *Semin Arthritis Rheum* 1991; 20: 201-18.
- Rahn DW, Malawista SE. Lyme disease. *Ann Intern Med* 1991; 114: 472-81.
- Fallon BA, et al. Lyme disease: a neuropsychiatric illness. *Am J Psychiatry* 1994; 151:1571-83.
- Staneck G, O'Connell S, Cimmino M, et al. European Union Concerted Action on Risk Assessment in Lyme Borreliosis: Clinical case definitions for Lyme borreliosis. *Wien Klin Wochenschr* 1996; 108: 741-7.
- Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. *MMWR Recomm Rep* 1997; 46: 1-55.
- Dattwyler RJ, Luft BJ, Kunkel MJ, et al. Ceftriaxone compared with

doxycycline for the treatment of acute disseminated Lyme disease. *N Engl J Med* 1997; 337: 289-94.

Tugwell P, Dennis D, Weinstein A, et al. Laboratory evaluation in the diagnosis of Lyme disease. *Ann Intern Med* 1997; 127: 1109-23.

Nahimana I, Praz G, Francioli P. Borréliose de Lyme: actualités. *Rev Med Suisse Rom* 2000; 120: 31-7.

Wormser GP, Nadelman RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease. *Clin Infect Dis* 2000; 31 (Suppl. 1): S1-14.

Klemmner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. *N Engl J Med* 2001; 345: 85-92.

Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose Doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. *N Engl J Med* 2001; 345: 79-84.

Shapiro AE. Doxycycline for tick bites - nor for everyone. *N Engl J Med* 2001; 345: 133-4.

Steere AC. Lyme disease. *N Engl J Med* 2001; 345: 115-25.

Kaplan RF, Trevino RP, Johnson GM, et al. Cognitive function in post-treatment Lyme disease: Do additional antibiotics help? *Neurology* 2003; 60: 1916-22.

Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post-Lyme disease (STOP-LD): A randomized double masked clinical trial. *Neurology* 2003; 60: 1923-30.

Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2003; 138: 697-704.

Evison J, Aebi C, Francioli P et al. Borréliose de Lyme. *Rev Med Suisse* 2006; 2: 919-24 (1 part), et 925.34 (2nd part) et 935-40 (third part).

Salmonellose

Aserkoff B, Bennett JV. Effect of antibiotic therapy in acute salmonellosis on the fecal excretion of salmonellae. *N Engl J Med* 1969; 281: 636-40.

Goldberg MB, Rubin RH. The spectrum of salmonella infection. *Infect Dis Clin North Am* 1988; 2: 571-98.

Wistrom J, Jertborn M, Ekwall E, et al. Empiric treatment of acute diarrheal disease with norfloxacin: a randomized placebo controlled study. Swedish study group. *Ann Intern Med* 1992; 117: 202-8.

Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant *Salmonella typhi*: a worldwide epidemic. *Clin Infect Dis* 1997; 24 (Suppl.1): S106-9.

Mandell GL. Principles and Practice of Infectious diseases. 5th edition. Churchill Livingstone, 2000.

Oehri I, Frei R, Sponagel L et al. Salmonellosen. *Schweiz Med Forum* 2005; 5: 1000-7.

Endocardite

Von Reyn CF, Levy BS, Arbeit RD, et al. Infective endocarditis: an analysis based on strict case definitions. *Ann Intern Med* 1981; 94: 505-18.

Durack DT, Lukes AS, Bright DK, et al. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. *Am J Med* 1994; 96: 200-9.

Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci and HACEK microorganisms. *JAMA* 1995; 274: 1706-13.

Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. *JAMA* 1997; 277:1794-1801.

Bayer AS, Bolger AF, Taubert KA, et al. Diagnosis and management of infective endocarditis and its complications. *Circulation* 1998; 98: 2936-48.

Little J. The American Heart Association's guidelines for the prevention of bacterial endocarditis: a critical review. *Gen Dent* 1998; 46: 508-15.

Moreillon P, for the Swiss working group for endocarditis prophylaxis. *Schweiz Med Wochenschr* 2000; 130: 1013-26.

Mylonakis E, Calderwood SB. Infective endocarditis in adults. *N Engl J Med* 2001; 345: 1318-30.

Legionella pneumophila

Fraser DW, Tsai TR, Orenstein W, et al. Legionnaires' disease: description of an epidemic of pneumonia, *N Engl J Med* 1977; 297: 1189-97.

Edelstein PH. Legionnaires' disease. *Clin Infect Dis* 1993; 16: 741-9.

Plouffe JF, File TM, Breimann RF. Reevaluation of the definition of Legionnaire's disease: use of the urinary antigen assay. *Clin*

Infect Dis 1995; 20: 1286-91.

Stout JE, Yu VL. Legionellosis. *N Engl J Med* 1997; 337: 682-7.

Gilbert DN, Moellering RC, Sande MA. The Sandford Guide to antimicrobial therapy; 2003.

Listeria monocytogenes

Bula CJ, Bille J, Glauser MP. An epidemic of food-borne Listeriosis in western Switzerland: description of 57 cases involving adults. *Clin Infect Dis* 1995; 20: 66-72.

Sizthwick FS, Purich DL. Intracellular pathogenesis of Listeriosis. *N Engl J Med* 1996; 334: 770-6.

Calder JAM. Listeria meningitis in adults. *Lancet* 1997; 350: 307.

Dalten CG, Austin CC, Sobel J, et al. An outbreak of gastroenteritis and fever due to *Listeria monocytogenes* in milk. *N Engl J Med* 1997; 336: 100-5.

Lorber B. Listeriosis. *Clin Infect Dis* 1997; 24: 1-11.

Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. *N Engl J Med* 1997; 337: 970-6.

Mylonakis E, Hohmann EL, Calderwood SB. Central nervous system infection with *Listeria monocytogenes*. 33 years' experience at a general hospital and review of 776 episodes from the literature. *Medicine (Baltimore)*. 1998; 77: 313-36.

Lorber B. *Listeria monocytogenes*. In: Principles and Practice of Infectious Diseases. 5th ed. Mandell GL, et al. Churchill Livingstone, Philadelphia 2000; p. 2208.

Mylonakis E, Paliou M, Hohmann EL, et al. Listeriosis during pregnancy: a case series and review of 222 cases. *Medicine (Baltimore)* 2002; 81: 260-9.

Hof H. An update on the medical management of listeriosis. *Expert Opin Pharmacother* 2004; 5: 1727-35.

Ooi ST, Lorber B. Gastroenteritis due to *Listeria monocytogenes*. *Clin Infect Dis* 2005; 40: 1327-32.

Brouwer MC, van de Beek D, Heckenberg SG. Community-acquired *Listeria monocytogenes* meningitis in adults. *Clin Infect Dis* 2006; 43: 1233-8.

Brucellose

Falagas ME, Biziotes IA. Quinolones for Treatment of Human Brucellosis: Critical Review of the Evidence from Microbiological and Clinical Studies. *Antimicrob Agents Chemother* 2006; 50: 22-23.

Roushan MRH, Mohraz M, Hajiahmadi M, et al. Efficacy of Gentamicin plus Doxycycline versus Streptomycin plus Doxycycline in the Treatment of Brucellosis in Humans. *Clinical Infectious Diseases* 2006; 42: 1075-80.

Maladie de griffes de chat

Holley HP. Successful treatment of cat-scratch disease with ciprofloxacin. *JAMA* 1991; 265: 1563-5.

Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. *Pediatr Infect Dis J* 1992; 11: 474-8.

Bass JW, Freitas BC, Freitas AD. Prospective randomized double-blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. *Pediatr Infect Dis J* 1998; 17: 447-52.

Chia JK, Nakata MM, Lami JL, et al. Azithromycin for the treatment of cat-scratch disease. *Clin Infect Dis* 1998; 26: 193-4.

Morsure d'animaux et d'humains

Stucker FJ, Shaw GY, Boyd S, et al. Management of animal and human bites in the head and neck. *Arch Otorinolaryngol Head Neck Surg* 1990; 116: 789-93.

Weber DH, Ganson AR. Infections resulting from animal bites. *Infect Dis Clin North Am* 1991; 5: 663-80.

Goldstein EJC. Bite wounds and infection. *Clin Infect Dis* 1992; 14: 633-8.

Klein NC, Cunha BA. Pastorella multocida pneumonia. *Semin Respir Infect* 1997; 12: 54-6.

Talan DA, Citron DM, Abrahamian FM, et al. Bacteriology analysis of infected dog and cat bites. *N Engl J Med* 1999; 340: 85-92.

Medeiros I, Saconato H. Antibiotic prophylaxis for mammalian bites. *Cochrane Database Syst Rev* 2001; 2: CD001738.

Green BT, Ramsey KM, Nolan PE. Pasteurella multocida meningitis: case report and review of the last 11 years. *Scand J Infect Dis* 2002; 34: 213-7.

Gilbert DN, Moellering RC, Sande MA. The Sandford Guide to antimicrobial therapy; 2003.

Broder J, Jerrard D, Olshaker J, et al. Low risk of infection in selected human bites treated without antibiotics. *Am J Emerg Med* 2004; 22: 10-13.

Taplitz RA. Managing bite wounds: current recommended antibiotics for treatment and prophylaxis. *Postgrad Med* 2004; 116: 49-59.
Prä- und postexpositionelle Totwundprophylaxe beim Menschen.
Schweizerische Bundesamt für Gesundheitswesen 01.07.2004

Clostridium difficile

Kelly CP, Pothoulakis C, LaMont JT. *Clostridium difficile* colitis. *N Engl J Med* 1994; 330: 257-62.
Blossom DB, McDonald CL. The Challenges Posed by Reemerging *Clostridium difficile* Infection. *Clin Infect Dis* 2007; 45: 222-7.

Syphilis

Larsen SA, Steiner BM, Rudolph AH. Laboratory diagnosis and interpretation of tests for syphilis. *Clin Microbiol Rev* 1995; 8: 1-21.
Young H. Syphilis. *Serology. Dermatol Clin.* 1998; 16: 691-8.

MRSA / MSSA -- SASM / SARM

Boyce JM. Methicillin-resistant *Staphylococcus aureus*. Detection, epidemiology, and control measures. *Infect Dis Clin North Am* 1989; 3: 901-13.
Mulligan ME, et al. Methicillin-resistant *Staphylococcus aureus*: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. *Am J Med* 1993; 94: 313-28.
Sanford MD, Widmer AF et al. Efficient detection and long-term persistence of carriage of methicillin-resistant *S. aureus*. *Clin Infect Dis* 1994; 19: 1123-8.
Working party Report: Revised guidelines for the control of methicillin-resistant *Staphylococcus aureus* infection in hospital. *J of Hosp Infection* 1998; 39: 253-90.
Mandell, Douglas, and Bennett's. Principles and Practice of infectious diseases. Churchill Livingstone 5th ed, 2000.
Oliveira DC, Tomasz A, de Lencastre H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin-resistant *Staphylococcus aureus*. *Lancet Infect Dis.* 2002; 2: 180-9.
Wunderlingk RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of the double-blind studies of patients with methicillin-resistant *Staphylococcus aureus* nosocomial pneumonia. *Chest* 2003; 124: 1789-97.
Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant *Staphylococcus aureus*. *Pediatr Infect Des J* 2004; 23: 123-7.
Harbarth S, Francois P, Schrenzel J et al. Community-associated methicillin-resistant *Staphylococcus aureus*. *Emerg Infect Dis* 2005; 11: 962-5.
Zimmerli W. Infektiologie: Der ambulante erworbene methicillinresistente *Staphylococcus aureus* (CA-MRSA). *Schweiz Med Forum* 2005; 5: 1285-7.
Gorwitz RJ, Jernigan DB, Powers HJ, et al. Strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the CDC. March 2006. www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf
Daum RS. Skin an doft-tissue infections caused by Methicillin-resistant *Staphylococcus aureus*. *N Engl J Med* 2007; 357: 382-90.

Malaria (paludisme)

INTERNET:
- www.safetravel.ch and NET: cdc.com
- www.sti-ch (= Schweiz. Tropeninstitut). Notfallnummer: 061/284.81.44
- www.hc-sc.gc.ca/pphb-dgspspp/publicat/ccdr-rmtc/97vol23/23s5/index_f.html
Markwalder K., Hatz C. *Malaria-Therapie* 1998. *Schweiz Med Wochenschr* 1998; 128: 13-27.
Warrell DA, Molyneux ME, Beales PF. Severe and complicated malaria. WHO malaria action programme. *Trans R Soc Trop Med Hyg* 1990; 84 (Suppl. 2): 1-65.
Winters R.A., Murray H.W. *Malaria - The Mime Revisited: Fifteen More Years of Experience at a New York City Teaching Hospital.* *The American Journal of Medicine.* 1992; 93: 243-6.
Gilles HM, Warrel DA. *Bruce-Chwatt's Essential of Malariaology.* Edward Arnold, 1993.
Recommandations canadiennes pour la prévention et le traitement du paludisme (malaria) chez les voyageurs internationaux 1995. Relevé des maladies transmissibles au Canada, RMTC 1995, volume 21S3, octobre.
Swenson JE, MacLean JD, Gyorkos TW, et al. Imported malaria.

Clinical presentation and examination of symptomatic travelers. *Arch Intern Med* 1995; 155: 861-8.
Office fédéral de la santé publique, Division Epidémiologie et maladies infectieuses - Guide méthodologique des maladies transmissibles - Janvier 1996.
White NJ. The treatment of malaria. *N Engl J Med* 1996; 335: 800-6.
Recommandations canadiennes pour la prévention et le traitement du paludisme (malaria) chez les voyageurs internationaux 1997. Relevé des maladies transmissibles au Canada, RMTC (www.hc-sc.gc.ca/pphb-dgspspp/publicat/ccdr-rmtc/97vol23/23s5/index_f.html).
Warrell DA. Cerebral malaria: clinical features, pathophysiology and treatment. *Ann Trop Med Parasitol* 1997; 91: 875-84.
Newton CR, Taylor TE, Whitten RO. Pathophysiology of fatal falciparum malaria in African children. *Am Trop Med Hyg* 1998; 58: 673-83.
Genton B. Tests rapides pour le diagnostic des maladies tropicales. *Med Hyg* 1999; 57: 1120-6.
Warrell DA. The management of severe malaria. *Parasitology* 1999; 41: 287-94.
Mandell GL. Principles and Practice of Infectious diseases. 5th edition Churchill Livingstone 2000.
World Health Organisation. Severe Falciparum Malaria. *Trans R Soc Trop Med Hyg* 2000; 94 (SI): 1-90
Genton B. Malaria: Prophylaxe und Therapie - Ist die Mefloquin-Aera vorbei? *Schweiz Med Forum* 2001; 1: 337-44.
Hatz C. Clinical Treatment of Malaria in Returned Travelers. In: Schlagenhauf P. (Hrsg). *Travelers' Malaria.* BC Decker, Hamilton - London 2001; 431-445.
D'Acremont V et al. Treatment of imported malaria in an ambulatory setting: prospective study. *BMJ.* 2002; 324: 875-7.
D'Acremont V, Burnand B, Ambresin AE, Genton B. Practice guidelines for evaluation of fever in returning travelers and migrants. *J.Travel Med.* 2003;10:S25-S52.
Whitty CJ, Lalloo D, Ustianowski A. Malaria: an update on treatment of adults in non-endemic countries. *BMJ* 2006; 333: 241-5.

SIDA / AIDS, virostatiques

Société canadienne (1-800-499-1986)
INTERNET:
• www.cdnaids.ca
• www.hivnet.ch
Krawczynski K, Alter MJ, Tankersley DL, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. *J Infect Dis* 1996; 173: 822-8.
Owens DK, Holodny M, Garber AM, et al. Polymerase chain reaction for the diagnosis of HIV infection in adults. A meta-analysis with recommendations for clinical practice and study design. *Ann Intern Med* 1996; 124: 803-15.
Bush MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. *Am J Med* 1997; 102: 117-26.
Office fédéral de la santé publique (OFSP). 22.12.1997.
Bulletin de l'Office fédéral de la santé publique (OFSP). Expositions à du sang en milieu professionnel et traitement prophylactique post-expositionnel en Suisse jusqu'à fin 1996. *Bulletin de l'OFSP* 1998; 27: 14-19.
CDC: Public health service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. *MMWR* 1998; 47: 1-31.
Hirschel B, Kaiser L. (eds.). In: *Le Sida. Guide du praticien - Diagnostic, traitement, prise en charge.* M&H, 1998.
Jost M et al. Prévention des maladies infectieuses transmises par voie sanguine dans le secteur sanitaire. *SUVA* 1998; 2869/30.f. *Bulletin de l'Office fédéral de la santé publique (OFSP). Nouveautés dans le diagnostic de l'infection par le VIH et complément au "concept de test VIH"*. OFSP 1998; 29 novembre 1999.
1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with Human Immunodeficiency Virus. *USPHS/IDSA Prevention of Opportunistic Infections Working Group.* Infectious Diseases Society of American. *Ann Intern Med* 1999; 131: 873-908.
1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). *MMWR* 1999; 48 (RR-10): 1-59, 61-6.
Bürgisser P, Spertini F. Test de diagnostic et de suivi de l'infection par le VIH: progrès récents. *Med Hyg* 1999; 57: 867-71.
Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic

- illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. *JAMA* 1999; 282: 2220-6.
- Rime Dubey B, Telenti A, Francioli P. Prise en charge des expositions professionnelles à du sang ou à d'autres liquides biologiques contaminés par les hépatites B et C et le VIH. *Rev Med Suisse Rom* 1999; 119: 587-92.
- Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. *JAMA* 2000; 283: 381-90.
- Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. *JAMA* 2000; 283: 74-80.
- Whitcup SM. Cytomegalovirus reinitis in the era of highly active antiretroviral therapy. *JAMA* 2000; 283: 653-7.
- 1999 USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with HIV: part I. Prevention of exposure. *Am Fam Physician* 2000; 61: 163-74.
- 1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with HIV: Part II. Prevention of the first episode of disease. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention. U.S. Public Health Service/Infectious Diseases Society of America. *Am Fam Physician* 2000; 61: 441-2, 445-9, 453-4.
- 1999 USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with HIV: Part III. Prevention of disease recurrence. United States Public Health Service/Infectious Diseases Society of America. *Am Fam Physician* 2000; 61: 771-8, 780, 785.
- Bassetti S, Battegay M, Sudre P. Access to antiretroviral therapy. *JAMA* 2000; 283: 883-4; discussion 884.
- Flepp M, Jost J, Hirschi B, et al. Subkommission Klinik (SKK) der Eidg. Kommission für AIDS-Fragen (EKAF): Empfehlungen zur antiretroviralen HIV-Therapie 2001. *Bulletin, des Bundesamtes für Gesundheit* 2000; 51: 994-1000.
- Gallant JE. Strategies for long-term success in the treatment of HIV infection. *JAMA* 2000; 283: 1329-34.
- Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. *JAMA* 2000; 283: 2417-26.
- Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. *N Engl J Med* 2000; 342: 1416-29.
- Ledergerber B, Egger M, Telenti A. AIDS-Related opportunistic illnesses and potent antiretroviral therapy. *JAMA* 2000; 283: 2653-4.
- Furrer H. Behandlung und Prävention der wichtigsten HIV-assoziierten Infektionen. *Schweiz Med Forum* 2001; 1: 605-12.
- Tillmann HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus reduced mortality among HIV-infected patients. *N Engl J Med* 2001; 345: 715-24.
- Updated U.S. Public Health Service Guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for postexposure prophylaxis. *MMWR* 2001; 58 (RR-11): 1-52.
- Xiang J, Wunschmann S, Diekema D, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. *N Engl J Med* 2001; 345: 707-14.
- Guidelines for the use of antiretroviral agents in HIV-1-infected adults. *MMWR* 2003; July 14.
- Robbins GK, De Gruttola V, Shafer RW et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. *N Engl J M* 2003; 345: 2293-303.
- Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. *MMWR Recomm Rep* 2004; 53: 1-112.
- Gulick RM, J. Ribaud HJ, Shikuma CM et al. Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection. *New Engl J Med* 2004; 350: 1850-61.
- Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. *JAMA* 2006; 296: 827-43.
- Andersson J, Ernberg I. Management of Epstein-Barr virus infections. *Am J Med* 1988;85:107-15.
- Haake DA, Zakowski PC, Haake DL, et al. Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. *Rev Infect Dis* 1990; 12: 788-98.
- Orenl, Sobel JD. Human herpesvirus type 6: review. *Clin Infect Dis* 1992; 14: 741-6.
- Reusser P, Gambertoglio JG, Lilleby K, et al. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. *J Infect Dis* 1992; 166: 303-310.
- Wallach MR, et al. Treatment of adult varicella with oral acyclovir. A randomized placebo-controlled trial. *Ann Intern Med* 1992; 117: 358-63.
- Rooney JF, et al. Oral acyclovir to suppress frequently recurrent herpes labialis: A double-blind placebo-controlled trial. *Ann Intern Med* 1993; 118: 268-72.
- Wood MJ, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. *N Engl J Med* 1994; 330: 896-900.
- Kost RG, Strauss ST. Postherpetic neuralgia – pathogenesis, treatment and prevention. *N Engl J Med* 1996; 335: 32-42.
- Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. *Ann Intern Med* 1996; 125: 831-2.
- Jackson JL, Gibbons R, Meyer G, et al. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. *Arch Intern Med* 1997; 157: 909-12.
- Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. *J Infect Dis* 1998; 178: 603-10.
- Rowbotham M, Harden N, Stacey B. Gabapentin for the treatment of postherpetic neuralgia. *JAMA*, 1998; 280: 1837-42.
- Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex virus. *Clin Infect Dis* 1998; 26: 541-55.
- Reusser P. Management of viral infections. In: *Klasterky J, Schimpff SC, Senn H-J, eds. Supportive care in cancer: A handbook for oncologists. 2nd ed. New York: Marcel Dekker, 1999: 87-112.*
- Cathomas G. Human herpes virus 8: a new virus discloses its face. *Virchows Arch* 2000; 436: 195-206.
- Furuta Y, Ohtani F, Kawabata H, et al. High prevalence of varicella-zoster virus reactivation in herpes simplex virus-seronegative patients with acute peripheral facial palsy. *Clin Infect Dis* 2000; 30: 529-33.
- Reusser P. Antiviral therapy: Current opinions and challenges. *Schweiz Med Wschr* 2000; 130: 101-12.
- Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. *JAMA* 2001; 285: 3100-6.
- Gnann JW, Whitley. Herpes Zoster. *N Engl J Med* 2002; 347: 340-6.
- Raschilas F, Wolff M, Delatour F, et al. Outcome of and prognostic factors for herpes simplex encephalitis in adults patients: results of a multicenter study. *Clin Infect Dis* 2002; 35: 254-60.
- Hjalgrim H, Asking J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. *N Engl J Med* 2003; 349: 1324-32.
- Swiss Herpes Management Forum. Schweizer Empfehlungen für das Management des Herpes genitalis und Herpes-simplex-Virus Infektion des Neugeborenen. *Schweiz Ärztezeitung* 2005; 86: 780-92.
- Meylan P, Kempf W, Gerber S, et al. Recommendations suisses pour la prise en charge des infections dues au virus de la varicelle-zoster. *Forum Med Suisse* 2007; 7: 895-905.

Tétanos

WWW: www.bag.admin.ch

Ahmadsyah I, Salim A. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. *Br Med J* 1985; 291: 648-50.

Sun KO, Chan YW, Cheung RT, et al. Management of tetanus: a review of 18 cases. *J R Soc Med* 1994; 87: 135-7.

Sanford J. Tetanus – Forgotten but not gone. *N Engl J Med* 1995; 332: 812.

Mandell GL. Principles and Practice of Infectious diseases. 5th edition. Churchill Livingstone. 2000.

Rage

Herpès: HSV, VZV-Zoster, EBV, CMV

Corey L, Nahmias AJ, Guinan ME, et al. A trial of topical acyclovir in genital herpes simplex virus infections. *N Engl J Med* 1982; 306: 1313-9.

Centers for Disease Control and Prevention. Human rabies prevention - United States, 1999. Recommendations to the advisory committee on immunization practices (ACIP). *Morb Mortal Wkly Rep* 1998; 48 (RR-1): 1-21.

Diphthérie

Wilson AP. Treatment of infection caused by toxigenic and non-toxicogenic strains of *Corynebacterium diphtheriae*. *J Antimicrob Chemother* 1995; 35: 717-20.

Vaccins:

Grippe

Tétanos

Pneumocoque

Hépatites

NET: www.cdc.gov/disease/flu/weekly.htm

NET: www.influenza.ch (centre de grippe national, Genève)

INFLUENZA

Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. *N Engl J Med* 1994; 331: 778-84.

Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. *N Engl J Med* 1995; 333: 889-93.

Recommandations pour la prévention de la grippe. Office fédéral de la santé publique. *Bulletin OFSP. Suppl. XIII, août 1996.*

Magnat JL. Vaccins anti-grippal et anti-pneumococcique chez la personne âgée. *Med Hyg* 1997; 55: 977-80.

Bulletin de l'OFSP. Une nouvelle possibilité de traiter les infections par le virus grippal. *Bulletin 44/99, OFSP 1 novembre 1999.*

Bundesamt für Gesundheit, Arbeitsgruppe Influenza, Schweizerische Kommission für Impffragen. Empfehlung zur Grippeprävention, in: Bundesamt für Gesundheit, ed. *Infektionskrankheiten. Diagnose und Bekämpfung.* Bern: Bundesamt für Gesundheit, Suppl. XIII; 2000.

Wenzel RP. Expanding the treatment options for influenza. *JAMA* 2000; 283: 1057-9.

Bundesamt für Gesundheit, Arbeitsgruppe Influenza, Schweizerische Kommission für Impffragen. Empfehlung zur Grippeprävention, in: Bundesamt für Gesundheit, ed. *Infektionskrankheiten. Diagnose und Bekämpfung.* Bern: Bundesamt für Gesundheit, Suppl. XIII; 2000.

European Influenza Surveillance Scheme. Low and decreasing levels of influenza activity in Europe. 15 April 2005: 151.

Brief der EKIF an die Kantonsärzte vom 14. Juni 2006

EVM statement: Influenza vaccine supply for the 2006/7 season: low yield of recommended strain may lead to delivery delays. 9. Juni 2006

World Health Organization. Recommended composition of influenza virus vaccines for use in the 2006-2007 influenza season. *Weekly epidemiological record* No. 9, 2006; 81: 82.

TETANOS

Weinstein L. Tetanus. *N Engl J Med* 1974; 289: 1293-6.

Centers for disease control. Diphtheria, tetanus, and pertussis; recommendations for vaccine use and other preventive measures: recommendations of the immunization practices advisory committee (ACIP). *MMWR* 1991; 40: 1-28.

PNEUMOCOQUE

Butler JC, Breimann RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. *JAMA* 1993; 270: 1826-31.

Farr BM, Johnston L, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. *Arch Intern Med* 1995; 155: 2336-40.

Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to 5 years after pneumococcal vaccination of elderly persons. *Clin Infect Dis* 1995; 21: 616-20.

Magnat JL. Vaccins anti-grippal et anti-pneumococcique chez la personne âgée. *Med Hyg* 1997; 55: 977-80.

Nuorti PJ, Butler JC, Breiman RF. Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices (ACIP). *MMWR* 1997; 46, RR-8: 1-24.

Ketterer JP, Rochat Th. Vaccin anti-pneumococcique. *Med Hyg* 1999; 57: 2329-33.

Mühlemann K, Francioli P, et al. Prévention des infections à pneumocoques par la vaccination. *Schweiz Aertzeitung* 2000; 81: 561-7.

Prevention and control of influenza: Recommendations of the advisory

committee on immunization practices (ACIP). *MMWR* 2000; 49, RR-03: 1-38.

Pharyngite aiguë / RAA

NET: www.idsociety.org

Gerber MA. Comparison of throat cultures and rapid strep tests for diagnosis of streptococcal pharyngitis. *Pediatr Infect Dis J* 1989; 8: 820-4.

Djani AS, Ayoub E, Bierman FZ, et al. Guidelines for the diagnosis of rheumatic fever: Jones criteria, updated 1993. *Circulation* 1993; 87: 302-7.

Bisno AL, Gerber MA, Gwaltney JM, et al. Diagnosis and management of group A streptococcal pharyngitis; A practice guideline. *Clin Infect Dis* 1997; 25: 574-583.

Nadal D, Weber R. Diagnose und Therapie der akuten Tonsillopharyngitis durch Gruppe A beta-hämolysierende Streptokokken. *Schweiz Ärztezeitung* 1999; 80: 599-601; version française p: 602-4.

Zwart S, Sachs AP, Ruijs GJ, et al. Penicillin for acute sore throat: randomised double blind trial of seven days versus three days treatment or placebo in adults. *BMJ* 2000; 320: 150-4.

Bisno AL, Gerber MA, Gwaltney JM, et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. *Clin Infect Dis* 2002; 25: 113-25.

Gilbert DN, Moellering RC, Sande MA. *The Sanford Guide to antimicrobial therapy*; 2003.

Candidose

Graybill JR, Vasquez J, Darouiche RO, et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in hiv/aids patients. *Am J Med* 1988; 104: 33-9.

Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. *N Engl J Med* 1994; 331: 1325-30.

Fisher JF, Newman CL, Sobel JD. Yeast in the urine: solutions for a budding problem. *Clin Infect Dis* 1995; 20: 183-9.

Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. *Arch Intern Med* 1995; 155: 2429-35.

Witt MD, Lewis RJ, Larsen RA, et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. *Clin Infect Dis* 1996; 22: 322-8.

Edwards JE, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. *Clin Infect Dis* 1997; 25: 43-59.

Sobel JD. Vaginitis. *N Engl J Med* 1997; 337: 1896-1903.

Van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. *N Engl J Med* 1997; 337: 15-21.

Denning DW. Invasive aspergillosis. *Clin Infect Dis*. 1998; 26: 781-5.

Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. *Clin Infect Dis* 1998; 26: 1383-96.

Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics and antifungal therapy. *Clin Infect Dis* 1999; 16: 1-9.

Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. *N Engl J Med* 1999; 340: 764-71.

Fisher JF. Candida: when and how to treat it. *Curr Infect Dis Rep* 2000; 2: 523-30.

Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. *Clin Infect Dis* 2000; 30: 662-78.

Lundstrom T, Sobel J. Nosocomial candiduria: a review. *Clin Infect Dis* 2001; 32: 1602-7.

Mora-Duarte J et al. Comparison of Caspofungin and Amphotericin B for invasive Candidiasis. *New Engl J Med* 2002; 347: 2020-9.

Kullberg BJ, Pappas P, Ruhnke M et al. Voriconazole compared with a strategy of amphotericin B followed by fluconazole of candidemia in non-neutropenic patients. Abstract O245, 14th ECCMID, Prague, May 1-4, 2004

Infection urinaire

Pyélonéphrite

Prostatite / Épididymite

Warren JW, Tenney JH, Hoopes JM, et al. A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral

catheters. *J Infect Dis* 1982; 146: 719-23.

Wong ES, McKeivitt M, Running K, et al. Management of recurrent urinary tract infections with patient-administered single-dose therapy. *Ann Intern Med* 1985; 102: 302-7.

Schaeffer AJ. Catheter-associated bacteriuria. *Urol Clin North Am* 1986; 13: 735-47.

Warren JW. Catheter-associated urinary tract infections. *Infect Dis Clin North Am* 1987; 1: 823-54.

Pezzo M. Detection of urinary tract infections by rapid methods. *Clin Microbiol Rev* 1988; 2: 268-80.

Dickinson GM, Bisno AL. Infections associated with indwelling devices: concept of pathogenesis; infection associated with intravascular devices. *Antimicrob Agents Chemother* 1989; 33: 597-607.

Lipsky BA. Urinary tract infections in men: epidemiology, pathophysiology, diagnosis, and treatment. *Ann Intern Med* 1989; 110: 138-50.

Stapleton A, Latham RH, Johnson C, Stamm WE. Postcoital antimicrobial prophylaxis for recurrent urinary tract infection: a randomized, double-blind, placebo-controlled trial. *JAMA* 1990; 264: 703-6.

Pappas PG. Laboratory in the diagnosis and management of urinary tract infections. *Med Clin North Am* 1991; 75: 313-25.

Humbert G. French consensus on antibiotherapy of urinary tract infections. The French Society for Infectious Diseases. *Infection* 1992; 20 (Suppl 3): S171-2.

Neu HC. Urinary tract infections. *Am J Med* 1992; 92(Suppl.4A): 63S-70S.

Rubin RH, Shapiro ED, Andriole VT, et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. *Clin Infect Dis* 1992; 15 (Suppl. 1): S216-S27.

Stamm WE, Hooton TM. Management of urinary tract infections in adults. *N Engl J Med* 1993; 329: 1328-34.

Hatton J, Hughes M, Raymond Ch. Management of bacterial urinary tract infections in adults. *Ann Pharmacother*. 1994; 28: 1264-72.

Lipsky BA. Prostatitis and urinary tract infection in men: what's new; what's true? *Am J Med* 1999; 106: 327-34.

Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. *Clin Infect Dis* 2000; 30: 662-78.

Tambyah PA, Maki DG. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. *Arch Intern Med* 2000; 160: 678-82.

Gilbert DN, Moellering RC, Sande MA. The Sandford Guide to antimicrobial therapy; 2003.

Mandell, Douglas, Bennett's Principles and Practices of Infectious Diseases. Sixth Edition 2005.

Nicolle LE, Bradley S, Colgan R, et al. American guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis* 2005;40: 643-54.

Naber KG, Bishop MC, Bjerklund-Johansen TE et al. Guidelines on The Management of Urinary and Male Genital Tract Infections. European Association of Urology 2006.

Janet Peterson, Simrati Kaul, Mohammed Khashab et al. A Double-Blind, Randomized Comparison of Levofloxacin 750 mg Once-Daily for Five Days With Ciprofloxacin 400/500 mg Twice-Daily for 10 Days for the Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis. *Urology* 2008; 17-22. © 2008 Elsevier Inc.

Splénectomie

Ruben FL, Hankins WA, Zeigler Z. Antibody responses to meningococcal polysaccharide vaccine in adults without a spleen. *N Engl J Med* 1983; 76: 115-21.

McMullin M, Johnston G. Long term management of patients after splenectomy. *BMJ* 1993; 307: 1372-3.

Waghorn DJ. Prevention of post-splenectomy sepsis. *Lancet* 1993; 341: 248.

British committee for standard in haematology, clinical haematology task force. Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. *BMJ* 1996; 312: 430-4.

Genne D. Recommandations pour la prévention et le traitement des infections chez les patients splénectomisés ou souffrant d'une rate non fonctionnelle. *Med Hyg* 2001; 59: 2306-10.

Anthrax

INTERNET: <http://www.bt.cdc.gov>.

La Force FM. Anthrax. *Clin Infect Dis* 1994; 19: 1009-14.

Centers for Disease Control, and Prevention. Bioterrorism alleging use of anthrax and interim guidelines for management: United States, 1998. *Morb Mortal Wkly Rep* 1999; 48: 69-74.

Dixom TC, Meselson M, Guillemin J, et al. Anthrax. *N Engl J Med* 1999; 341: 815-26.

Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological and public health management. Working group on civilian biodefense. *JAMA* 1999; 283: 1735-45. [Erratum: *JAMA* 2000; 283: 1963]

Shafazand S, Doyle R, Ruoss S, et al. Inhalational Anthrax. Epidemiology, Diagnosis, and Management. *Chest* 1999; 116: 1369-76.

Swartz AN. Recognition and management of anthrax - an update. *N Engl J Med* 2001; 345: 1621-6.

Infection de cathéter

Bryant JK, Strand CL. Reliability of blood cultures collected from intravascular catheter versus veinpuncture. *Am J Clin Pathol* 1987; 88: 113-6.

Mansfield PF, Hohn DC, Fornage BD, et al. Complications and failures of subclavian-vein catheterization. *N Engl J Med* 1994; 331: 1735-8.

Raad I. Intravascular-catheter-related infections. *Lancet* 1998; 351: 893-8.

McKinley S, Mackenzie A, Finfer S, et al. Incidence and predictors of central vnos catheter related infection in intensive care patients. *Anaesth Intensive Care* 1999; 27: 164-9.

Mermel LA, Farr BM, Sherertz RJ, Raad II, et al. Guidelines for the management of intravascular catheter-related infections. *Clin Infect Dis* 2001; 32: 1249-72.

Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients. *JAMA* 2001; 286: 700-7.

O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for prevention of intravascular catheter-related infections. *Clin Infect Dis* 2002; 35: 1281-307.

O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. *MMWR Recomm Rep* 2002; 51(RR-10): 1-29.

McGee DC, Gould MK. Preventing complications of central venous catheterization. *N Engl J Med* 2003; 348: 1123-33.

Ostéomyélite

Waldvogel FA, Vasey H. Osteomyelitis: the past decade. *N Engl J Med* 1980; 303: 360-70.

Lew DP, Waldvogel FA. Osteomyelitis. *N Engl J Med* 1997; 336: 999-1007.

Fernandez M, Carrol CL, Baker CJ. Dicitis and vertebral osteomyelitis in children: a 18-year review. *Pediatrics* 2000; 105: 1299-304.

McHenry MC, Easley KA, Locker GA. Vertebral osteomyelitis: long term outcome for 253 patients from 7 Cleavland-area hospitals. *Clin Infect Dis* 2002; 34: 1342-50.

Gilbert DN, Moellering RC, Sande MA. The Sandford Guide to antimicrobial therapy; 2003.

Lee MV, Minotti A. Acute vertebral osteomyelitis. *N Engl J Med* 2003; 349: 2525.

Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. *Am J Med* 2003; 114: 723-8.

HÉMATOLOGIE

INTERNET: www.2bib.ch/hemato.pdf

Schmidt PM: Bases physiopathologiques en hématologie générale, v. 8.0, 2005

Anémie

Healton B, Savage D, Brust JCM et al. Neurologic aspects of cobalamin deficiency. *Medicine* 1991; 70: 229-44.

Guyatt GH, Oxman AD, Ali M, et al. Laboratory diagnosis of iron-deficiency anemia: an overview. *J Gen Intern Med* 1992; 7: 145-53.

Lee R, et al (eds). Clinical hematology. 1993, Lea & Febiger.

Stalder M. Une anémie peut en cacher une autre. *Rev Med Suisse Rom* 19193; 113: 1019-23.

Beris P, Tobler A. Diagnostic de l'anémie. *Med Hyg* 1997; 55: 1812-6.

Ruedin P. Traitement de l'anémie liée à l'insuffisance rénale chronique. *Med Hyg* 1998; 56: 2081-4.

Olivieri NF. The beta-thalassemias. *N Engl J Med* 1999; 341: 99-

109. [Erratum: N Engl J Med 1999; 341: 1407].
Bernini LF, Hartevelde CL. Alpha-thalassaemia. Baillieres Clin
Haematol 1998; 11: 53-90.

Fer

Working group on fortification of salt with iron: Use of common salt fortified with iron in the control and prevention of anemia – a collaborative study. Am J Clin Nutr 1982; 35: 1442.

Crosby WH, O'Neil-Cutting MA. A small-dose iron tolerance test as an indicator of mild iron deficiency. JAMA 1984; 251: 1986-7.

Wallach J. Interpretation of Diagnostic Tests. Little Brown, 1996.

Hoffman R. Hematology Basic Principles & Practice. Mosby 1999, p: 417.

Électrophorèse (protéines)

Merino J. Patología del metabolismo de las proteínas y los aminoácidos. In: Rodés J, et. al. (eds.). El Manual de Medicina. Masson, 1993. p: 1193-6.

Transfusions sanguines

Consensus conference: pnoT'nUpÉWF°fieX)

new WHO classification. *Pathologie* 2001; 22: 429-43.

Harrison CN, Path MRC, Campbell PJ et al. Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia. *N Engl J Med* 2005; 353:33-45.

Tefferi A, Thiele J, Orazi A, Kvasnicka HM et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. *Blood* 2007; 8 may.

Thrombopénie, thrombocytose

Fauci A, Braunwald E, (eds.) et al. In: Harrison: Principles of Internal Medicine. 1998 Mc Graw Hill.

Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. *N Engl J Med* 2006; 355: 809-17.

Aster RH, Bougie D. Drug-induced immune thrombocytopenia. *N Engl J Med* 2007; 357: 580-7.

Coagulation sanguine

Van Wynsberghe D, Noback CR, Carola R. (eds.). Human Anatomy and Physiology. McGraw-Hill, 1995.

Wallach J. Interpretation of Diagnostic Tests. Little Brown, 1996.

Gaville M, Angeliello-Scherrer A. Quantification of the anticoagulatory effect of novel anticoagulants and management of emergencies. *Cardiovasc Med* 2012; 15: 170-9.

Hémophilie,

Maladie de Von WILLEBRAND

Sadler JE, Davie EW. Hemophilia A, hemophilia B, and von Willebrand's disease. In: The molecular basis of blood diseases. G Stamatoyanopoulos et al (eds.). Philadelphia, Saunders 1987; p: 575-630.

Beutler E, Lichtmann MA, Coller TJ, et al. (eds.). In: Williams Hematology, Fifth Edition 1995, McGraw Hill, p: 1413-29, and p: 1458-80.

Meili EO, Hartmann S. Association Suisse des hémophiles. Commission médicale. Recommendations pour le traitement de l'hémophilie. Universitätsspital Zürich. April 1996. (non publié: Tel: 01/281.08.55, ou E-mail: administration@shg.ch).

Lämmle B. (ed.). Hadorn Therapie-Handbuch 2000, p: 315-25.

Pier MM. Treatment of von Willebrand's Disease. *N Engl J Med* 2004; 351: 683-94.

Purpura (voir «INVESTI-MÉD»)

Kitchens CS. The purpuric disorders. *Semin Thromb Hemost* 1984; 10: 173-89.

Hoffbrand AV, Pettit JE. Essential Haematology. Blackwell Scientific Publications, 1993.

George JN, El-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. *N Engl J Med* 1994, 331: 1207-11.

Varet B. Le livre de l'interne: hématologie. Médecine-Sciences. Flammarion, 1997.

Eldor A. Thrombotic thrombocytopenic purpura: diagnosis, pathogenesis and modern therapy. *Baillière's Clinical Haematology*, 1998; 11: 475-95.

Fauci A, Braunwald E, (eds.) et al. In: Harrison: Principles of Internal Medicine. 1998 Mc Graw Hill.

Gillis S, Eldor A. Immune thrombocytopenic purpura in adults: clinical aspects. *Baillière's Clinical Haematology*, 1998; 11: 361-72.

Provan D, Chisholm M, Duncombe AS, et al. Oxford Handbook of Clinical Haematology, Oxford University Press, 1998.

Pallister CJ. Haematology (Biomedical Sciences Explained). Butterworth-Heinemann, 1999.

Cines DB, Blanchette VS. Immune thrombocytopenic purpura. *N Engl J Med* 2002; 346: 995-1008.

Cheng Y, Wong RSM, Soo YOY, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. *N Engl J Med* 2002; 349: 831-6.

CIVD

Colman R, Robboy S, Minna J. Disseminated intravascular coagulation (DIC): an approach. *Am J Med* 1972; 52: 679-87.

Fenstein D. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. *Blood* 1982; 60: 284-7.

Bick RL. Disseminated intravascular coagulation. *Hem Onc Clin North Am* 1992; 6: 1259-81.

Williams E. Disseminated intravascular coagulation. In: Loscalzo J, Schafer A (eds.). Thrombosis and hemorrhage. Blackwell Science 1994, pp. 921-44.

Baglin T. Disseminated intravascular coagulation: diagnosis and treatment. *BMJ* 1996; 312: 683-7.

Boneu B. Disseminated intravascular coagulation. Etiology, diagnosis. *Rev Prat* 1987; 47:215-8.

Levi M, Ten Cate H. Current concepts: disseminated intravascular coagulation. *N Engl J Med* 1999; 341: 586-92.

Thrombophilie, Syndrome anti-phospholipides

Asherson RA, Chan JKH, Harris EN, et al. Anticardiolipin antibody, recurrent thrombosis, and Warfarin withdrawal. *Ann Rheum Dis* 1985; 44: 823-5.

Hughes GRV, Harris NN, Gharavi AE. The anticardiolipin syndrome. *J Rheum* 1986; 13: 486-9.

Mackworth-Young CG, Loizou S, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. *Ann Rheum Dis* 1989; 48: 362-7.

Brandt TJ, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants: an update. *Thromb Haemost* 1995; 74: 1185-90.

Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. *N Engl J Med* 1995; 332: 993-7.

Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. *Blood* 1995; 10: 3685-91.

Cavenagh JD, Colvin BT. Guidelines for the management of thrombophilia. *Postgrad Med J* 1996; 72: 87-94.

Price DT, Ridjler PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. *Ann Intern Med* 1997; 127: 895-903.

Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. *Arthritis Rheum* 1999; 42: 1309-11.

Graves M. Antiphospholipid antibodies and thrombosis. *Lancet* 1999; 353: 1348-53.

Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. *N Engl J Med*. 2002; 346: 752-63.

Crowther MA, Ginsberg JS, Math JJ, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with antiphospholipid antibody syndrome. *N Engl J Med* 2003; 349: 1133-8.

Hémopathies malignes

INTERNET: www.2bib.ch/hemato.pdf

Schmidt PM: Bases physiopathologiques en hématologie générale, v. 8.0. 2005 (p. 94-152 et 166)

Jaffe ES, Harris NL, Stein H, et al (ed.). *Tumor of haematopoietics and lymphoid tissues*. World Health Organization classification of tumors. Pathology and genetics. IARC Press, 2001 (351 pages).

Drépanocytose (anémie falciforme)

Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: rates and risk factors. *N Engl J Med* 1991; 325: 11-6.

Brookoff D, Polomano R. Treating sickle cell pain like cancer pain. *Ann Intern Med* 1992; 116: 364-8.

Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. *Blood* 1993; 81: 1109-23.

Carache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. *N Engl J Med* 1995; 332: 1317-22.


Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. *N Engl J Med* 1995; 333: 206-13.

Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. *Blood* 1999; 94: 1555-60.

Ballas SK. Sickle cell disease: current clinical management. *Semin Hematol* 2001; 38: 307-14.

Stuart MJ, Setty BN. Acute chest syndrome of sickle cell disease: new light on an old problem. *Curr Opin Hematol* 2001; 8: 111-22.

Ballas SK. Sickle cell anaemia: progress in pathogenesis and treatment. *Drugs* 2002; 62: 1143-72.

 www.cancer.gov/cancertopics

Cancer colo-rectal

Van Gossum A, Miguel Munoz Navas M, Fernandez-Urien I, et al. Capsule Endoscopy versus Colonoscopy for the Detection of Polyps and Cancer. *N Engl J Med* 2009; 361: 264-70.

CA mammaire

ces références sont en cours

DERMATOLOGIE

Textbook

Saurat JH. *Dermatologie et maladies sexuellement transmissibles*.

Masson 1999.

www.kopflaus.ch

Lebwohl M. et al. Therapy for head lice based on life cycle, resistance, and safety considerations. *Pediatrics* 2007; 119: 965-74.

Dermatite atopique=Eczéma atopique

Hannifin JM et al. *Acta Dermatovener* 1980; 92: 44.

Williams H.C, Jburney PG, Hay RJ et al. The U.K. working Party's diagnostic criteria for atopic dermatitis. *Br J Dermatol* 1994; 131: 383-96.

Lucky AW, Leach AD, Laskarzewski P et al. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. *Pediatr Dermatol* 1997; 14: 321-4.

Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. *J Am Acad Dermatol* 2001; 44 (Suppl 1):S58-64.

Devillers, ACA, de Waard-van der Spek F.B., Mulder PGH et al. Treatment of Refractory Atopic Dermatitis Using «Wet-Wrap» Dressings and Diluted Corticosteroids: Results of Standardized Treatment in both Children and Adults. *Dermatology* 2002; 204: 50-55.

Williams H. New treatment for atopic dermatitis. *BMJ* 2003; 324: 1533-4.

Leung DY, Bieber T. Atopic dermatitis. *Lancet* 2003; 361: 151-60.

Hanfin JM, Cooper KD, Ho VC et al. Guidelines of care for atopic dermatitis, developed in accordance with the AAD. *J Am Acad Dermatol* 2004; 50: 391-404.

Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. *J Allergy Clin Immunol* 2004; 113: 925-31.

Luger TA, Tahfa M, Folwster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 0.1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. *J Dermatol Treat* 2004; 15:169-78.

National Institute for Clinical Excellence. Final appraisal determination: tacrolimus and pimecrolimus for atopic eczema.

www.nice.org.uk/pdf/P&T_FAD.pdf

Williams HC. Atopic dermatitis. *N Engl J Med* 2005; 352: 2314-24.

Gale

Delisle BR. La gale humaine. *Le Médecin du Québec* 1998; 33, 59-60.

Bigby M. A systematic review of the treatment of scabies. *Arch Dermatol* 2000; 136: 387-9.

Del Giudice P. Ivermectin in scabies. *Curr Opin Infect Dis* 2002; 15: 123-6.

Elston DM. Controversies concerning the treatment of lice and scabies. *J Am Acad Dermatol* 2002; 46: 794-6.

Leone PA. Scabies and pediculosis pubis: an update of treatment regimens and general review. *Clin Infect Dis* 2007; 44 (Suppl 3): S153-9.

Psoriasis

Greaves MW, Weinstein GD. Treatment of psoriasis. *N Engl J Med* 1995; 332: 581-9.

Nickloff BJ, Wrono-Smith T. Superantigens, autoantigens, and pathogenic T cells in psoriasis. *J Invest Dermatol* 1998; 110: 459-60.

Drew GS. Psoriasis. *Prim Care* 2000; 27: 385-406.

Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. *J Clin Pharm Ther.* 2000; 25: 1-10.

Granstein RD. New treatments for psoriasis. *N Engl J Med* 2001; 345: 284-7.

Heydendael VMR, Spuls P, Cpmeer RC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. *N*

Engl J Med 2003; 349: 658-65.

Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. *N Engl J Med* 2003; 349: 2014-22.

Loves MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. *Nature* 2007; 445: 866-73.

Stern RS. Psoralen and ultraviolet A light therapy for psoriasis. *N Engl J Med* 2007; 357: 682-90.

Erysipèle (cellulite)

Leppard BJ, Seal DV, Colman G, et al. The value of bacteriology and serology in the diagnosis of cellulite end erysipelas. *Br J Dermatol* 1985; 112: 559-67.

Hook EW 3d, Hooton TM, Horton CA, et al. Microbiologic evaluation of cutaneous cellulitis in adults. *Arch Intern Med* 1986; 146: 295-7.

Duvanel T, Auckenthaler R, Rohrer P, et al. Quantitative cultures of biopsy specimens from cutaneous cellulitis. *Arch Intern Med* 1989; 149: 239-6.

Chartier C, Grosshans E. Erysipelas. *Int J Dermatol* 1990; 29: 459-67.

Sjjoblom AC, Eriksson B, Jorup-Ronstrom C, et al. Antibiotic prophylaxis in recurrent erysipelas. *Infection* 1993; 21: 390-3.

Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. *N Engl J Med* 1996; 334: 240-5.

Eriksson B, Jorup-Ronstrom C, Karikonen K, et al. Erysipelas: clinical and bacteriologic spectrum and serological aspects. *Clin Infect Dis* 1996; 23: 1091-8.

Dan M, Heller K, Shapiro I, et al. Incidence of erysipelas following venectomy for coronary artery bypass surgery. *Infection* 1987; 15: 107-8.

Mertz KR, Baddur LM, Bell JL, et al. Breast cellulitis following breast conservation therapy: a novel complication of medical progress. *Clin Infect Dis* 1998; 26: 481-6.

Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. *BMJ* 1999; 318: 1591-4.

Perl B, Gottherr NP, Raveh D, et al. Cost-effectiveness of blood cultures for adult patients with cellulitis. *Clin Infect Dis* 1999; 29: 1483-8.

Mandell GL. *Principles and Practice of Infectious diseases*. 5th edition. Churchill Livingstone 2000.

Gottlieb T, Atkins BL, Shaw DR. Soft tissue, bone and joint infections. *Med J Aust* 2002; 176: 609-15.

Bassetti S, Itin P, Flückiger U. Primäre bakterielle Hautinfektion. *Schweiz Med Forum* 2003; 35: 819-7.

Stevens DL et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. *Clin Infect Dis* 2005;41: 1373-406.

Érythème nouveau

Bohn S, Buchner S, Itin P. Erythema nodosum: 112 cases. epidemiology, clinical aspects and histopathology. *Schweiz Med Wochenschr* 1998; 128: 85.

Cribier B, Caille A, Heidi E, et al. Erythema nodosum and associated disease. A study of 129 cases. *Int J Dermatol* 1998; 37: 667-72.

Petit A. Erythema nodosum. *Ann Dermatol Venerol* 2001; 128: 167-71.

Prurit

Hagermark O, Wahlgren CF. Treatment itch. *Semin Dermatol* 1995; 14: 320-5.

Kantor GR, Bernhard JD. Investigation of the pruritic patient in daily practice. *Semin Dermatol* 1995; 14: 290-6.

Yosipovitch G, David M. The diagnostic and therapeutic approach to idiopathic generalized pruritus. *Int J Dermatol* 1999; 38: 881-7.

Krajnik M, Zyllicz Z. Understanding pruritus in systemic disease. *J Pain Symptom Manage* 2001; 21: 151-68.

Vitiligo

WEB: American Academy of Dermatology (Ad). Public Resources, Patient Education - Vitiligo, American Academy of Dermatology. [Consulté le 1er décembre 2003].

www.aad.org/pamphlets/Vitiligo.html

Kragballe K. Vitamin D3 analogues. *Dermatol Clin* 1995; 13: 835-9.

Kieffer MA. Topical vitamin D analogs. *Dermatol Nurs* 2004; 16: 89-90, 93, 100.

Berneburg M, Rocken M, Benedit F. Phototherapy with narrowband vs broadband UVB. *Acta Derm Venerol* 2005; 85: 98-108.

Grimes PE. New insights and new therapies in vitiligo. *JAMA* 2005;

Kostovic K, Pasic A. New treatment modalities for vitiligo: focus on topical immunomodulators. *Drugs* 2005; 65: 447-9.

Pemphigoïde bulleuse - Pemphigus

- Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. *Lancet* 1999; 345: 667-75.
- Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. *N Engl J Med* 2002; 346: 321-7.
- Bystrin JC, Rudolph JL. Pemphigus. *Lancet* 2005; 366: 61-73.
- Ehrenberger-Lang A, Leisner A, Rhyner M, et al. Bullöse Erkrankung mit hoher Letalität. *Forum* 2006; 6: 945-6.
- Joly P, Mouquet H, Rojeau J-C, et al. A single cycle of rituximab for the treatment of severe pemphigus. *N Engl J Med* 2003; 197: 545-52.
- Diaz LA. Rituximab and pemphigus - a therapeutic advance. *N Engl J Med* 2007; 357: 605-9.

Toxidermies

- Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. *N Engl J Med* 1994; 331: 1272-85.
- Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. *Science* 1998; 282: 490-3.
- Bastuji-Garin S, Foucharon N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. *J Invest Dermatol* 2000; 115: 149-53.
- Prins C, Kerdell FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. *Arch Dermatol* 2003; 139: 26-32.
- Trent JT, Kirsner RS, Romanelli Pet al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. *Arch Dermatol* 2003; 139:39-43.

RHUMATOLOGIE

INTERNET:

www.arthritis.ca
www.rheuma-net.ch
Textbooks

- Colvin RB, Bhan AK, McCluskey RT (eds.). *Diagnosis Immunopathology*. Raven Press 1995.
- Frank MM, Austen KF, Claman HN, Unanue ER (eds.). *Samter's Immunologic Disease*. Little Brown 1995.
- Kahn MF, Peltier A, Meyer O, Piette JC (eds.). *In: Maladies et syndromes systémiques*. Paris: Flammarion Médecine-Sciences, 1999.
- Fox RI. Sjogren's syndrome: Current therapies remain inadequate for a common disease. *Expert Opin Invest Drugs* 2000; 9: 207-16.
- PM Villiger, Seitz M. *Rheumatologie in Kürze*. Thieme Verlag 2006.

Arthrite, Arthrite septique

- Gottlieb NL, Riskin WG. Complications of local corticosteroid injections. *JAMA* 1980; 243:1547-8.
- Goldenberg DL, Reed JI. Bacterial arthritis. *N Engl J Med* 1985; 312: 764-71.
- Baker DG, Schumacher HR. Acute monoarthritis. *N Engl J Med* 1993; 329: 1013-20.
- American College of Rheumatology ad hoc committee on clinical guidelines. Guidelines for the initial evaluation of the adult patient with acute musculo-skeletal symptoms. *Arthritis Rheum* 1996; 39: 1-8.
- Schumacher HR Jr. Synovial fluid analysis and synovial biopsy. In: Kelley ED Jr, Ruddy S, Sledge CB, (eds.). *Textbook of rheumatology*; pp 609-25. Philadelphia, W.B. Saunders 1997.
- Buchs N, Vischer TL. Que faire lors d'une arthrite d'apparition récente? Le triage par le laboratoire et l'imagerie. *Med Hyg* 1999; 57: 595-600.
- Theiler R. Arthrose. *Schweiz Med Forum* 2002; 23: 555-61.

Ponction articulaire

- Thumboo J, O'Duffy JD. A prospective study of the safety of joint and soft tissue aspirations and injections in patients taking warfarin sodium. *Arthritis Rheum* 1989; 41: 736-9.
- Yood RA. Use of gloves for rheumatologic procedures. *Arthritis*

Lemaire V, charbonnier B, Gruel Y, et al. Antiagrégants, anticoagulants et infiltrations: comment faire? *Rev Rhum* 2002; 69: 8-11.

Arthrite rhumatoïde

- Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988; 31: 315-24.
- Weaver A, Caldwell J, Olsen N, et al. Treatment of active rheumatoid arthritis with leflunomide compared to placebo or methotrexate. *Arthritis Rheum* 1998; 41: S131.
- Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double blind, randomised, multicenter trial. *Lancet* 1999; 353: 259-66.
- Villiger PM, Brühlmann P. Rheumatoïde Arthritis. In: Alexander K, et al (eds). *Thiemes Innere Medizin*. Stuttgart. Thieme Verlag, 1999, pp 1622-31.
- Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. *Arthritis Rheum* 2000; 43: 1901-2.
- Van der Heijde DMFM. Radiographic imaging: the «gold standard» for assessment of disease progression in rheumatoid arthritis. *Rheumatology* 2000; 39 (Suppl 1): 9-16.
- Tremblay JL, Morin F. La polyarthrite rhumatoïde (PAR). *Le Rhumatologue* 2002; 3: 1-8.
- American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. *Arthritis Rheum* 2002; 46: 328-46.
- Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-celle activation with fusion protein CTLA4lg. *N Engl J Med* 2003; 349: 1907-15.
- Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. *N Engl J Med* 2004; 350: 2167-79.

Maladie de STILL de l'adulte

- Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. *J Rheumatol* 1992; 19: 424-30.
- Fautrel B, Zing E, Goldmard J-L, et al. Proposal for a New Set of Classification Criteria for Adult-Onset Still Disease. *Medicine* 2002; 1: 194-200.

Spondyloarthropathies

- Amor B, Dougados M, Mijiyawa. Critères de classification des spondyloarthropathies. *Rev Rhum* 1990; 57: 85-9
- Amor B, Dougados M, Lestrat V, et al. Evaluation of the Amor criteria for spondylarthritis and European Spondylarthritis Study Group (ESSG). A cross-sectional analysis of 2,228 patients. *Ann Med Intern (Paris)* 1991; 142: 85-9.
- Dougados M, van der Linden S, Juhlin R, et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. *Arthritis Rheum* 1991; 34: 1218-27.
- Maksymowych WP, Chou CT, Russell AS. Matching prevalence of peripheral arthritis and acute anterior uveitis in individuals with ankylosing spondylitis. *Ann Rheum Dis* 1995; 54: 128-30.
- Gordman JD, Sack KE, Davis JC, et al. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. *N Engl J Med* 2002; 346: 1349-56.
- Piccozzi M, Weber M, Frey RA, et al. Spondylarthrite ankylosante (maladie de Bechterew). *Forum Med Suisse* 2002; 10: 232-7.
- Gladman TD, Hellwiel P, Marchesoni A, et al. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum* 2006; 54: 2665-73.
- Rudwaleit M, Metter A, Listing J, et al. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. *Arthritis Rheum* 2006; 54: 569-78.
- Weber U, Kissling O. Morbus Bechterew - neue Therapien, offene Fragen. *Schweiz Med Forum* 2006; 6: 163-71.
- Zochling J, van der Heijde D, Dougados M, Braun. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. *Ann Rheum Dis* 2006; 65: 423-32.
- Gladman DD, Mease PJ, Strand J, et al. Consensus on a core set of domains for psoriatic arthritis. *J Rheumatol* 2007; 34: 167-70.

Polyomyosite - Dermatomyosite

Tanimoto K, Nakano K, Kano S, et al. Classification criteria for pilymyositis and dermatomyositis. *J Rheumatol* 1995; 22: 668-74.

Mixed connective tissue disease

Alarcon-Segovia D, Villarreal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC, eds. *Mixed Connective Tissue Disease and Anti-nuclear Antibodies*. Amsterdam, Netherlands: Excerpta Medica; 1987:33-40. International Congress Series No. 719.

Amigues JM, Cantagrel A, Abbal M, et al. Comparative study of 4 diagnosis criteria sets for mixed connective tissue diseases in patients with anti-RNP antibodies. *J Rheumatol* 1996; 23: 2055-62.

Kahn MF, Appelboom T. Syndrome de Sharp. In: Kahn MF, et al. Ed. *Les maladies systémiques*, 3rd ed Paris; Flammarion 1991: 545-56.

Maladie de SÏÖGREN

Vitali C, Bombardieri S, Moutsopoulos HM et al. and the European Community Study Group on Diagnostic Criteria for Sjögren's Syndrome, incl. Manthorpe R. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. *Ann Rheum Dis* 1996; 55: 116-21.

R Manthorpe. Sjögren's syndrome criteria. *Ann Rheum Dis* 2002; 61: 482-4.

Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* 2002;61:554-8.

Liquide synovial

Cohen AS et al. Synovial Fluid. In: *Laboratory Diagnosis in the Rheumatic Disease*, 2nd edition, 1975.

Krey PR, Bailen DA. Synovial fluid leukocytosis. *Am J Med* 1979; 67: 436-42.

Eisenberg JM, et al. Usefulness of synovial fluid analysis in the evaluation of joint effusions. Use of threshold analysis and likelihood ratios to assess a diagnostic test. *Arch Intern Med* 1984; 144: 715-9.

Shmerling RH, Delbanco TL. Synovial fluid tests. What should be ordered? *JAMA* 1990; 264: 1009-14.

Goutte

Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. *Arthritis Rheum* 1977; 20: 895-900.

Emmerson BT. The management of gout. *N Engl J Med* 1996; 334: 445-51.

Rana SS, Giuliani MJ, Oddis CV, et al. Acute onset of colchicine myoneuropathy in cardiac transplant recipients: case studies of three patients. *Clin Neurol Neurosurg* 1997; 99: 266-70.

Cohen MG, Emmerson BT. Gout. In: *Rheumatology*. Klippel JH, Dieppe PA (eds.). Mosby Philadelphia, 1998, p: 8.14.1-14.

Minghelli G, Seydoux C, Goy JJ, et al. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. *Transplantation* 1998; 66: 268-71.

Bardin, T. Fenofibrate and losartan. *Ann Rheum Dis* 2003; 62: 497-498.

Takahashi S, Moriwaki Y, Yamamoto T, et al. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. *Ann Rheum Dis* 2003; 52: 572.

Fibromyalgie

Goldenberg DL. Diagnostic and therapeutic challenges of fibromyalgia. *Hosp Pract* 1989; September 30: 39-52.

Wolfe F, Smythe HA, Yunus MB, et al. The American college of rheumatology 1990 criteria for the classification of fibromyalgia. *Arthritis Rheum*, 1990; 33: 160-72.

Syndrme du tunnel carpien

Kaplan SJ, Glickel SZ, Eaton RG. Predictive factors in the non-surgical treatment of carpal tunnel syndrome. *J Hand Surg* 1990; 15: 108.

Périarthropathie huméroscapulaire

Hawkins RJ, Kennedy JC. Impingement syndrome in athletes. *Am J Sports Med* 1980; 8: 151-8.

Hedtmann A, Fett H. So-called humeroscapular periarthropathy-

classification and analysis based on 1266 cases. *Z Orthop Ihre Grenzgeb* 1989; 127: 643-9.

Sher JS, Uribe JW, Posada A, et al. Abnormal findings on magnetic resonance images of asymptomatic shoulders. *J Bone Joint Surg Am* 1995; 77: 10-5.

Würgler CC, Sheikh R, Jost B et al. Periarthropathia humeroscapularis. *Schweiz Med Forum* 2007; 7: 81-6.

Bursite

Schumacher HR Jr. Synovial fluid analysis and synovial biopsy. In: Kelley ED Jr, Ruddy S, Sledge CB, (eds.). *Textbook of rheumatology*. Philadelphia, W.B. Saunders 1997.

Algoneurodystrophie SUDECK

Sudeck P. Über die akute (reflektorische) Knochenatrophie nach Entzündungen und Verletzungen an den Extremitäten und ihre klinischen Erscheinungen. *Fortschr Gebiete Roentgenstr* 1901; 5: 277-93.

Kozin F, Genant HK, Beckerman C, et al. The reflex sympathetic dystrophy syndrome II. Roentgenographic and scintigraphic evidence of bilaterality and of periarticular accentuation. *Am J Med* 1976; 60: 332-38.

Merskey H, Bogduk N. Complex regional pain syndromes: classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Seattle: IASP Press 1994; 40-3.

Stanton-Hicks M, Janic W, Hassenbusch S, et al. Reflex sympathetic dystrophy: changing concepts and taxonomy. *PM* 1995; 63: 127-33.

Todorovic-Tirnanic M, Obradovic V, Han R, et al. Diagnostic approach to reflex sympathetic dystrophy after fracture: radiography or bone scintigraphy? *Eur J Nucl Med* 1995; 22: 1187-93.

Adami S, Fossaluzza V, Gatti D, et al. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. *Ann Rheum Dis* 1997; 56: 201-4.

Zollinger PE, Tuinebreijer WE, Kreis RW, et al. Effect of vitamin C on frequency of reflex sympathetic dystrophy in wrist fractures: a randomised trial. *Lancet* 1999; 354: 2025-8.

van Hilten BJ, van de Beek WJ, Hoff JJ, et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. *N Engl J Med* 2000; 343: 625-30.

Kemler MA, Barendse GA, van Kleef M, et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. *N Engl J Med* 2000; 343: 618-24.

Schwartzmann R, Popescu A. Reflex sympathetic dystrophy. *Curr Rheumatol Rep* 2002; 4: 165-9.

van de Beek WJT, Schwartzman RJ, van Nes SI, et al. Diagnostic criteria used in studies of reflex sympathetic dystrophy. *Neurology* 2002; 58: 522-6.

Ostéonecrose aseptique

Manking HJ. Nontraumatic necrosis of bone. *N Engl J Med* 1992; 326: 1473-9.

Chang C, Greenspan A, Gershwin ME. Osteonecrosis: current perspectives on pathogenesis and treatment. *Semin Arthritis Rheum* 1993; 23: 47-69.

Mirzai R, Chang C, Greenspan A, et al. Avascular necrosis. *Compr Ther* 1998; 24: 251-5.

Mirzai R, Chang C, Greenspan A, et al. The pathogenesis of osteonecrosis and the relationships to corticosteroids. *J Asthma* 1999; 36: 77-95.

Glesby MJ, Hoover DR, Vaamonde CM. Osteonecrosis in patients with human immunodeficiency virus: a case-control study. *J Infect Dis* 2001; 184: 519-23.

Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. *Ann Intern Med* 2002; 137: 17-25.

Paranéoplasie

John WJ, et al. (eds.). *Paraneoplastic syndromes*. In: *Cancer. Principles and Practice of Oncology*. De Vita VT. Lippincott-Raven 1997, p: 2397-2422.

Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. *N Engl J Med* 2003; 349: 1543-54.

Amyloïdose

Hill GS, Morel-Maroger L, Mery JP, et al. Renal lesions in multiple myeloma: the relationship to associated protein abnormalities.

Am J Kidney Dis 1983; 2: 423-38.
Bukbaum JN, Chuba JV, Hellman GC, et al. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain

deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. *Ann Intern Med* 1990; 112: 455-64.

- Solomon A, Weiss DT, Kattine AA, et al. Nephrotoxic potential of Bence Jones proteins. *N Engl J Med* 1991; 324: 1845-51.
- Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. *Lancet* 1993; 341: 1113-6.
- Skinner M, Lewis WD, Jones LA, et al. Liver transplantation as a treatment for familial amyloidotic polyneuropathy. *Ann Intern Med* 1994; 120: 133-4.
- Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. *N Engl J Med* 1997; 337: 898-909.
- Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. *N Engl J Med* 1997; 336: 1202-7.
- Kushwaha SS, Fallen JT, Foster V. Restrictive cardiomyopathy. *N Engl J Med* 1997; 336: 267-76.
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. *N Engl J Med* 2003; 349: 583-96.
- Demler LM, Hawkins PN, BPC. Hazenberg et al. Eprodisate for the Treatment of Renal Disease in AA Amyloidosis. *N Engl J Med* 2007; 356: 2349-60.
- Jaccard A, Moreau Ph, Leblond V, et al. High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis. *N Engl J Med* 2007; 357: 1083-93.

Auto-anticorps

- Tan EM, Robinson CA, Nakamura RM, et al. ANA's in systemic rheumatic disease: Diagnostic significance. *Postgrad Med* 1985; 78: 141-2, 145-8.
- Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. *Ann Intern Med* 1990; 112: 682-98.
- Wallach J. Interpretation of Diagnostic Tests. Little Brown, 1996.

Collagénose/connectivite/Vasculites

- Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis Rheum* 1994; 37: 187-92.
- Hunder G. Vasculitis: diagnosis and therapy. *Am J Med* 1996; 100 (Suppl. 2A): 37S-45S.
- Lie JT. Classification of histopathological specificity of systemic vasculitis. In: Ansell BM, Bacon PA, Lie JT (eds). The vasculitides. London: Chapman & Hall, 1996; 26-36.
- Jennette JC, Falk RJ. Small-vessel vasculitis. *N Engl J Med* 1997; 337: 1512-23.
- Olivieri J, Chizzolini C, Dayer JM. Vasculites: Un défi pour le clinicien. *Med Hyg* 1998; 56: 398-402.
- Michel B, Brühlmann P. Kollagenosen und Vaskulitiden. In: Flasnöcker M, (ed.). Thiemes Innere Medizin: TIM. Georg Thieme Verlag, New York, Stuttgart 1999, p. 1632-51.
- Hoffman GS. Classification of systemic vasculitides. *Clin Exp Rheumatol* 1998; 16: 111-5.
- Gross WL, Trabandt A, Reinhold-Keller E. Diagnosis and evaluation of vasculitis. *Rheumatology* 2000; 39: 245-52.
- Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. *N Engl J Med* 2003; 349: 160-9.
- Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum* 2013; 65:1.

Phénomène de RAYNAUD

- Allen EV, Brown GE. Raynaud's disease: a critical view of minimal requisites for diagnosis. *Am J Med Sci* 1932; 183: 187-200.
- Kluyen N, Rabe E. Clinical picture and treatment of the Raynaud syndrome of the upper extremity. *Phlebologie* 1987; 40: 447-54.
- Lally EV. Raynaud's phenomenon. *Curr Opin Rheumatol* 1992; 4: 825-36.
- LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. *Clin Exp Rheumatol* 1992; 10: 485-8.
- Bolster MB, Maricq HR, Leff RL. Office evaluation and treatment of Raynaud's phenomenon. *Cleve Clin J Med* 1995; 62: 51-61.
- Roussin A. Raynaud's phenomenon. Therapeutic choices. 3ème édition. Association des pharmaciens du Canada, 2000, chap. 33, p. 285.
- Block JA, Sequeira W. Raynaud's phenomenon. *Lancet* 2001; 357: 2042-48.

Roussin A. Le phénomène de Raynaud. Mythes et réalités. *Le Clinicien* Nov 2001; 85-95.

Wigley FM. Raynaud's phenomenon. *N Engl J Med* 2002; 347: 1001-8.

Sclérodémie systémique diffuse

- Steen VD, Medsger TA, Rodnan GP. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. *Ann Intern Med* 1982; 97: 652-9.
- Leroy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subset, and pathogenesis. *J Rheumatol* 1988; 15: 202-5.
- Steen VD, Costantino JP, Shapiro AP, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. *Ann Intern Med* 1990; 113: 352-7.
- Medsger TA. Treatment of systemic sclerosis. *Ann Rheum Dis* 1991; 50 (Suppl 4): 877-86.
- Pope J. Treatment of systemic sclerosis. *Curr Opin Rheumatol* 1993; 5: 792-801.

Périartérite noueuse (PAN)

Lightfoot RW, Michel AB, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. *Arthritis Rheum* 1990; 33: 1088-93.

Syndrôme de TAKAYASU

Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. *Arthritis Rheum* 1990; 33: 1129-34.

Purpura de HENOCH-SCHÖNLEIN

Mills JA, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990: Criteria for the classification of Henoch-Schönlein purpura. *Arthritis Rheum* 1990; 33: 1114-21.

Vasculite leucocytoclasique

Calabrese LH, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. *Arthritis Rheum* 1990; 33: 1108-13.

Maladie de BUERGER (Thrombangéite oblitérante)

Mozes M, Cahansky G, Deutsch V, et al. The Association of atherosclerosis and Buerger's disease: a clinical and radiological study. *J Cardiovasc Surg* 1970; 11: 52-7.

Maladie de BEHÇET

International study group for Behçet's disease. Criteria for diagnosis of Behçet's disease. *Lancet* 1990; 335: 1078-80.

Syndrôme de CHURG-STRAUSS = Granulomatose éosinophilique avec polyangiite (EGPA)

- Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. *Am J Pathol* 1951; 27: 277-94.
- Franco J, Artes MJ. Pulmonary eosinophilia associated with montelukast. *Thorax* 1999; 54: 558-60.
- Green RL, Vayonin AG. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. *Lancet* 1999; 353: 725-6.
- Guillevin L, Lhote F, Gayraud M. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. *Medicine (Baltimore)* 1996; 75: 17-28.
- Jennette JC, Falk RJ, Andrassy K. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis Rheum* 1994; 37: 187-92.
- Masi AT, Hunder GG, Lie JT. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). *Arthritis Rheum* 1990; 33: 1094-100.
- Tuggey JM, Hosker HS. Churg-Strauss syndrome associated with montelukast therapy. *Thorax* 2000; 55: 805-6.
- Wechsler ME, Finn D, Gunawardena D. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. *Chest* 2000; 117: 708-13.
- Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. *Medicine (Baltimore)* 2011; 90:19.

Lupus érythémateux disséminé (LED)

- Tan EM, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982; 25: 1271-7.
- Hess E. Drug related-lupus. *N Engl J Med* 1988; 318: 1460-2.
- Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. *Ann Intern Med* 1990; 112: 682-98.
- Colvin RB, Bhan AK, McCluskey RT (eds.). *Diagnosis of Immunopathology*. Raven Press 1995.
- Frank MM, Austen KF, Claman HN, Unanue ER (eds.). *Samter's Immunologic Disease*. Little Brown 1995.
- Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis* 1997; 40: 1725-34.
- Piette J-Ch, Le Thi Huong D, Amoura Z. Traitement du lupus érythémateux systémique. *Med Hyg* 1999; 57: 908-15.

Artérite temporale, Polymyalgia

- Bird HA, Esselincx W, Dixon AS, et al. An evaluation of criteria for polymyalgia rheumatica. *Ann Rheum Dis* 1979; 38: 434-9.
- Chuang TY, Hunder GG, Ilstrup DM, et al. Polymyalgia rheumatica: a 10-year epidemiology and clinical study. *Ann Intern Med* 1982; 97: 672-80.
- Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. *Semin Arthritis Rheum* 1984; 13: 322-8.
- Delecoeuillière G, Joly P, Cohen de Lara A, et al. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens. (11 years of survey of 210 patients). *Ann Rheum Dis* 1988; 47: 733-9.
- Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the diagnosis of giant cell arteritis. *Arthritis Rheum* 1990; 33: 1122-8.
- Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. *Ann Intern Med* 1995; 122: 502-7.
- Salvarani C, Gabriel SE, O'Fallon WM, et al. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. *Arthritis Rheum* 1995; 38: 369-73.
- Salvarani C, Gabriel SE, O'Fallon WM, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. *Ann Intern Med* 1995; 123: 192.
- Schmidt WA, Kraft HE, Vorpahl K et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. *N Engl J Med* 1997; 337: 1336-42.
- Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. *N Engl J Med* 1998; 339: 292-9.
- Martinez-Taboada VM, Rodriguez-Valverde V. Polymyalgia rheumatica with normal erythrocyte sedimentation rate: clinical aspects. *Clin Exp Rheumatol* 2000; 4 (Suppl. 20): S34-37.
- Gerster J.-Ch. Polymyalgia rheumatica et maladie de Horton. *Med Hyg* 2001; 59: 609-12.
- Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant cell arteritis. *N Engl J Med* 2002; 347: 261-71.
- Mazlumzadeh M, Hunder GG, Easley KA et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. *Arthritis Rheum* 2006; 54: 3310.

Granulomateuse avec polyangite (ancienement WEGENER)

- Nölle B, Specks U, Lüdemann J, et al. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener's granulomatosis. *Ann Intern Med* 1989; 111: 28-40.
- Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. *Arthritis Rheum* 1990; 33: 1101-7.
- Hoffman GS, Kerr GS, Leavitt RY. Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med* 1992; 116: 488-98.
- Weir A, Lipman M, Congleton J. Co-trimoxazole in Wegener's granulomatosis. *N Engl J Med* 1996; 335: 1769-70.
- De Groot K, Gross WL. Wegener's granulomatosis: disease course, assessment of activity and extent and treatment. *Lupus* 1998; 7: 285-91.

Syndrome de GOODPASTURE

- Rees AJ. Goodpasture's syndrome. In: Lichtenstein LM, Fauci AS (eds). *Current Therapy in Allergy, Immunology, and*

Rheumatology. Mosby, 1996. p: 120-6.

Cryoglobulinémie

- Ramos-Casals M, Stone JH, Cid MC, et al. The cryoglobulinaemias. *Lancet*. 2012; 379: 348-60.



Epistaxis

- Becker, Walter: *Hals-Nasen-Ohren-Heilkunde*. Stuttgart; New York: Thieme 1989
- Naumann, Hans-Heinz, Scherer, Hans Hermann (Hrsg.): *Differentialdiagnostik in der Hals-Nasen-Ohrenheilkunde*. Stuttgart; New York: Thieme, 1998
- Strutz, Jürgen; Mann Wolf (Hrsg.): *Praxis der HNO-Heilkunde, Kopf- und Halschirurgie*. Stuttgart; New York: Thieme, 2001

Vertige, nystagmus

- Coquoz E. Le vertige et le praticien. *Rev Med Suisse Rom* 1993; 113: 999-1002.
- Liard P et al. (ed.). *Les vertiges*. Karger 1993.
- Vibert D, Teppa H, Häusler R. Le traitement médicamenteux des vertiges. *Rev Med Suisse Rom* 1993; 113: 685-8.
- Vibert D. Le traitement physiothérapeutique des vertiges. *Rev Med Suisse Rom* 1993; 113: 689-91.
- Holston JR, Baloh RW. Acute vestibular syndrome. *N Engl J Med* 1998; 339: 680-5.
- Minor LD. Superior canal dehiscence syndrome. *Am J Otol* 2000; 21: 9-19.
- Brandt T. Vertigo, dizziness and falls in the elderly. In: *Vertigo, its multisensory syndromes*. London: Springer-Verlag 1999: 385-92.
- Fontana PE, Zekry D, Gold G. Vertiges: De la plainte au diagnostic. *Med Hyg* 1999; 57: 2221-7.
- Marill KA, Walsh MJ, Nelson BK. Intravenous lorazepam versus dimenhydrinate for treatment of vertigo in the emergency department: a randomized clinical trial. *Ann Emerg Med* 2000; 36: 310-9.
- Iring C, Richman P, Kaiafas C, et al. Intramuscular droperidol versus intramuscular dimenhydrinate for the treatment of acute peripheral vertigo in the emergency department: a randomized clinical trial. *Acad Emerg Med* 2002; 9: 650-3.
- Baloh RW. Vestibular neuritis. *N Engl J Med* 2003; 348: 1027-32.

Vertige positionnel paroxystique

- Dix MR, Hallpike CS. The pathology, symptomatology and diagnosis of certain disorders of the vestibular system. *Proc R Soc Med* 1952; 45: 341-54.
- Semont A, Freyss G, Witte E. Vertiges positionnels paroxystiques bénins et manœuvre libératoire. *Ann Otolaryngol (Paris)* 1980; 1096: 473-6.
- Semont A. Le vertige paroxystique bénin. In: *Le traitement des troubles vestibulaires*. Mémoire. Bibliothèque nationale de Paris, 1984.
- Zumstein V, Reglin F. Nystagmus positionnel. In: *Les vertiges*. Zumstein V, Reglin F. 1990; p: 15-16.
- Epley JM. Particle repositioning for benign paroxysmal positional vertigo. *Otolaryngol Clin North Am* 1996; 29: 323-31.
- Furman JM, Cass SP. Primary care: Benigne paroxysmal positional vertigo. *N Engl J Med* 1999; 341: 1590-6.

Maladie WALLENBERG

- Frumkin LR, Baloh RW. Wallenberg's syndrome following a neck manipulation. *Neurology* 1990; 40: 611-5.
- Rigueiro-Veloso MT, Pego-Reigosa R, Branas-Fernandez-F, et al. Wallenberg syndrome: a review of 25 cases. *Rev Neurol* 1997; 25: 1561-4.
- Dinichert A, Rufenacht DA, Tribolet N. Dissecting aneurysms of the posterior inferior cerebellar artery: report of four cases and review of the literature. *J Clin Neurosci* 2000; 7: 151-20.

Maladie de Ménière

- Ménière P. Pathologie auriculaire: mémoire sur les lésions de l'oreille interne donnant lieu à des symptômes de congestion cérébrale apoplectiforme. *Gaz Med Pars* 1861; 16: 597-601.
- Saeed SR. Diagnosis and treatment of Ménière's disease. *B MJ* 1998; 316: 368-72.

Déficit cochléo-vestibulaire aigu

Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study. *Arch Otolaryngol* 1980; 106: 772-6.

Holston JR, Baloh RW. Acute vestibular syndrome. *N Engl J Med* 1998; 339: 680-5.

Ogawa K, Takei S, Inoue Y, Kanzaki J. Effect of prostaglandin E1 on idiopathic sudden sensorineural hearing loss: a double-blinded clinical study. *Otol Neurotol* 2002; 23: 665-8.

Suzuki H, Furukawa M, Kumagai M et al. Defibrinogenation therapy for idiopathic sudden sensorineural hearing loss in comparison with high-dose steroid therapy. *Acta Otolaryngol* 2003; 123: 46-50.

Épiglottite

Carey MJ. Epiglottitis in adults. *Am J Emerg Med* 1996; 14: 421-4.

Hebert PC, Ducic Y, Boisvert D, et al. Adult epiglottitis in a canadian setting. *Laryngoscope* 1998; 108: 64-9.

Nakamura H, Tanaka H, Matsuda A, et al. Acute epiglottitis: a review of 80 patients. *J Laryngol Otol* 2001; 5: 31-4.

Sinusite aiguë (rhinosinusite aiguë)

Hamory BH, Sande MA, Sydnor A, et al. Etiology and antimicrobial therapy of acute maxillary sinusitis. *J Infect Dis* 1979; 139: 197-202.

Berg O, Carenfelt C, Rystedt G, et al. Occurrence of asymptomatic sinusitis in common cold and other acute ENT-infections. *Rhinology* 1986; 24: 223-5.

Gwaltney JM, Phillips CD, Miller RD, et al. Computed tomographic study of the common cold. *N Engl J Med* 1994; 330: 25-30.

Gwaltney JM. Acute community-acquired sinusitis. *Clin Infect Dis* 1996; 23: 1209-25.

Puhakka T, Makela MJ, Alanen A, et al. Sinusitis in the common cold. *J Allergy Clin Immunol*. 1998 ;102: 403-8.

Hickner JM, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. *Ann Intern Med* 2001; 134: 498-505.

Gilbert DN, Moellering RC, Sande MA. *The Sanford Guide to antimicrobial therapy*; 2003.

Piccirillo JF. Acute Bacterial Sinusitis. *New Engl J Med* 2004; 351: 902-10.

PSYCHIATRIE - Geriatrie

Delirium, démence

Inouye SK, van Dyk CH, Alessi CA. Clarifying Confusion: The Confusion Assessment Method. *Ann Intern Med* 1990; 113: 941-8.

Bennett DA, Wilson RS, Gilley DW et al. Clinical diagnosis of Binswanger's disease. *J Neurosurg Psychiatry* 1991; 54: 1122-3.

Canadian study of health and aging working group. Canadian study of health and aging: study methods and prevalence of dementia. *Can Med Assoc J* 1994; 150: 899-913.

American Psychiatric Association Diagnostic and Statistical Manual, 4th edition, APA Press, Washington DC, 1994.

Giannakopoulos P, et al. Démences et détérioration. *Pathologie Médicale*. Masson, 1995; 2: 405-17.

Giannakopoulos P, et al. Confusion mentale. *Pathologie Médicale*. Masson, 1995; 2: 418-28.

Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, Dementia, and cortical deposition of beta-amyloid protein: *N Engl J Med* 1995; 333: 1242-7.

Diagnostisches und statistisches Manual psychischer Störungen DSM-IV. Göttingen: Hogrefe-Verlag; 1996.

McKeith LG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. *Neurology* 1996; 47: 113-24.

Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. *The Nun Study*. *JAMA* 1997; 277: 813-7.

Hock C, Müller-Spahn F. Verwirrtheitszustände im Alter. *Schweiz Rundsch Med Prax* 1999; 88: 998-1006.

Inouye SK, Bogardus ST, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. *N Engl J Med* 1999; 340: 669-76.

Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of

carbamazepine for agitation and aggression in dementia. *Am J Psychiatry* 1998; 155: 54-61.

Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. *JAMA* 1999; 282: 254-60.

Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. *Neurology* 1999; 53: 1937-42.

Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of osteoporotic fractures research group. *Arch Intern Med* 2000; 160: 174-80.

Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med* 2002; 346: 476-83.

Verghese J, Lipton RB, Hall CB, et al. Abnormality of gait as a predictor factor of non-Alzheimer's dementia. *N Engl J Med* 2002; 347: 1761-8.

Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). *JAMA* 2003; 289: 2983-91.

Reisberg B, doddy R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med* 2003; 348: 1331-41.

Tarrot PN, Farlow R, Frossberg FT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. *KAMA* 2004; 291: 317-24.

Delirium tremens

Lipowski ZJ. Transient cognitive disorders (delirium, acute confusional states) in the elderly. *Am J Psychiatry* 1983; 140: 1426-36.

Erkinjuntti T, et al. Dementia among medical inpatients: evaluation of 2000 consecutive admissions. *Arch Intern Med* 1986; 146: 1923-6.

Lipowski ZL. Delirium in the elderly patient. *N Engl J Med* 1989; 320: 578-82.

CIM-10/ICD-10: Classification internationale des troubles mentaux et des troubles du comportement. Organisation Mondiale de la Santé, Genève, Paris, Masson, 1993, p: 1-305.

Brust JC. Agitation and delirium. In: Bogousslavsky J, Caplan L, (eds), *Stroke syndromes*. Cambridge: Cambridge Univ Press 1995: 134-9.

DSM-IV: Manuel diagnostique et statistique des troubles mentaux. Traduction française coordonnée par Gueffi JD, Paris, Masson, 1-1008, 1996.

Ghika J. Delirium chez la personne âgée. *Med Hyg* 1997; 55: 1037-41.

Winterthaler G, Ferrero F, Bertschy G. Syndrome de sevrage: alcool, médicaments, drogues. In: Restellini A, et al. (éds.), *Urgences Médicales*. Editions Médecine et Hygiène, 1997, p: 455-60.

Young J, Inouye SK. Delirium in older people. *BMJ* 2007; 334: 842-6.

Confusion Assessment Method (CAM)

Inouye SK, Bogardus ST, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. *N Engl J Med* 1999; 340: 669-76.

Richmond Scale

Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). *JAMA* 2003; 289: 2983-91.

Mini-mental state (FOLSTEIN)

Folstein MF, Folstein SE, McHugh PR. «Mini-mental state»: a practical method for grading the cognitive state of patients for the clinician. *J Psych Res* 1975; 12: 189-98.

État dépressif, trbli. panique

CIM-10/ICD-10: Classification internationale des troubles mentaux et des troubles du comportement. Organisation Mondiale de la Santé, Genève, Paris, Masson, 1-305, 1993.

Hirschfeld RM. Guidelines for the longterm treatment of depression. *J Clin Psych* 1994; 55(Suppl.): 61-9.

DSM-IV: Manuel diagnostique et statistique des troubles mentaux. Traduction française coordonnée par Gueffi JD, Paris, Masson, 1-1008, 1996.

Culpepper L. Escitalopram: a new SSRI for the treatment of depression in primary care. *Primary Care Companion J Clin Psychiatry* 2002; 4: 209-14.

Maladie d'ALZHEIMER

- McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease. *Neurology* 1984; 34: 939-44.
- Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. *JAMA* 1989; 262: 2551-6.
- Reisberg B, Schneider, Doody R, et al. Clinical global measures of dementia: position paper from the International Work Group on Harmonization of Dementia Drug Guidelines. *Alzheimer Dis Assoc Disord* 1997; 11 (Suppl.3): S8-S18.
- Giacobini E. Cholinergic foundations of Alzheimer's disease therapy. *J Physiol Paris* 1998; 92: 283-7.
- Mayeux R, Sano M. Treatment of Alzheimer's disease. *N Engl J Med* 1999; 341: 1670-9.
- Zekry D, Fontana P, Laszlo A. La prise en charge médicamenteuse de la maladie d'Alzheimer. *Med Hyg* 1999; 57: 2210-4.
- Seshadri S, Beiser A, Selhub J, et al. Plasma Homocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med* 2002; 346: 476-83.

Chute de la personne âgée

- Podsiadlo D, Richardson S. Tire Timed «Up & Go»: A test of basic functional mobility for frail elderly persons. *Ann Geriatr Soc* 1991; 39: 142-8.
- Duncan PW, Studenski S, Chandler S et al. Functional reach: predictive validity in a sample of elderly male veterans. *J Gerontol A Biol Sci Med Sci* 1992; 47: M93-98.
- Baraff LJ, Della Penna R, Williams N et al. Practice Guideline for the ED management of falls in community dwelling elder persons. *Ann Emerg Med* 1997; 30: 480-9.
- Tinetti ME, Baker DI, Dutcher J, Vincent JE, Rozett RT. Reducing the risk of falls among older adults in the community. Berkeley, CA: Peaceable Kingdom Press, 1997.
- Man-Son-Hing M, Nichol G, Lau A et al. Choosing Antithrombotic Therapy for Elderly Patients With Atrial Fibrillation Who Are at Risk for Falls. *Arch Intern Med*. 1999;159:677-85.
- American Geriatrics Society, British Geriatrics Society and American Academy of Orthopaedic Surgeons Panel on Fall Prevention. Guidelines for the Prevention of Falls in older Persons. *J Amer Geriatric Soc* 2001; 49: 664-72.
- Masud T, Morris RO. Epidemiology of falls. *Age and Ageing* 2001; 30-S4: 3-7.
- Rubenstein LZ, Powers CM, MacLean CH. Quality Indicators for the Management and Prevention of Falls and Mobility Problems in vulnerable elders. *Ann Int Med*. 2001; 135(8): 686-93.
- Wettstein A, Conzelmann M, Heiss HW (Hrsg). *Checkliste Geriatrie*. Georg Thieme Verlag Stuttgart New York 2001.
- Ensrud KE, Blackwell TL, Mangione CM et al. Central nervous system-active medications and risk for falls in older women. *J Am Geriatric Soc* 2002; 50: 1629-37.
- Grob D, Stuck AE. Der Sturz im Alter. In: *Medizinische Notfälle*. Thieme 2003; 439-47.
- Man-Son-Hing M, Laupacis A. Anticoagulant-Related Bleeding in Older Persons With Atrial Fibrillation. *Arch Intern Med* 2003; 163: 1580-86.
- Chang JT, Morton SC, Rubenstein LZ et al. Interventions for the prevention of falls in older adults: systematic review and meta-analysis of randomised clinical trials. *BMJ* 2004; 328: 680.

FORMULES

Éthanol — Alcool

- Jennet B, Gleave J, Wilson P. Brain death in three neurosurgical units. *BMJ* 1981; 282: 533-9.
- Pursell RA, Pudek M, Brubacher J, et al. Derivation and validation of a formula to calculate the contribution of the osmolal gap. *Ann Emerg Med* 2001; 38: 653-9.

Bilan azoté

- Lee HA, et al. A method of determining daily nitrogen requirements. *Postgrad Med J* 1975; 51: 441-5.
- Protein and energy requirements: a joint FAO/WHO memorandum. *Bull World Health Organ* 1979; 57: 65-79.
- Park GR. Rapid calculation of nitrogen losses. *Intensive Care Med*

1980; 6: 243-4.

Scrimshaw NS. Criteria for valid nitrogen balance measurement of protein requirements. *Eur J Clin Nutr* 1996; 50 (Suppl 1): S196-7.

Calcium

Messaï E, (ed.). In: *Guide des chiffres et formules utiles en pratique médicale*. Arnette Blackwell, 1995, p: 38.

Chlore: déficit

Brimouille S, Vincent JL, Dufaye P, et al. Hydrochloric acid infusion for treatment of metabolic alkalosis: effects on acid-base balance and oxygenation. *Crit Care Med* 1985; 13: 738-42.

Clairance (créatinine, eau libre, Hb), osmolalité

- Smith HW. The kidney: structure and function in health and disease. Oxford University Press, New York 1951, 231-238.
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; 16: 31-41.
- National Kidney Foundation (NFK) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; 39 (Suppl. 2): S1-S246.
- Cameron J, Greger R. Renal function and testing of function, in AM Davidson, JS Cameron, JP Grunfeld, et al., *Oxford textbook of clinical nephrology*. Oxford University Press Oxford 1998, 39-69.
- Rahn KH, Heidenreich S, Bruckner D. How to assess glomerular function and damage in humans. *J Hypertens* 1999; p. 309-317.

Fer

- Working group on fortification of salt with iron: Use of common salt fortified with iron in the control and prevention of anaemia – a collaborative study. *Am J Clin Nutr* 1982; 35: 1442.
- Crosby WH, O'Neill-Cutting MA. A small-dose iron tolerance test as indicator of mild iron deficiency. *JAMA* 1984; 251: 1986-7.
- Lee R, et al. (eds.). *Clinical hematology*. 1993, Lea & Febiger.
- Wallach J. *Interpretation of Diagnostic Tests*. Little Brown, 1996.
- Ruedin P. Traitement de l'anémie liée à l'insuffisance rénale chronique. *Med Hyg* 1998; 56: 2081-4.

Glycémie et HbA1c

Peters AL, Davidson MB, Schrieger DL, et al. A clinical approach to the diagnosis of diabetes mellitus: an analysis using glycated hemoglobin levels. *JAMA* 1996; 276: 1246-52.

Gradient: albumine sérum-ascite

- Reynolds TB, Ito S, Iwatsuki S. Measurement of portal pressure and its clinical application. *Am J Med* 1970; 49: 649-57.
- Runyon BA. Care of patients with ascites. *N Engl J Med* 1994; 330: 337-42.

LDL-Cholestérol

- Friedewald WT, Levy RL, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. *Clinical Chemistry* 1972; 18: 499-502.
- Recommendations of the Second Joint Task Force of European and other Societies on coronary Prevention. Prevention of coronary heart disease in clinical practice. *Eur Heart J* 1998; 19: 1434-1503.

Osmolalité

Truniger B, Briner V. Troubles du bilan aqueux. *Forum Med Suisse* 2001; N° 1: 779-83.

PARKLAND

Scheuler JJ, Munster AM. The Parkland formula in patient with burns and inhalation injury. *J Trauma* 1982; 22: 869-71.

Poids idéal, indice de la masse corporelle

- Bray GA, et al. Evaluation of the obese patient. *JAMA* 1976; 235: 1447.
- Physical status: the use and interpretation of anthropometry: report of a WHO expert committee. *WHO Tech Rep Ser* 1995; 854: 1-452.
- International Obesity Task Force (IOTF). Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva, 3-5 June, 1997 (WHO/NUT/NCD/97.2).

Calte EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort on U.S. adults. *N Engl J Med* 1999; 341: 1097-1105.

Pression artérielle moyenne

Hall JB, Schmidt GA, Wood LDH, (eds.). *Principles of critical care*. McGraw-Hill, 1998.

Sodium: déficit, natrémie corrigée, fraction d'extraction

Steffes MW, Freier EF. A simple and precise method of determining true sodium, potassium and chloride concentrations in hyperpepemia. *J Lab Clin Med* 1976; 88: 683-88.

Oh MS, Carroll HJ. Regulation of intracellular and extracellular volume. In: Arieff AI, DeFronzo RA (eds.). *Fluid, electrolyte, and acid-base disorders*. 2nd edition New York: Churchill Livingstone, 1995; 1-28.

Vitesse de sédimentation

Gilbertsen VA. Erythrocyte sedimentation rates in older patients. *Postgrad Med* 1965; 38: A44-A52.

Bottiger LE, Svedberg CA. Normal erythrocyte sedimentation rate and age. *Br Med J* 1967; 2: 85-7.

Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. *Br Med J* 1983; 2: 266.

Bedell SE, et al. Erythrocyte sedimentation rate. *Am J Med* 1985; 78: 1001-9.

Sox HC, Liang MH. The erythrocyte sedimentation rate. Guidelines for rational use. *Ann Intern Med* 1986; 104: 515-23.

Lessung HP, Delmenico S. Une vitesse de sédimentation augmentée. *Schweiz Med Forum* 2007; 7: 765-9.

RADIOLOGIE

NET: www.MRIsafety.com

TEXTBOOK: Meire H, Cosgrove D, Dewburg K, et al. (ed.). *Clinical ultrasound, a comprehensive text*. Churchill Livingstone 2001.

Échographie, échocardiographie

Gladisch R. (ed.). *Praxis der abdominalen Ultraschalldiagnostik*. Schlatter, 1992.

Coady MA, Rizzo JA, Hammond GL, et al. What is the appropriate size criterion for resection of thoracic aortic aneurysms? *J Thorax Cardiovasc Surg* 1997; 1113: 476-91.

Deuzat M. (ed.). *Ultrasonographie vasculaire diagnostique*. Vigot, 1991.

Mylonakis E, Calderwood SB. Infective endocarditis in adults. *N Engl J Med* 2001; 345: 1318-30.

Radiographie standard, thorax

Fleischner FG, Udis SW. Dilatation of the azygos veins, a roentgen sign of venous engorgement. *Am J Roentgenol* 1952; 67: 659-75.

Chang CH. The normal roentgenographic measurement of the right descending pulmonary artery. *Am J Roentgenol* 1962; 87: 929-35.

Felson B. (ed.). *Principles of chest roentgenology*. Saunders 1974.

Conrardy PA, Goodman LR, Laing F, et al. Alteration of endotracheal tube position: flexion and extension of the neck. *Crit Care Med* 1976; 4: 7-12.

Bismuth V, Bléry M, Rémy J, et al. *Traité de radiodiagnostic. Tome IV. Appareil pulmonaire et médiastin*. Masson, 1977.

Vasile N. (ed.). *I.R.M. corps entier*. Vigot, 1988.

Rich S, Chomka E, Hasara L, et al. The prevalence of pulmonary hypertension in the United States. Adult population estimates obtained from measurements of chest roentgenograms from the NHANES II Survey. *Chest* 1989; 96: 236-41.

Remy J, Caodeville R, Coussemant A. *Le poumon pathologique. Atlas de sémiologie radiologique*. Arnet. Paris, 1990.

Bernadac P, Anthoine D, Hennequin L, et al. *Poumon cardiaque. Editions techniques. Encyl Med Chir (Paris-France)*.

Radiodiagnostic Cœur- Poumon- Larynx, 32489R10, 1991.

Armstrong P, Wastie ML. (eds.). *Diagnostic Imaging*. Blackwell, 1994.

Armstrong P, Wilson AG, Dee P, et al. (eds.). *Imaging of diseases of the chest*. Mosby 2000.

Muller N, Fraser R, Colman N, et al. *Radiologic diagnosis of diseases of the chest*. WB Saunders, 2001.

Divers

Steens RD, Summers QA, Tarala RA. Pulmonary alveolar proteinosis

in association with Fanconi's anemia and psoriasis. A possible common pathogenic mechanism. *Chest* 1992; 102: 637-8.

Eisenberg RL, Margulis AR (eds.). *In: Radiology: What to order when*. Lippincott - Raven, 1996.

Bonow RO et al. ACC/AHA guidelines for the management of patients with valvular heart disease. *Circulation* 1998; 98: 1949-84. Also published in: *J Heart Valve Dis* 1998 ; 7: 672-707 and *JACC* 1998; 32: 1486-588.

Webb R, Muller N, Naidich DP. (ed.). *High-resolution CT of the lung*. Lippincott Williams 2001.

Shellock FG, Crues JV. Commentary: MR safety and the american college of radiology white paper. *Am J Roentgenol* 2002; 178: 1349-52.

Nodule pulmonaire solitaire

Cummings SR, Lillington GA, Richard RJ. Estimating the probability of malignancy in solitary pulmonary nodules: a Bayesian approach. *Am Rev Respir Dis* 1986; 134: 449-52.

Swensen SJ, Silverstein MD, Edell ES, et al. Solitary pulmonary nodules: clinical prediction model versus physicians. *Mayo Clin Proc* 1999; 74: 319-29.

Henschke CI, Yankelevitz D, Westcott J, et al. Work-up of the solitary pulmonary nodule. *Radiology* 2000; 215: (Suppl.) 607-9.

Ost D, Fein AM, Feinsilver SH. The solitary pulmonary nodule. *N Engl J Med* 2003; 348: 2535-42.

Douleurs, Opioides

NET:

- www.douleur.ch
- www.palliative.org
- www.palliative.info
- www.doloplus.com

Twycross RG. Control of pain. *J R Coll Physicians Lond* 1984; 18: 32-9.

Foley KM. The treatment of cancer pain. *N Engl J Med* 1985; 313: 84-95.

World Health Organization (WHO). *Cancer Pain Relief and Palliative Care: Report of a WHO Expert Committee*. Geneva: WHO, 1986.

Wall PD, Melzack R. (eds.). *Textbook of Pain*. Churchill Livingstone, 1989.

Kunz KM, Thesen JA, Schroeder ME. Severe episodic pain: management with sublingual sufentanil. *J Pain Symptom Manage* 1993; 8: 189-90.

Koo D, Hall E, Motson R et al. Palliation of malignant intestinal obstruction using octreotide. *Eur J Cancer* 1994; 30A: 375-6.

Mercadante S, Lodi F, Sapio M et al. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. *J Pain Symptom Manage* 1995; 10: 564-8.

Zech DFJ, Grond S, Lynch J, et al. Validation of World Health Organization guidelines for cancer pain relief: 10-year prospective study. *Pain* 1995; 63: 65-76.

Hanks GW, de Conno F, Ventafridda V, et al. Morphine in cancer pain: modes of administration. *BJM*, 1996; 312: 823-26.

Levy MH. Pharmacologic treatment of cancer pain. *N Engl J Med* 1996; 335: 1124-32.

McQuay HJ, Tramér M, Nye BA, et al. A systematic review of antedepressants in neuropathic pain. *Pain* 1996; 68: 217-27.

Rosner H, Rubin L, Kestenbaum A et al. Gabapentin adjunctiv therapy in neuropathic pain states. *Clin J Pain* 1996; 12: 56-8.

Manfredi PL, et al. (ed.). *Comprehensive medical management: Opioid analgesia*. In: *Parris WCV, (ed.) Cancer Pain Management: Principles and Practice*, Butterworth-Heinemann, 1997, p: 49-63.

Rosenberg JM, Harrell C, Ristic H, et al. The effect of gabapentin on neuropathic pain. *Clin J Pain*, 1997; 13: 251-55.

Tudela LL, et al. *Protocolo de cuidados paliativos en atención primaria. Formación medica continua*, 1997, p. 23.

Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. *JAMA*, 1998; 280: 1831-36.

Hewitt DJ, Portenoy RK. Adjuvant drugs for neuropathics cancer pain. In: *Portenoy RK, Bruera E (eds.) Topics in Palliative Care*. Oxford University Press, New York Oxford 1998, p: 41-62.

Collège des médecins du Québec. *Traitement de la douleur: le point sur l'utilisation des narcotiques*. QMC, décembre 1998.

Grond St, Radbruch L, Meuser Th, et al. Assessment and treatment of neuropathic cancer pain following WHO guidelines. *Pain*; 1999;

79: 15-20.
 Portney RK, Lesage P. Management of cancer pain. *Lancet* 1999; 353: 1695-1700.
 Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. *Lancet* 1999; 353: 1959-64.
 Cavigelli A, Dietz V. Poststationäre Nachsorge bei Querschnittsgelähmten: ausgewählte internistische Aspekte. *Schweiz Med Wochenschr* 2000; 130: 851-60.
 Guay DPR. Adjuvantive agents in the management of chronic pain. *Pharmacotherapy* 2001; 21: 1070-81.
 Association des pharmaciens des établissements de santé du Québec. Guide pratique des soins palliatifs. 3ième édition 2002.
 Breibart W, Chandler S, Easel B, et al. An alternative algorithm for dosing transdermal fentanyl for cancer-related pain. *Oncology* 2000; 14: 695-705. Discussion 705, 709-17.
 Pereira J, Lawlor P, Vigano A, et al. Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. *J Pain Symptom Manage* 2001; 22: 672-87.
 Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. *BMJ* 2004; 328: 991.
 Gilron I, Bailey JM, Tu D, et al. Morphine, Gabapentin, or Their Combination for Neuropathic Pain. *N Engl J Med* 2005; 352: 1324-34.
 Fiellin DA, Pantaloni MV, Chawarski MC, et al. Counseling plus Buprenorphine-Naloxone Maintenance Therapy for Opioid Dependence. *N Engl J Med* 2006; 355: 365-74.

Ophthalmologie

Glaucome à angle fermé

Asbury T, Vaughan D, Riordan-Eva P, (eds.). *General ophthalmology*. Appleton & Lange, 1999.
 Trobe JD. (ed.). *The physician's guide to eye care*. American Academy of Ophthalmology, 2000.

Décollement de la rétine

Asbury T, Vaughan D, Riordan-Eva P, (eds.). *General ophthalmology*. Appleton & Lange, 1999.
 Trobe JD. (ed.). *The physician's guide to eye care*. American Academy of Ophthalmology, 2000.

Urologie

Prostate. Hyperplasie prost. bénigne

Berry SJ, Coffey DS, Walsh PC et al. The development of human benign prostatic hyperplasia with age. *J Urol* 1984; 132: 474-79.
 Chapple CR. Selective α 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. *Eur Urol* 1996; 29: 129-67.
 Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. *N Engl J Med* 1996; 335: 533-9.
 Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate specific-antigen. *JAMA* 1996; 276: 1309-15.
 Lieber MM. Pharmacologic therapy for prostatism. *Mayo Clin Proc* 1998; 73: 590-6.
 Carter HB, Partin AW. Diagnosis and staging of prostate cancer. *Campbell's Urology*. Walsh PC, Retik AB, Vaughan ED, et al (eds.). WB Saunders 1998; 3: 2519.
 Lowe FC, Roehrborn CG, Robertson C, et al. Meta-analysis of clinical trials of Permixon® (abstract). *J Urol* 1998; 159: 257.
 Carter HB, Pearson JD. Prostate-specific antigen testing for early diagnosis of prostate cancer: formulation of guidelines. *Urology* 1999; 54: 780-6.
 Krane R, Beemsterboer P, Rietbergen J, et al. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). *Prostate* 1999; 39: 316-22.
 Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. *Urology* 1999; 53: 671-8.
 Vallancien G. Alpha-blockers in benign prostatic hyperplasia. *Urology* 1999; 54: 773-5.
 Iselein C. Antigène spécifique de la prostate (PSA): quelle utilité clinique? *Med Hyg* 2000; 58: 1795-6.
 Barry MJ. Prostate-specific-antigen testing for early diagnosis of prostate cancer. *N Engl J Med* 2001; 344: 1373-7.
 Thompson IM, Goodman PJ, Tangen CM, et al. The influence of

Finasteride on the development of prostate cancer. *N Engl J Med* 2003; 349: 215-24.
 Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. *N Engl J Med* 2003; 349: 366-81.
 Punglia RS, D'Amico A, Catalona WJ, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. *N Engl J Med* 2003; 349: 335-42.

Hyperactivité vésicale

Van Kerrebroeck P, Serment G, Dreher E. Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder. *NeuroUrol Urodyn* 1997; 16: 478-9.
 Ouslander JG. Management of overactive bladder. *N Engl J Med* 2004; 350: 786-99.

GYNÉCOLOGIE

Prééclampsie, HELLP-Syndrome

White WB. Management of hypertension during lactation. *Hypertension* 1984; 6: 297-300.
 Sibai BM, Mabie WC, Shamsa F, et al. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. *Am J Obstet Gynecol* 1990; 162: 960-7.
 Paran E, Holzberg G, Mazor M, et al. Beta-adrenergic blocking agents in the treatment of pregnancy-induced hypertension. *Int J Clin Pharmacol Ther* 1995; 33: 119-23.
 Hohlfeld P, Marty F, De Grandi P, et al. *Le livre de l'interne obstétrique*. Médecine-Sciences Flammarion 1998.
 Sibai BM. Treatment of hypertension in pregnant women. *N Engl J Med* 2000; 335: 257-65.
 Umans JG, Lindheimer MD. Antihypertensive treatment. In: *Hypertensive disorders in pregnancy*. Lindheimer MD, et al (eds.). Appleton & Lange, Stamford 1999; p. 581-604.
 Vogt B, Mohaupt M. Traitement de l'hypertension: ciblé sur le vieillard et la femme enceinte. *Forum* 2001; 22: 571-5.

Hypertension artérielle et grossesse

Galery E. Hypertension in pregnancy: practical management recommendations. *Drugs* 1995; 49: 555-62.
 Sibai BM. Treatment of hypertension in pregnant woman. *N Engl J Med* 1996; 335: 257-65.
 Heleva ME, Burrows RF, Smith J, et al. Report of the canadian hypertension society consensus conference: 1. Definitions, evaluations and classification of hypertensive disorders in pregnancy. *Can Med Assoc J* 1997; 157: 715-25.
 Moutquin JM, Garner PR, Burrows RF, et al. Report of the canadian consensus conference: 2. Nonpharmacologic management and prevention of hypertensive disorders in pregnancy. *Can Med Assoc J* 1997; 157: 907-19.
 Rey E, LeLorier J, Burgess E, et al. Report of the canadian hypertension society consensus conference: 3. pharmacologic treatment of hypertensive disorders in pregnancy. *Can Med Assoc J* 1997; 157: 1245-54.

LABORATOIRE ET NORMES

Textbooks
 Berkow R. *The Merck Manual of diagnosis and therapy*. 16th ed. Merck & Co. Inc, 1992.
 Jacobs DS, Demott, Grady, et al. *Laboratory Test Handbook*. 4th ed. Lexi-Comp, Inc, 1996.
 Dufour R. *Clinical of laboratory data. A practical guide*. Lippincott Williams & Wilkins, 1998.
 Wallach J. *Interpretation of Diagnostic Tests*. 7th ed. Lippincott Williams & Wilkins, 2000.
 Braunwald E, Fauci, Kasper, et al. *Harrison's 15th editions. Principles of International Medicine*. Mc Graw-Hill, 2001.
 Young DS. *Effects of drugs on clinical laboratory tests*. 5th ed. AACCPress, 2000.
 Young DS. *Effects of disease on clinical laboratory tests*. 4th ed. AACCPress, 2001.
 Laposata M. *Laboratory medicine. Clinical pathology in the practice of medicine*. ASCP Press, 2002.

Acide folique

Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. *N Engl J Med* 2001; 335: 1593-1600.

ALT, AST

- Cohen JA, Kaplan MM. The SGOT/SGPT ratio - an indicator of alcoholic liver disease. *Dig Dis Sci* 1979; 24: 835-8.
- Rej R. Aminotransferases in disease. *Clin Lab Med* 1989; 9: 667-87.
- Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. *N Engl J Med* 2000; 342: 1266-71.
- Lee WM. Drug-induced hepatotoxicity. *N Engl J Med* 2003; 349: 474-85.

BNP

- Cheng, V, Kazanagra J. A Rapid Bedside Test for B-Type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. *Am Coll Cardiol* 2001; 37: 386-91.
- Dao Q, Krishnaswamy P, Kazanagra R, et al.: Utility of B-Type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. *J Am Coll Cardiol* 2001; 37: 379-85.
- Koglin J, Pehlivani S, Schwablmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. *J Am Coll Cardiol* 2001; 38: 1934-41.
- Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med*, 2001; 347, 161-7.
- Hess OM, Suter T, Mohacsi P. Editorial: Medikamentöse Therapie der Herinsuffizienz. *J Kardiologie* 2002; 9: 167-8.
- Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. *Rev Cardiovasc Med* 2002; 3 (Suppl. 4): S10-7.
- Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. *J Am Coll Cardiol* 2002; 39: 202-9.
- Hohl CM, Mitelman BY, Wyer P, et al. Should emergency physicians use B-type natriuretic peptide testing in patients with unexplained dyspnea? *Can J Emerg Med* 2003; 5: 166-8.
- Kuster GM, Tanner H, Printzen G, Suter TM, et al. B-type natriuretic peptide for diagnosis and treatment of congestive heart failure. *Swiss med wly* 2003; 133: 623-8.
- Mueller Ch, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. *N Engl J Med* 2004; 350: 647-54.

Bilirubine

- Beck K. Icterus. Schattauer. Stuttgart 1968.

CK-MB

- Ong L, Reiser P, et al. Left ventricular function and rapid release of creatine kinase MB in acute myocardial infarction. *N Engl J Med* 1983; 309: 1-6.
- Schifferli J. Intérêt clinique des isoenzymes de la créatine kinase. *Praxis* 1983; 18: 605-8.
- Lee T, Goldman L. Serum enzyme assays in the diagnosis of acute myocardial infarction. *Ann Intern Med* 1986; 105: 221-33.
- Lee TH, et al. Ruling-out acute myocardial infarction. A prospective multicenter validation of a 12 hour strategy for patients at low risk. *N Engl J Med* 1991; 324: 1239-46.

C-réactive protéine

- Wallach J. Interpretation of Diagnostic Tests. Little Brown, 1996.
- Fauci A, Braunwald E, (eds.) et al. In: Harrison: Principles of Internal Medicine. 1998 Mc Graw Hill.
- Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. *Circulation* 2003; 107: 360-9.
- Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and markers of inflammation in the prediction of coronary heart disease. *N Engl J Med* 2004; 350: 1387-97.

D-dimères

- Perrier A, Desmarais S, Miron MJ, et al. Non-invasive diagnosis of venous thromboembolism in outpatients including clinical probability, D-dimer and ultrasonography. *Lancet* 1999; 353: 190-5.
- Kearon C, Ginsberg JS, Douketis J, et al. Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. *Ann Intern Med* 2001; 135: 108-11.

Hémoglobine glycosilée (HbA1c)

- The diabetes control and complications trial research group. The

effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. *N Engl J Med* 1993; 329: 977-86.

- UK Prospective diabetes study (UKPDS) group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS group. *Lancet* 1998; 352: 837-53.
- Phillippe J. L'hémoglobine glyquée (HbA1c). *Med Hyg* 2000; 58: 1800-1.

Natriurétique peptide

- Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med* 2002; 347: 161-7.

Homocyst(é)ine

- Nygaard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med* 1997; 337: 230-6.
- Maghadasian MH, McManus BM, Frohlich JJ. Homocyst(e)ine and coronary artery disease. *Arch Intern Med* 1997; 157: 2299-2308.
- Welch GN, Loscalzo J. Homocysteine and atherothrombosis. *N Engl J Med* 1998; 338: 1042-50.
- Martinelli I, Taioli E, Bucciarelli P, Akhavan S, et al. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. *Arterioscler Thromb Vasc Biol* 1999; 19: 700-3.
- Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. *Lancet* 1999; 345: 407-13.
- Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. *N Engl J Med* 2001; 335: 1593-1600.
- Seshadri S, Beiser A, Selhub J, et al. Plasma Homocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med* 2002; 346: 476-83.

Marqueurs tumoraux

- Bates S. Clinical applications of serum tumor markers. *Ann Int Med* 1991; 115: 632-8.
- Raymond W, Norton RE, Norton SE. Use of biological markers in the diagnosis of cancer of unknown primary tumor. *Semin Oncol* 1993; 20: 251-60.
- Lovis C. Les marqueurs tumoraux. *Med Hyg* 1995; 53: 1038-48.

Oxygène

- O'Donohue WJ. Home oxygen therapy. *Clin Chest Med* 1997; 18: 535-45.
- Hall JB, Schmidt GA, Wood LDH, (eds.). Principles of critical care. McGraw-Hill, 1998.
- Rochat Th. Oxygénothérapie au long cours à domicile. *Med Hyg* 1998; 56: 2312-4.
- Anderhub AP, Bloch K, Breitenbüchler A, et al. Lignes directrices 2006 pour l'oxygénothérapie de longue durée à domicile. *Forum Med Suisse* 2007; 7: 87-90.

Potassium

- Whang R, Whang DD, Ryan MP. Refractory potassium deficiency. *Arch Intern Med* 1992; 152: 40-45.
- Cohn JN, Kowey PR, Whelton PK, et al. New Guidelines for potassium replacement in clinical practice. *Arch Intern Med* 2000; 160: 2429-36.

Pancytopenie

- Fauci A, Braunwald E, (eds.) et al. In: Harrison: Principles of Internal Medicine. 1998 Mc Graw Hill.

Phosphatase alcaline

- Wallach J. Interpretation of Diagnostic Tests. Little Brown, 1996.

Troponines

- Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality on patients with acute coronary syndromes. *N Engl J Med* 1996; 335: 1342-9.
- Wallach J. Interpretation of Diagnostic Tests. Little Brown, 1996.
- Hamm CW, Goldmann BU, Heeschen C, et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. *N Engl J Med* 1997; 337: 1648-53.
- Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. *Circulation* 1997; 96: 2953-8.

Smith SC, Ladenson JH, Mason JW, et al. Elevations of cardiac troponin I associated with myocarditis: experimental and clinical correlates. *Circulation* 1997; 95: 163-8.

Hamm CW, Braunwald E. A classification of unstable angina revisited. *Circulation* 2000; 102: 118-22.

Vitesse de sédimentation

Gilbertsen VA. Erythrocyte sedimentation rates in older patients.

Postgrad Med 1965; 38: A44-A52.

Bottiger LE, Svedberg CA. Normal erythrocyte sedimentation rate and age. *Br Med J* 1967; 2: 85-7.

Bedell SE, et al. Erythrocyte sedimentation rate. *Am J Med* 1985; 78: 1001-9.

Sox HC, Liang MH. The erythrocyte sedimentation rate. Guidelines for rational use. *Ann Intern Med* 1986; 104: 515-23.

Laboratoire: unités SI traditionnelles

Young DS. Standardized reporting of laboratory data. *N Engl J Med* 1974; 290: 368-73.

Le SI pour les professions de la santé. Genève OMS, 1978.

SI-Einheiten in der Medizin. Herbert Lippert. Urban & Schwarzenberg, München/Wien/Baltimore, 1978.

Lundberg GD, Iverson C, Radulescu G. Now read this: the SI units are here. *JAMA* 1986; 255: 2329-39.

Young DS. Implementation of SI units for clinical laboratory data. *Ann Intern Med* 1987; 106: 114-29.

PHARMACOLOGIE CLINIQUE

NET: jml.georgetown.edu/jeps/pharmacology

Textbooks, cf. aussi chapitre «Douleurs»

Chernow B (ed). *Essential of Critical Care Pharmacology*. Williams & Wilkins, 1989.

Goodman & Gilman's *The Pharmacological basis of therapeutics*. McGrawHill, 1997.

Anderson PO, Knoben JE, Troutman WG (eds). *Handbook of clinical drug data*. Appleton & Lange 1999.

Compendium des produits et spécialités pharmaceutiques (CPS). Association des pharmaciens du Canada, 2003.

Lacy CG, Armstrong LL, Lance LL (eds.). *Drug information handbook*. Lexi-Comp Inc 2002.

Antibiotiques

Roger M, St-Antoine P, Coutlee F. Vancomycin-resistant enterococci in health care facilities. *N Engl J Med* 2001; 345: 768-9.

Gilbert DN, Moellering RC, Sande MA. *The Sanford Guide to antimicrobial therapy*; 2003.

Allergie aux bêta-lactames

Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and related antibiotics. *Clin Allergy* 1988; 18: 515-40.

Shepherd GM. Allergy to β -lactames antibiotics. *Immunol Allergy Clin North Am* 1991; 11: 611-33.

Anderson JA. Allergic reactions to drugs and biological agents.

JAMA 1992; 268: 2845-57.

Lin RY. A perspective on penicillin allergy. *Arch Intern Med* 1992; 152: 930-7.

Segreti J, Trenholme GM, Levin S. Antibiotic therapy in the allergic patient. *Med Clin North Am* 1995; 79: 935-42.

Anticoag. orale, Héparine, HBPM

Cole MS, et al. Coumarin necrosis - a review of the literature.

Surgery 1988; 103: 271-7.

Smith P, Ameson H, Holme I. The effect of warfarin on mortality and reinfarction. *N Engl J Med* 1990; 323: 147-52.

Hirsh J. Oral anticoagulant drugs. *N Engl J Med* 1991; 324: 1865-75.

Hirsh J, Levine MN. Low molecular weight heparin. *Blood* 1992; 79: 1-17.

Aster RH. Heparin-induced thrombocytopenia and thrombosis. *N Engl J Med* 1995; 332: 1374-6.

Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. *N Engl J Med* 1995; 333: 11-7.

Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. *N Engl J Med* 1995; 332: 1330-5.

Weitz JL. Low-molecular-weight heparins. *N Engl J Med* 1997; 337: 688-98. [Erratum: *N Engl J Med* 1997; 337: 1567].

Fifth consensus conference on antithrombotic therapy (1998): summary recommendations. *Chest* 1998; 114 (Suppl.): 439S-769S.

Recommendations of the Second Joint Task Force of European and other Societies on coronary Prevention. Prevention of coronary heart disease in clinical practice. *Eur Heart J* 1998; 19: 1434-1503.

Kelton JG. The clinical management of heparin-induced thrombocytopenia. *Semin Haematol* 1999; 36(Suppl.1): 17-21.

Raible MD. Hematologic complications of heparin-induced thrombocytopenia. *Semin Haematol* 1999; 25(Suppl.1): 17-21.

Walenga JM, Jeske WP, Wood JJ, et al. Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. *Semin Haematol* 1999; 36(Suppl.1): 22-8.

Verstraete M, Prentice CR, Samama M, et al. A European view on the North American fifth consensus on antithrombotic therapy. *Chest* 2000; 117: 1755-70.

Hirsh J. New anticoagulants. *Am Heart J* 2001; 142 (2 Suppl.): S3-8.

Sixth ACCP Consensus Conference on antithrombotic therapy. *Chest* 2001; 119 (Suppl. 1): 1S-336S.

Dager WE, White RH. Treatment of heparin-induced thrombocytopenia. *Ann Pharmacother* 2002; 36: 489-503.

Chong BH. Heparin-induced thrombocytopenia. *J Thromb Haemost* 2003; 3: 1471-8.

Verma AK, Levine M, Shalansky SJ, et al. Frequency of heparin-induced thrombocytopenia in critical care patients.

Pharmacotherapy 2003; 23:745-53.

Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. *Curr Hematol Rep* 2003; 2:148-57.

Antidépresseurs

Calanca A, Broyo C, Buclin T. (eds.). *Vade-mecum de thérapeutique psychiatrique*. Editions Médecine & Hygiène, 1997.

Woggon B. (ed.). *Behandlung mit Psychopharmaka*. Verlag Huber, 1998.

Antiémétiques

ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. *Am J Health-Syst Pharm* 1998; 56: 729-64.

Antidiabétiques oraux

Gerich JE. Oral hypoglycemic agents. *N Engl J Med* 1989; 321: 1231-45.

Jönsson A, Rydberg T, Ekberg G, et al. Slow elimination of glyburide in NIDDM subjects. *Diabetes Care* 1994; 17: 142-5.

DeFronzo RA, et al. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. *N Engl J Med* 1995; 333: 541-9.

Stumvoll M, et al. Metabolic effect of metformin in non-insulin dependent diabetes mellitus. *N Engl J Med* 1995; 333: 550-4.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998; 352: 854-65.

Barman Balfour JA, Plosker GL. Rosiglitazone. *Drugs* 1999; 57: 921-30.

Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROActive Study: A randomized controlled trial. *Lancet* 2005; 366: 1279-89.

Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone in patients with type 2 diabetes and preexisting cardiovascular disease: date from the PROActive study. *Diabetes Care* 2007; July 31.

Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis. *N Engl J Med* 2007; 357: 28-38.

Antihistaminiques

Desager JP, Horsmans Y. Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. *Clin Pharmacokinet* 1995; 28: 419-32.

Antihypertenseurs

Taira N. Differences in cardiovascular profile among calcium antagonists. *Am J Cardiol* 1987; 59: 24B-29B.

The fifth report of the joint national committee on detection, evaluation, and treatment of high blood pressure. *Arch Intern Med* 1993; 153: 154-83.

Lüscher TF, Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension. *Drugs* 1998;

55: 509-17.

- Abernethy DR, Schwartz JB. Drug therapy: Calcium-antagonist drugs. *N Engl J Med* 1999; 341: 1447-57.
- Birkenhäger WH, Leeuw PW. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. *J Hypertens* 1999; 17: 873-81.
- Burnett JC. Vasopeptidase inhibition: a new concept in blood pressure management. *J Hypertens* 1999; 17(Suppl. 1): 37-43.
- Yusuf S et al. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on death from cardiovascular events in high-risk patients. *N Engl J Med* 2000; 342: 145-53.

AINS, incl. ASPIRINE

- Settipane GA. Adverse reactions to aspirin and related drugs. *Arch Intern Med* 1981; 141: 328-32.
- Slepian IF, Mathews KP, McLean JA. Aspirin-sensitive asthma. *Chest* 1985; 87: 386-91.
- Duc J, Pécaud A. A propos d'un cas d'arrêt respiratoire. Intolérance à l'aspirine et aux anti-inflammatoires non stéroïdiens. *Med Hyg* 1988; 46: 705-9.
- Fries JF, et al. Identification of patients at risk for gastropathy associated with NSAID use. *J Rheumatol* 1990; 17 (Suppl. 20): 12-19.
- Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. *N Engl J Med* 1991; 325: 1593-6.
- Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. *Kidney Int* 1993; 44: 643-53.
- Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. *N Engl J Med* 1995; 333: 1392-1400.
- Bakowsky VS, Hanly JG. Complications of nonsteroidal antiinflammatory drug gastropathy and use of gastric cytoprotection: experience at a tertiary care health centre. *J Rheumatol* 1999; 26: 1557-63.
- Hawkey CJ. Cox-2 inhibitors. *Lancet* 1999; 353: 307-14.
- Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. *Arthritis Rheum* 2000; 43: 103-8.
- Everts B, Währborg P, Hedner. COX-2-specific inhibitors - the emergence of a new class of analgesic and anti-inflammatory drugs. *Clin Rheumatol* 2000; 19: 331-43.
- FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. *N Engl J Med* 2001; 345: 433-42.
- Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. *Proc Natl Acad Sci USA* 2002; 99: 13926-31.
- U.S. Preventive Services Task Force (Chair: Berg AO). Aspirin for the prevention of cardiovascular events: recommendation and rationale. *Ann Intern Med* 2002; 136: 157-60.
- August P. Initial treatment of hypertension. *N Engl J Med* 2003; 348: 610-17.
- Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. *N Engl J Med* 2003; 348: 883-90.
- Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. *N Engl J Med* 2003; 348: 891-9.
- Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. *J Am Coll Cardiol* 2003; 41: 961-5.
- Ridker PM, Nancy R. Cook, and I-Min Lee, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med* 2005; 352: 1293-1304.

Cholestérol, hypolipémiants

- Société Suisse de Cardiologie, Groupe de travail Lipides et Athérosclérose. Recommandations 1999 pour l'indication au traitement du facteur de risque «cholestérol». *Schweiz Ärztezeitung* 1999; 80: 544-8.
- Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. *J Am Coll Cardiol* 2002; 40: 2125-34.
- Gupta EK, Ito MK. The first in a novel class of selective cholesterol-absorption inhibitors. *Heart Dis* 2002; 4: 399-404.
- Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. *Circulation* 2002; 106: 1943-8.
- Cortisone
- Kaiser H. Cortisonderivate in Klinik und Praxis. Thieme, Stuttgart, 1977.
- Haynes RC, Murad F. Adrenocortical steroids. In: Goodman-Gilman

A, et al. (eds.). The pharmacological basis of therapeutics. Macmillan, New York, 1985.

- Keenan GF. Management of complications of glucocorticoid therapy. *Chest* 1997; 18: 507-20.
- McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. *Chest* 1997; 111: 732-43.
- Israel E, Banerjee TR, Fitzmaurice GM, et al. Effect of inhaled glucocorticoids on bone density in premenopausal women. *N Engl J Med* 2001; 345: 941-7.

Diurétiques

- Jacobson HR. Diuretics. Mechanisms of action and uses. *Hosp Pract* 1987; December: 129-56.
- Chernow B (ed). *Essential of Critical Care Pharmacology*. Williams & Wilkins, 1989.
- Brater DC. Diuretic therapy. *N Engl J Med* 1998; 339: 387-95.

Hypnotiques

- Greenblatt DJ, Shader RI, Abernethy DR. Current status of benzodiazepines (First of two parts). *N Engl J Med* 1983; 309: 354-8.
- Greenblatt DJ, Shader RI, Abernethy DR. Current status of benzodiazepines (Second of two parts). *N Engl J Med* 1983; 309: 410-6.
- Calanca A, Broyo C, Buclin T. (eds.). *Vade-mecum de thérapeutique psychiatrique*. Editions Médecine & Hygiène, 1997.

Magnésium

- Reinhart RA. Magnesium metabolism. A review with special reference to the relationship between intracellular content and serum levels. *Arch Intern Med* 1988; 48: 2415-20.

Neuroleptiques

- Kapsambelis V, Gekiere C, Ginestet D. Classification clinique des neuroleptiques. Étude critique et perspectives actuelles. *Encéphale* 1990; 16: 60-70.
- Pabis DJ, Stanislav SW. Pharmacotherapy of aggressive behaviour. *Ann Pharmacotheor* 1996; 30: 278-87.
- Calanca A, Broyo C, Buclin T. (eds.). *Vade-mecum de thérapeutique psychiatrique*. Editions Médecine & Hygiène, 1997.

Grossesse et médicaments/lacatation

- Kunz J, Schreiner WE. In: *Pharmakotherapie während der Schwangerschaft und Stillperiode*. 1. Aufl. Thieme Verlag Stuttgart, New York, 1982.
- Knoben JE, Anderson PO. *Handbook of Clinical Drug Data*. 7th ed. Hamilton Press 1993; Anderson P. Drug use during breastfeeding. *Clin Pharm*. 1991; 10: 596-624.
- Briggs GG, Freeman RK, Yaffe SJ. (eds.). In: *Drugs in pregnancy and lactation*. Williams & Wilkins 1994.
- Sibai BM. Treatment of hypertension in pregnant women. *N Engl J Med* 1996; 335: 257-65.
- Cloherty JP, Stark AR 1997. *Manual of neonatal care*, 4th edn. Little, Brown & Co Boston.
- Delaloye J-F, De Grandi P, Vial Y, Hohlfeld P. (eds.). In: *Médicaments, Grossesse et lactation*. Editions Médecine & Hygiène, Genève, 1997.
- Koren G, Pastuszak A, Ito S. *Drugs in pregnancy*. *N Engl J Med* 1998; 338: 1128-37.

Midazolam

- Shapiro BA, Warren J, Egol AB, et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: an executive summary. *Crit Care Med* 1995; 23: 1596-600.

Cytochrome P450

- www.informed.ch/pharma-kritik/pk21d-98.html
www.hospitalist.net/highlight.htm
- Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. *Mayo Clin Proc* 1997; 72: 835-47.
- Michalets EL. Clinically significant cytochrome P-450 drug interactions. *Pharmacotherapy* 1998; 18: 84-112.
- Desmeules J, Bonnabry P, Dayer P. Hepatic metabolism of drugs. In: *Bircher J, et al. (eds.). Oxford textbook of clinical hepatology*. Oxford University Press, 1999.
- Oestreicher KM, Desmeules J, Piquet V, et al. Interactions médicamenteuses: le rôle des cytochromes P450. *Med Hyg* 1999; 57: 793-800.

Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St-John's Wort, an herbal preparation used in the treatment of depression. *J Pharmacol Exp Ther* 2000; 294: 88-95.

Taketomo CK et al. Cytochrom P-450 enzymes and drug metabolism. In: *Pediatric dosage handbook*. 8th edition 2001-2001: 1076-84.

Bonnabry P, Sievering J, Leemann T, et al. Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. *Clin Pharmacokinet* 2001; 40: 631-40.

Ahya SN, Flood K, Paranjothi S. (eds.). *The Washington Manual of Medical Therapeutics*. Lippincott Williams & Wilkins, 2001, p: 590-607.

Compendium des produits et spécialités pharmaceutiques (CPS) 2003.

Bisphosphonates (cf. Ostéoporose)

Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. *N Engl J Med* 1990; 323: 73-9.

Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis; efficacy and safety after 7 years of treatment. *Am J Med* 1997; 103: 468-76.

Russel RFF, Rogers MG. Bisphosphonates: from the laboratory to the clinic and back again. *Bone* 1999; 25: 97-106.

Tonino RP, Meunier PF, Emkey R, et al. Skeletal benefits of alendronate: 7-years treatment of postmenopausal osteoporotic women. *J Clin Endocrinol Metab* 2000; 85: 3109-15.

B RÉVIAIRE

NET: <http://jml.georgetown.edu/jepts/pharmacology>

Textbooks

Chernow B (ed). *Essential of Critical Care Pharmacology*. Williams & Wilkins, 1989.

Goodman & Gilman's *The Pharmacological basis of therapeutics*. McGrawHill, 1997.

Morant J, Ruppanner H, (eds.). *Arzneimittel Kompendium der Schweiz* 2001. Documed 2002.

Canadian Pharmacists Association. *Compendium of pharmaceuticals and specialties - CPS* 2002.

Amiodarone

Mason JW. Amiodarone. *N Engl J Med* 1987; 316: 455-66.

Martin WJ, Resenow EC. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 1). *Chest* 1988; 93: 1067-75.

Sunderji R, Kanji Z, Gin K. Pulmonary effects of low dose amiodarone: a review of the risks and recommendations for surveillance. *Can J Cardiol* 2000; 16: 1435-40.

Agratoban

McKeage K, Polsker GL. *Drugs* 2001; 611: 515-22; discussion 523-4.

Clopidogrel

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet* 1996; 348: 1329-39.

Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. *Ann Intern Med* 1998; 129: 394-405.

Harding SA, Boon NA, Flapan AD. Antiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa, or all three? *Heart* 2002; 88: 11-4.

Digoxine

Smith TW. Digitalis: mechanisms of action and clinical use. *N Engl J Med* 1988; 318: 358-65.

The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med* 1997; 336: 525-33.

Levi D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. *N Engl J Med* 2002; 347: 1397-1402.

Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. *N Engl J Med* 2002; 347: 1403-11.

Milrinone

Colucci WS, Wright RF, Jaski BE et al. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual

patient responsiveness. *Circulation* 1986; 73: III 175-83.

Mehra MR, Ventura HO, Kapoor C et al. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. *Am J Cardiol* 1997; 80: 61-4.

Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. *N Engl J Med* 1988; 318: 358-75.

Stevenson LW. Inotropic therapy for heart failure. *N Engl J Med* 1998; 339: 1848-50.

Yamani HM, Haji SA, Starling RC et al. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: hemodynamic efficacy clinical outcome, and economic impact. *Am Heart J* 2001; 142: 998-1002.

Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. *J Am Cardiol* 2001; 38: 2101-13 (also in: *Circulation* 2001; 104: 2996-3007.)

Midazolam

Shapiro BA, Warren J, Egol AB, et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: an executive summary. *Crit Care Med* 1995; 23: 1596-600.

Vasopressine (ADH)

Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. *Circulation* 1997; 96 (Suppl): II-286-90.

Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilatation of septic shock. *Circulation* 1997; 95: 1122-5.

Schrier RW, Cadnapaphornchai MA, Umenishi F. Water-losing and water-retaining states: role of water channels and vasopressin receptor antagonist. *Heart Dis* 2001; 3: 210-4.

Annan D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA* 2002; 288: 862-71.

Chen P. Vasopressin: new uses in critical care. *Am J Sci* 2002; 324: 146-54.

Patel BM, Chittock DR, Russel JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. *Anesthesiology* 2002; 96: 576-82.